Differentiation of Alzheimer's disease dementia, mild cognitive impairment and normal condition using PET-FDG and AV-45 imaging : a machine-learning approach by Anjum, Ayesha
฀
฀%N฀VUE฀DE฀LOBTENTION฀DU฀
฀%0$503"5%&-6/*7&34*5²%&506-064&
฀
$ÏLIVRÏ฀PAR฀
 $ISCIPLINE฀OU฀SPÏCIALITÏ฀
฀
฀
฀
฀
0RÏSENTÏE฀ET฀SOUTENUE฀PAR฀฀
฀
฀
฀4ITRE฀
฀
฀
฀
฀
฀
฀
฀
฀
%COLE฀DOCTORALE฀
5NITÏ฀DE฀RECHERCHE฀
$IRECTEURS	฀DE฀4HÒSE฀
2APPORTEURS฀
LE฀   
         MEMBRES	฀DU฀JURY฀:
Université Toulouse III Paul Sabatier (UT3 Paul Sabatier)
Génie Electrique, Electronique et Télécommunications (GEET)
Differentiation of Alzheimer's disease dementia, Mild Cognitive Impairment
and Normal condition using PET-FDG and AV-45 Imaging. A Machine-Learning
Approach.
Mercredi 25 Septembre 2013
Ayesha ANJUM
Radiophysique et Imagerie Médicale
Michèle ALLARD
Habib ZAIDI
Abdel-Kader BOULANOUAR
Pierre PAYOUX
INSERM Unit 825
Jacques DARCOURT Président
Xavier FRANCERIES Examinateur
  
 
  
  
 
 
 
 
To 
My Parents 
 
  
ACKNOWLEDGEMENT 
 
Foremost, I would like to express my sincere gratitude to my director of thesis 
Abdel kader BOULANOUAR for the continuous support of my Ph.D study and 
research, for his patience, motivation, enthusiasm, and immense knowledge. His 
guidance helped me in all the time of research and writing of this thesis. I could not 
have imagined having a better advisor and mentor for my Ph.D study. I am also very 
thankful to my co-director Dr Pierre PAYOUX for his help and encouragement. 
I would like to thank the rest of my thesis committee: Professor Habib Zaidi, 
Professor Michèle Allard, Professor Jacque Darcourt, and Mr Xavier Franceries for 
accepting to be the part of my committee of thesis. 
I am also really appreciative to the entire team of technicians in PET center for 
their help and support. I thank my fellow lab mates in INSERM U825 and for all the fun 
we have had during my time in Lab. Also I thankful to all my friends from Pakistan for 
their support and help In particular, I am really grateful for my dear friends Inam 
Saddozai, Syed Tameez Gillani, Nosheen Gillani, Humara Dar, Muazzam Suhail and 
Abid Aslam for their support and encouragement. 
Last but not the least; I would like to thank my family: my parents for their 
endless support and prayers for me. 
  
 
3 
 
TABLE OF CONTENTS 
SUMMARY ...................................................................................................................................... 7 
Part A       Scientific Context and state of the art ................................................................... 13 
I. GENERAL INTRODUCTION .................................................................................................... 15 
1. THE ANATOMY OF HUMAN BRAIN ....................................................................................................... 17 
1.1. The Brain .................................................................................................................................... 17 
1.2. Brodmann Areas ......................................................................................................................... 22 
2. POSITRON EMISSION TOMOGRAPHY ................................................................................................... 25 
2.1. Neurophysiological Mechanism ........................................................................................................... 25 
2.2. Principle of PET ........................................................................................................................... 27 
2.3. Emission Of Positrons ................................................................................................................. 27 
2.4. Detection of Photons .................................................................................................................. 28 
2.5. Types of Coincidence Events ....................................................................................................... 30 
2.6. Attenuation ................................................................................................................................ 31 
2.7. Reconstruction and Treatment of Images ................................................................................... 33 
II. ALZHEIMER DISEASE ............................................................................................................ 35 
1. PRESENTATION OF ALZHEIMERS DISEASE ............................................................................................. 37 
1.1. Clinical Aspect of Alzheimer’s Disease ......................................................................................... 37 
1.2. Mechanism of pathology ............................................................................................................ 40 
1.3. Brain Imaging in Alzheimer disease ............................................................................................. 45 
1.3.1. Magnetic Resonance Imaging (MRI) in Alzheimer’s disease ........................................................ 46 
1.3.2. Positron emission tomography (pet) in Alzheimer’s disease ........................................................ 51 
1.4. Diagnosis of Alzheimer disease ................................................................................................... 57 
III. Multivariate Techniques in Neuroimaging ............................................................................ 65 
1. MACHINE LEARNING ............................................................................................................................ 67 
1.1. The Support Vector Machine ...................................................................................................... 67 
1.2. The Artificial Neural Network ...................................................................................................... 75 
2. FEATURE EXTRACTING TECHNIQUES .................................................................................................... 84 
2.1. Principle Component Analysis .............................................................................................................. 84 
2.2. Independent Component Analysis ....................................................................................................... 86 
 4 
 
2.3. Group Independent Component Analysis ............................................................................................. 90 
Part B      EXPERIMENTAL CONSIDERATION ........................................................................... 93 
IV. MATERIALS AND METHODS .................................................................................................. 95 
1. DATA/POPULATION.............................................................................................................................. 97 
1.1. Diagnostic Criterias .............................................................................................................................. 97 
2. METHODOLOGY ................................................................................................................................. 103 
2.1. Feature Extraction.............................................................................................................................. 103 
2.1.1. Process Involved In Feature Extraction ............................................................................................... 104 
2.2. The SVM Model ................................................................................................................................. 107 
2.3. The ANN Model.................................................................................................................................. 109 
V. RESULTS ............................................................................................................................ 113 
1. STUDY 1: CLASSIFICATION ................................................................................................................. 115 
1.1. Assessment by Leave One Out Cross Validation ................................................................................. 116 
1.2. RESULTS ............................................................................................................................................. 117 
1.3. CONCLUSIONS .................................................................................................................................... 125 
1.4. DISCUSSION ....................................................................................................................................... 127 
2. STUDY 2: ROBUSTNESS OF THE CLASSIFICATION AGAINST IMPERFECT TRAINING ............................ 131 
2.1. HYPOTHESIS TESTING ......................................................................................................................... 132 
2.2. PERMUTATION TESTS ......................................................................................................................... 133 
     RESULTS ............................................................................................................................................. 133 
2.4. DISCUSSION ....................................................................................................................................... 137 
3. STUDY 3: LEARNING SET IS DIFFERENT FROM TESTING SET WITH INDIVIDUAL PCA ICA. .................. 140 
3.1. RESULTS ............................................................................................................................................. 141 
3.2. DISCUSSION ....................................................................................................................................... 143 
4. STUDY 4: SPATIAL INTERPRETATION OF ICA ...................................................................................... 147 
4.1. RESULTS ............................................................................................................................................. 148 
4.2. DISCUSSION ....................................................................................................................................... 152 
DISCUSSIONS .............................................................................................................................. 153 
CONCLUSIONS ............................................................................................................................ 161 
BIBLIOGRAPHY............................................................................................................................ 165 
Scientific Contributions .............................................................................................................. 189 
 5 
 
RESUME en FRANÇAIS ................................................................................................................ 191 
 

7 
 
SUMMARY 
Alzheimer’s disease (AD) is first documented in 1907. It is named after the German 
physician called Alois Alzheimer. It is defined as the progressive dementia which results in 
severe cognitive impairments and loss of memory. Neuro-imaging has played a major role in 
the study of Alzheimer’s disease. Different medical imaging techniques such as positron 
emission tomography (PET) and magnetic resonance imaging (MRI) have shown off some 
statistically characteristic changes in the brain of AD patient. Different Imaging biomarkers such 
as F-18 FDG PET for glucose hypometabolism and Florbetaben AV45-PET for brain   amyloid 
load reported to be helpful in the diagnosis of Alzheimer’s disease.(J. M. Hoffman et al., 2000; 
Rosen et al., 2002);(Barthel & Sabri, 2011; Schroeter, Raczka, Neumann, & von Cramon, 2008; 
Schroeter, Raczka, Neumann, & Yves von Cramon, 2007; Schroeter, Stein, Maslowski, & 
Neumann, 2009). 
In order to find the appropriate non-invasive technique for the early detection of 
Alzheimer’s disease is important to develop the early treatment of the disease. For this 
purpose, an automated image-based classifier could provide an important diagnostic support to 
clinicians. Numerous studies have been approached in the literature such as Garibotto V et al., 
2013; Frederiksen KS et al., 2012; Duara R et al., 2012; Dukart J et al., 2013; Gray KR et al., 2013; 
Gray KR et al., 2012; Vandenberghe R et al., 2013; Caroli A et al., 2012; Joshi AD et al., 2012; 
Zhang D et al.,2012; Padilla P et al.,2007 and Segovia F et al.,2010 provide an automatic tool for 
the diagnosis of AD. These approaches could be further divided into two main categories; the 
first one is univariate approach and the other is multivariate approach. The univariate approach 
includes statistical parametric mapping (SPM) which mostly focus on voxel based analysis, 
comparison of the value of single image with the mean value of the group images. SPM is 
basically used to compare the group of images not specifically a single subject. The Multivariate 
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approach focus on the analysis of the images by extracting feature and the classification of 
different group and classes. 
In multivariate approaches, the main issue is the sample size problem. Some times the 
number of subjects is less than the number of feature required in training step. One solution is 
to adapt Principal Component Analysis to reduce the number of features and the other is to 
group voxels in VOI’s and to select a limited number of VOI’s on anatomical basis accounting for 
cerebral regions known to be involved in Alzheimer disease. The task of the supervised learner 
is to predict the class of the input object after having seen a number of training examples. The 
most widely used classifiers are: Support Vector Machines (SVMs) and Artificial Neural 
Networks (ANN). 
Regarding PET images, the application in classification of support vector machines 
(SVM)(Dukart et al., 2011b; K. R. Gray et al., 2011) and Artificial neural networks (ANN)(M. 
López, 2009),(Mhd. Saeed Sharif, Abbod, Amira, & Zaidi, 2012) have been showing to improve 
differentiation and diagnosis f AD with MCI and normal subjects. In most of the studies, some 
researchers have used single biomarker for the classification purpose and some have used 
single classification algorithm, which can restrict the results. Usually the authors use only a 
single frame to define some VOI’s from the images and introduce the mean values of these 
VOI’s as input for the classifiers. (Dukart, et al., 2011b) selected 9 regions: angular gyrus (BA 39, 
Left and Right), posterior superior temporal sulcus (BA 21/22), right Anterior medial frontal 
cortex (BA 9/10), anterior cingulate gyrus (BA 32), right Inferior precuneus (BA 31), dorsal 
posterior cingulate cortex (BA 23), left Posterior superior temporal sulcus (BA 21/22), and 
middle inferior temporal sulcus BA 20). These VOI’s were selected as they represent the areas 
of maximum reductions in glucose utilization in AD. They used also 6 VOI’s from MRI images 
which represent the maxima of atrophy in AD. 
In (Katherine R. Gray et al., 2012), the authors selected 83 regions in FDG-PET images, 
defined from anatomical MRI images. They used both baseline images and 12-mounths follow-
up FDG-PET images, in order to investigate their combined use for classification. In order to 
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compare AD and MCI images to control images, the signal intensity should be normalized the 
same way in AD, MCI and controls FDG-PET image normalization is often performed relative to 
the cerebral global mean. As we know that Mild cognitive impairment (MCI) an alzheimer’s 
disease (AD) have lower cerebral glucose metabolic rate as compare to normal individuals. So 
by doing normalization to the cerebral global mean  gives some artificial values whilst scaling 
down normal subjects, resulting in under-estimation of the relative hypo metabolism in AD and 
MCI subjects as  compare to normal subject(Yakushev et al., 2009). Moreover, such 
normalization also shows some hyper metabolism in the AD and MCI subjects in cerebral 
regions that are least affected in AD, including the cerebellum, brainstem, basal ganglia, and 
sensorimotor cortex (Herholz et al., 2002).Thus, PET-FDG image normalization remains an issue, 
although some works suggest that in order to improve the discrimination between the group, 
one should use the single intensity in these using least affected regions for normalization rather 
than the cerebral global mean value(Borghammer, Aanerud, & Gjedde, 2009,Yakushev, 2009). 
Our approach differs from VOI’s selection approach; we used dynamic data which allow 
applying decomposition of the images into Principal components and Independent 
components. We used the time courses of these components as features to classify subjects. 
We deal with the normalization problem by transforming the PCA and ICA images in percent 
change using the original data. This is very new in the domain of Alzheimer, normal and MCI 
discrimination using PET images as ICA is mainly used for fMRI images to analyze dynamic 
imaging. 
The main approach of our study was to develop a machine learning automated 
classification method. We employed two different classification techniques i.e. Support vector 
machines (SVM) and Artificial neural networks (ANN). We used biomarker AV-45 alongside 18-
FDG for the classification of AD patients from MCI and controls. Their image datasets were in 
detail explored with principal component analysis (PCA) & independent component analysis 
(ICA) statistical methods. 
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To the best of our knowledge, this is the first study which has taken in to account the 
SVM & ICA based classification of pet images using AV-45. We also focused on for two or three 
different data sets by using feature extraction in a group and also feature extraction by each 
individual independently. We validated the statistical significance of the classifier by doing 
permutation testing. We assessed the robustness of the classifiers against imperfect learning 
set i.e. when some subjects are taken as controls while they are AD and inversely when some 
others are considered as AD while they are controls. Using group ICA for feature extraction 
looks so promising that some of its components allowed us to discriminate the AD from normal 
subject with the classification rate of 100%. This is the first study which can discriminate the AD 
with other with 100% accuracy. The result of permutation testing allowed us to validate the 
performance of our classifier. 
In this study we divided the dissertation in two parts, in the first part each chapter describes 
the different fundamental aspects of the brain, positron emission tomography, a brief 
introduction of alzheimer’s disease and the role of different imaging modalities and some basic 
classification techniques and algorithms used in this work. In the second part, we divided 
different experiments and their results in four different studies. The first study is classification. 
The aim of this study is to discriminate the AD subjects from other subjects like MCI and normal   
by using SVM and ANN algorithms.  In study 2, we validate the robustness of the classification 
using imperfect training. The main aim of this study is to see the performance of our 
classificatory on permuted data. In study 3, we discuss the results when another test data set is 
introduced to a classifier trained on one data set. Study 4 contains the results of spatial 
interpretation of ICA .In the discussion section, we will explore our method and to compare it to 
other methods in literature. 
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1. THE ANATOMY OF HUMAN BRAIN 
The human nervous system controls the body’s movement by receiving and transmitting 
information in the form of electrical and chemical signals which are further responsible of all 
cognitive abilities such as memory , emotions etc. It is made up of two parts, peripheral nervous 
system (PNS) and central nervous system (CNS). The CNS consists of brain and spinal cord 
where as PNS consists of all the nerves extending to and from the brain and spinal cord. The 
brain consists of very soft and delicate neural tissues protected by skin, skull and cerebrospinal 
fluid. 
1.1. The Brain 
The brain serves as a body’s information processing centre. It takes the information from 
the neuron (nerve cell bodies and their axons and dendrites) and sends it further to different 
body organs to react or move in some way. The major parts of the brain are cerebellum, 
cerebrum (cerebral hemispheres), brain stem as shown in Figure 1. 
: The four major 
divisions of  
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Figure 1: The four major divisions of Brain.               (http://www.edoctoronline.com) 
1.1.1. CEREBRUM 
It is the upper most part of the brain which actually contains 83% mass of the whole 
brain. It has pair of cerebral hemispheres separated by the longitudinal fissure. It is related with 
the functions of: the motor area, sensory area and associative area.  
The upper layer of these pair of hemispheres is made up of grey matter, called cerebral 
cortex. Under cerebral cortex there is a layer of white matter 1which is made up of nerve fiber 
called myelinated commissural nerve fibers. Nerve fibers (axons) are thin tissues that project 
from a nerve cell and transfer the electrical impulse to and from the brain. These fibers further 
connect with the pair of hemispheres via thick layer of white matter called corpus callosum. 
Others fibers like association fibers binds different regions of hemispheres. Myelinated fibers 
form a thick fan shaped band called internal capsule.  
In every individual, the function of each cerebral hemisphere is not the same. In some 
persons left hemispheres can be dominant and in some may be right side. The dominant 
hemisphere controls analytical, mathematical and linguistic functions whereas non-dominant 
controls face recognition, auditory and emotional aspects. 
1.1.1.1. LOBES OF THE CEREBRAL CORTEX 
The cerebral hemispheres are divided into four lobes as shown in Figure 2. (1) Frontal, (2) 
Parietal, (3) Temporal, (4) occipital 
 Frontal lobe 
It is the largest part of the four lobes. The most important structure in frontal lobe is the 
precentral gyrus which contains the motor cortex responsible of the motion of the body. Any 
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injury on precentral gyrus region may result in paralysis on the half of the body. The other most 
important structure in inferior frontal lobe is Broca region, which is responsible for the speech. 
 
Figure 2: Lobes of the cerebral hemispheres. 
(Reference source: http://bio1152.nicerweb.com/Locked/media/ch49/brain-lobes.html) 
 Parietal Lobe 
It is a part of the brain which is superior to the occipital lobe posterior to the frontal lobe. 
This lobe can be divided into three major parts, the post central gyrus, the inferior parietal 
lobule and posterior parietal lobule.  
The parietal lobe combines sensory inputs from different parts of body, mainly determining 
spatial sense. It includes somatosensory cortex and the dorsal stream f the visual system. This 
allows the sections of the parietal cortex to map the objects perceived visually into body 
coordinate positions. Many parts of the parietal lobe are also responsible for language 
processing and taste.  
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 Temporal lobe 
The temporal lobe is a part of the cerebral cortex that is positioned under the lateral fissure 
on both cerebral hemispheres of the brain. The temporal lobes are involved in the maintenance 
of visual memories, processing sensory input, understanding of language, stockage of memories 
and emotions. The temporal lobe contains the hippocampus that contributes an important role 
in explicit long-term memory storage. Therefore injury to this area can leads in impairment in 
new memory formation leading to permanent or temporary amnesia. 
 Occipital lobe 
It is located at the back side of the brain. It contains the primary visual cortex. 
Retinal sensors send stimuli to the lateral geniculate bodies. The visual cortex receives basic 
sensory information from the same sided external half part of the retina and from the inside 
half of the retina on the other side of the head. The lingula receives information from the 
contra lateral inferior retina representing the superior visual field. The inputs pass through the 
thalamus before projecting to the cortex .Any injury to the visual cortex of the occipital lobe 
can leads a person with partial or complete blindness. 
1.1.2. CEREBELLUM 
The cerebellum is often called “little brain”. It plays a significant role in motor control. It 
is the most concerned part with coordination of voluntary motor function when any 
information is received from the cerebral hemispheres. The cerebellum does not initiate 
movement by itself, but it contributes to coordination, precision in movement and accurate 
timing. 
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It may also contribute in some cognitive functions such as language , fear regulation, 
pleasure responses and attention (Wolf, Rapoport, & Schweizer, 2009)but it is mostly related to 
movement-related functions. Any injury to the cerebellum does not cause paralysis, but it may 
produce movement disorder, disturbed posture or bad motor learning.  Fine EJ, Ionita CC, Lohr 
L (2002). 
1.1.3. BRAIN STEM 
The brainstem is the posterior part of the brain which is made up of all unpaired 
structures adjoining the cerebrum with the spinal cord as in Figure 1. The upper structures in 
the brainstem are often collectively referred to as the diencephalon. The structures are 
epithalamus, hypothalamus, the thalamus and the sub thalamus. The epithalamus is mainly 
represented as the pineal gland which synthesizes melatonin and enzymes sensitive to daylight. 
The thalamus is regarded as the key for the understanding of the central nervous system. It is 
involved in the distribution of sensory and motor signals to specific regions of the cerebral 
cortex. The hypothalamus lies under the thalamus. It controls major endocrine functions by 
secreting hormones that induce smooth muscle of digestive system, contractions of the 
reproductive system and excretory systems. Right under the diencephalon is the midbrain and 
beneath the mid brain are the Pons and medulla oblongata/hindbrain. (Figure 1) 
The midbrain is a part of the central nervous system associated with vision, hearing, 
motor control, temperature regulation and alertness. It contains the nuclear complex of the 
oculomotor nerve as well as the trochlear nucleas; these cranial nerves innervate (or activate) 
muscles that move the eye and control the shape of the lens and diameter of the pupil. 
The Pons is a structure located on the brain stem.  It is above the medulla, under the midbrain, 
and anterior to the cerebellum. This white matter includes path that conduct signals from 
the cerebrum  to the cerebellum and medulla, and the path that carry the sensory signals up 
into the thalamus. The size of the Pons is about 2.5 cm or 1 inch in length. It is made up of two 
pairs of thick stalks called cerebellar peduncles. They attach the cerebellum to the Pons and 
midbrain. The Pons contains nuclei that communicate signals from the forebrain to the 
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cerebellum, along with nuclei that deal with sleep, respiration, facial expressions, facial 
sensation, bladder control, swallowing, equilibrium, taste, hearing, eye movement, and 
posture. The medulla oblongata/medulla is the lower half of the brainstem. The medulla 
contains the cardiac, respiratory, vomiting and vasomotor centers and deals with autonomic, 
involuntary functions, such as breathing, heart rate and blood pressure. 
1.2. Brodmann Areas 
A Brodmann area is a region of the cerebral cortex  based on its structure and organization 
of cells. The German anatomist Korbinian Brodmann (1868-1918) firstly defined and numbered 
the Brodmann areas based on the cytoarchitectural organization of neurons. He observed the 
organization of the neuron in the cerebral cortex using the Nissl stain. In 1909 Brodmann 
published his maps of cortical areas of many species including human brain as shown in (Figure 
3). He also explains many other observations and findings regarding the general cell types. He 
found that the same Brodmann area number in different species does not necessarily indicate 
homologous areas. 
Brodmann areas have been refined, discussed and renamed for years but it remains the 
most important and cited cytoarchitectural organization of the human cortex. Mostly defined 
Brodmann areas are based on their neuronal organization; it has since been correlated closely 
to diverse cortical functions. For example, Brodmann areas 1, 2 and 3 are the primary 
somatosensory cortex; area 4 is the primary motor cortex; area 17 is the primary visual cortex; 
and areas 41 and 42 correspond closely to primary auditory cortex. Higher order functions of 
the association cortical areas are also consistently localized to the same Brodmann areas 
by functional imaging, and other methods (e.g., the consistent localization of Broca's speech 
and language area to the left Brodmann areas 44 and 45). However, functional imaging can only 
identify the approximate localization of brain activations in terms of Brodmann areas. Since 
their actual boundaries in any individual brain require its histological examination. 
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Figure 3 shows the Brodmann Areas 
Reference: Le Grand Larousse du Cerveau 2010 
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2. POSITRON EMISSION TOMOGRAPHY 
The parallel advancement in the fields of physics and neurophysiology has led to the 
relatively recent emergence of brain imaging techniques. The emergence of new brain imaging 
techniques and methodology has enabled the doctors and researchers to observe the inside 
brain functions at different point of time without dissection.  
There are two types of medical imaging, the anatomical imaging and functional imaging. 
The anatomical imaging allows us to observe not only the brain structures but also the 
abnormalities in the brain such as tumors, clotting etc. It is done by anatomical MRI. Functional 
imaging done by PET, fMRI, EEG etc., can observe brain activity during the execution of a task or 
at rest. It can be used in basic research for the better comprehension of the role of various 
brain structures. 
A little introduction to neurophysiological mechanisms will be presented first before 
addressing the physical principles of positron emission tomography (PET). 
2.1. Neurophysiological Mechanism 
The principle of brain imaging techniques has Neurophysiological bases. It provides us the 
cerebral metabolic information. Brain consists of neurons which are made up of dendrites, 
Soma (cell body), axon and the terminal as shown in Figure 4. 
Each neuron transmits information to other neuron by emitting neurotransmitters from 
axon terminal. These neurotransmitters are received by the receptors on other neuron 
dendrites. These activities are fast for a millisecond. All these activities need energy input in 
from of adenosine triphosphate (ATP). This ATP consumption by nerve cells leads to form more 
ATP by the degradation of oxygen and glucose, non-storable energy substrates in the nerve cell 
(metabolic activity). The oxygen and glucose to the neurons being brought by the bloodstream, 
the creation of new molecules of ATP causes increased local blood flow (hemodynamic activity). 
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Therefore, an increase in regional blood flow is reflecting the increased neuronal activity and a 
decrease in regional blood flow indicates the decrease in neuronal activity. 
For a better comprehension of the origin of imaging signals, knowledge of the 
mechanisms is important. While the molecular events taking place for small fractions of second, 
the hemodynamic events that are detectable with a delay (of the order of a few seconds) and 
provided that the cellular activity is sustained quite a long time. 
 
Figure 4  shows the neurophysiological Bases of Functional Cerebral Imaging. 
(Hyder F et al., 2004) 
For a PET study, a neurotransmitter is produced and then labeled with a radioactive 
agent produced in a cyclotron. Radionuclides used in PET imaging are short half-life isotopes 
which are further labeled with glucose, water, ammonia or other molecules that bind to 
receptors. These are called radiotracers. Some common isotopes are shown in Table 1. 
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Isotopes  Names   Half life 
(min) 
Energy Range(mm) 
(      ( KeV)                    (rms) 
11C Carbon-11          20.4          960               0.69 
15O Oxygen-15                 2.1    1720              1.44 
18F Flourine-18              109.8     640               0.38 
Table 1 Physical Properties Of Some Common Isotopes Used In PET Scanning. 
2.2. Principle of PET 
Positron emission tomography (PET) is a nuclear medicine imaging technique which not 
only provide three-dimensional images but also enables us to observe the regional brain 
function in non-invasive and quantitative manner. While conducting a Pet study, a positron 
emitting radionuclide (tracer) labeled with biologically active molecule is introduced into the 
body which further distributes into the body according to its uptake, metabolism and excretion 
characteristics. It emits the pair of gamma rays. The system detects these emitted gamma rays 
and constructs a three-dimensional image of the tracer concentration by computer analysis. 
This technique enables Pet imaging an in-vivo analog which plays an overwhelming role in 
providing information about cerebral function with high sensitivity which in complementary to 
the anatomical information provided by other structural imaging tools such as magnetic 
resonance imaging (MRI) or x-ray compute tomography (CT). 
2.3. Emission Of Positrons 
An intravenous injection of radioisotope (mostly 15O or 18F), labeled with biologically 
active molecule, is introduced into human body. At any given time, the radioisotope will decay, 
emitting a positron and a neutrino. It is also known as positive beta decay. 
              Eq 1 
Where ρ is proton, n is neutron, β+ is positron and ѵe is neutrino. 
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Figure 5 Emission of gamma rays photons “ϒ” and annihilation. A production of two 511KeV 
gamma rays which are emit at an angular separation of 180o.                                                 
Reference: http://depts.washington.edu/nucmed/IRL/pet_intro/intro_src/section2.html 
Neutrino leaves the body without interacting hence remained undetectable whereas 
positron further loses energy in collision with other electrons in the tissue (typically less 
than2mm) and within a very short distance annihilates with one of these electrons. This results 
in annihilation of electron and positron which transformed into two gamma rays photons of 
energy 511 KeV in two opposite directions as shown in Figure 5. These photons have high 
probability to escape the body due to their high energy hence can be detected by the scanners. 
2.4. Detection of Photons 
After the localization of event, the pair of gamma rays photons emitted by the same 
process of annihilation should be detected. The detectors which are used in PET scanners are 
based on scintillators, a clear, dense and crystalline material, which is coupled with 
photomultipliers tube. 
When these gamma rays photons interact with a scintillator crystal, some of the 
deposited energy converts into light. The light produced during this interaction is not powerful 
enough to be used /detected. To convert a weak light into a strong measurable signal, 
photomultiplier tube is used. Light striking the photocathode of tube produces electrons which 
are accelerated by applying a strong electric field through many multiplying stages to the 
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output. Approximately 106 electrons are generated at the output photomultiplier, results in 
producing a powerful signal which is easily detected as shown in Figure 6. 
 
Figure 6 shows basic positron emission tomography (PET) detector. 
Reference: www.google.com 
To advance the efficiency of the photomultiplier tube, strongly reflective materials such 
as magnesium oxide or barium sulfate are used surround the faces of the crystal not touching 
with photomultipliers.  
Each detector of a PET scanner is connected to a coincidence circuit, and for each 
detected photon ϒ, a temporal pulse is associated, there is a coincidence when the pulses occur 
at the same time as shown in Figure 7. 
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Figure 7 Principle of coincidence detection in PET camera.                                                      
Reference: http://depts.washington.edu/nucmed/IRL/pet_intro/intro_src/section2.html 
 
2.5. Types of Coincidence Events 
Before approaching the detector, photons interacts with the subject's body and not be 
detected at the same time. In other way, two photons detected simultaneously do not 
necessarily belong to a pair of photons emitted by a single annihilation process. The 
coincidence events in PET are of three types as shown in  
 
Figure 8.  
True coincidence 
Soon after any annihilation event, when two gamma rays photons arrived at the 
detectors in coincidence, no photon further face any interaction  or any other form of event 
before detection. 
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Scattered coincidence 
When two or at least one gamma rays photon changed its direction prior to the 
detection under Compton scattering process, the resulting coincidence will be having wrong 
line of response. Such events are called Scattered Coincidences. Many techniques for the 
scatter correction have been implemented(A. R. Bergstrom, 1983)(Wienhard et al., 1992), 
(Spinks et al., 1992). This correction is important in 3- dimensional PET studies. 
Random Coincidence 
Random coincidence occurs when two photons from different annihilation events are 
occurred on the detectors within the coincidence time window. These events are measured and 
subtracted in new PET cameras by using a delayed coincidence window technique(E. J. 
Hoffman, Huang, Phelps, & Kuhl, 1981). 
 
 
 
 
 
 
Figure 8Three types of coincidence events are detected by PET scanner. 
2.6. Attenuation 
The loss of detection of true coincidences due to their scattering or absorption of the 
photons in the tissue out of the detector field of view is called attenuation. It may cause image 
noise, image artifact or even image distortion. Mostly the gamma ray attenuation is due to 
511 KeV 
True 
coincidence 
300 KeV 
Scattered 
coincidence 
511 KeV 
Random coincidence 
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tissue. The gamma rays which emits from the upper side of the brain reach to the detector 
easily as they have to less travel between the tissues as compare to the rays which emits from 
inside the brain. So the gamma ray coming from center is more attenuated. On the average, 
only one in five gamma ray pairs emitted from the center will make it out of the head without 
being lost to the attenuation. To correct this effect of attenuation it is necessary to know, for 
each pair of detectors, the percentage of photons attenuated along the line of response. No 
doubt that all detection lines do not have the same distance to travel through the brain.  
At the start of the PET scan, we compare the attenuation of an external source when 
the subject is present or absent, thereby to establish an attenuation factor for each LOR. This 
factor is then applied to the number of coincidences recorded and corrected for scattered and 
random events. The principle of measuring attenuation coefficient is shown in Figure 9. 
The first way to measure the attenuation correction factor in PET is to use an external 
positron-emitting source(Phelps, Hoffman, & Terpogossian, 1975)(Ranger, Thompson, & Evans, 
1989; Thompson, Ranger, & Evans, 1989). On the other hand attenuation correction can be 
measured based on the contour of the head (M. Bergstrom, Litton, Eriksson, Bohm, & 
Blomqvist, 1982; Siegel & Dahlbom, 1992)and the known attenuation coefficients of brain 
tissue and skull at 511KeV. 
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Figure 9 Principle of measuring the attenuation coefficients in PET (left) and image of these 
coefficients (right).  
Reference: www.google.com 
 
2.7. Reconstruction and Treatment of Images 
The complexity of the reconstruction of PET images is due to the fact that the events 
detected by a couple of detectors may have occurred at any place of detection line. These 
numbers of events are the sum of all of positrons annihilations which have a line of detection. It 
is said that this sum is the projection of the positron density distribution along the line. To find 
the number of annihilations that have taken place in each point, several mathematical methods 
can be used, knowing that a given point in the brain spends several lines of annihilation. 
The final stage of reconstruction is to convert the number of annihilation at each point 
in the brain to a activity concentration. At the end of the reconstruction process, we obtain a 
series of contiguous slices of the brain that contain the value of concentration areas emitting 
positron.
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1. PRESENTATION OF ALZHEIMERS DISEASE 
Alzheimer's disease is a neurodegenerative disease (progressive loss of neurons) 
untreatable brain tissue that can further progress and can do irreversible loss of mental 
functions, including memory. This is the common form of dementia in humans. It was first 
described by German physician AloisAlzheimer1906 (Berchtold & Cotman, 1998). 
The exact causes of Alzheimer's disease are not exactly known. Alzheimer's disease is 
multifactorial and involves several different mechanisms. The sporadic form of the disease is 
the most common and accounts for over 90-95% of the cases. It may occur spontaneously, with 
no known cause, and usually after the age of 65, from which the risk of occurrence increases 
from year to year. A second form of AD, much rarer form is the so-called "family." Constituting 
less than 1 % of cases, it has a specific genetic origin. It generally affects younger people, and 
shows a complete penetrance. (Tanzi and Bertram , 2005).  
To simplify, the term "Alzheimer's disease” will refer in this manuscript to the sporadic 
form of the disease. However, there are known risk factors: some genetic anomalies, factors of 
cardiovascular risk or intoxication by certain heavy metals. The first symptom is often a loss of 
memory (amnesia), starts with small distractions which further progress with the passage of 
time. Earliest memories are still relatively preserved. Neurological involvement extends 
thereafter the associative cortex frontal and temporo-parietal, leading to further cognitive 
impairment (confusion, irritability, aggression, mood and emotions, executive functions and 
language) and the loss of long-term memory. Destruction of neurons continues until the loss of 
autonomic functions and death. 
1.1. Clinical Aspect of Alzheimer’s Disease 
The first complaint typically reported by patients with AD is a disorder of memory, 
especially episodic memory. This type of long-term memory, originally described by Endel 
Tulving, refers to the memory of personally experienced events, made part of their temporal 
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and spatial context of acquisition, and is associated with autonoetic consciousness (Tulving, 
2002).These early problems in AD mainly affect the memory of recent events, while the oldest 
events are preserved. With the time cognitive impairment will continue. 
Memory disorders become worsen progressively and are accompanied by other disorders 
which affect various areas of cognition: disorders order phasic, praxis, gnostic. Other areas may 
also be affected in some patients, such as attentional and executive functions. (Binetti et al., 
1996; Greene et al., 1995; Rizzo et al., 2000a).These cognitive deficits are usually accompanied 
with behavioral psycho: will occur thymic changes (apathy, irritability), the visual disturbances 
(visual-perceptual visuospatial), and behavioral disorders (agitation, disinhibition). There may 
also be disturbances of sleep and appetite disorders. These disorders are often assessed by 
clinicians using the questionnaire NPI (Neuro-Psychiatric Inventory), which relates to both the 
frequency of disorders, their severity, and their impact on daily life. (Cummings et al.,1994). 
Cognitive decline described will gradually lead to a loss of autonomy. However, the 
progression of neuropsychological disorders changes over time but also vary from one patient 
to another. Some patients may have different stages shorter or longer with little change in 
clinical conditions while others get worse faster. In more advanced stages, the patient will lose 
all ability to communicate and become mute. There are several clinical stages of disease 
progression. We define a first period in the early stage symptoms called "pre-dementia" or 
stage "prodromal". It consists of patients with mild memory impairment, the subjects in the 
early stages of AD (Petersen, 2004). The next stage after prodromal stage is called dementia 
where the other cognitive areas and the daily routine /autonomy of the patient are affected. 
Mild cognitive impairment (MCI) is a syndrome which is characterized as a cognitive 
impairment which is more than which is expected from a healthy and educated elder and less 
than to be considered as dementia. This stage is a transition/ intermediate stage between 
normal aging and dementia. Contrary from dementia, in which patients have a substantial 
cognitive decline, MCI patients do suffer with subtle difficulties which do not affect their normal 
daily routine life notably. However mild cognitive impairment (MCI) patients are at risk to 
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convert to dementia, especially AD. In early 80’s clinical dementia rating (CDR) (Hughes CP et 
al., 1982) and the global deterioration scale for ageing and dementia (GDS) (DSM-III) were 
developed for the clinical staging system and till date these systems are being used in clinics for 
the assessment of normal aging and dementia. The values of CDR vary from healthy controls 
(CDR 0) to mild impairment CDR (0.5) to dementia (CDR 1). In Reisberg B et al., 1982 and Flicker 
C et al., 1997 the term mild cognitive impairment was introduced with 3rd stage of GDS. There 
are total 7 stages in which 1- 4 deals with MCI. In Stage 1, individual is considered as clinically 
healthy elder. In stage 2, individual may face some subjective cognitive impairment such as 
difficulties in recalling names. Individuals at GDS stage 3 suffers with mild cognitive and 
executive functioning impairment. At stage 4 individuals have notable cognition and functioning 
impairment with affects their daily life, hence meets the criteria for mild dementia. Some 
longitudinal studies considering MCI individuals have shown a prevalence in elderly individuals 
between 3-19%, with an incidence of 8–58/1000/yr, and a risk to progress to dementia is 11–
33% over 24 months( Ritchie K et al.,2004).  On the other hand, it is reported that 44% of mild 
cognitive impairment patients at their first visit were become normal after 12 months (Ganguli 
Met al., 2004; Ritchie K et al., 2004) .These study shows that there are many factors which are 
responsible of cognitive impairment in older individuals other than neurodegenerative disorder 
such as genetic, educational, hormonal or by the use of some drugs. By taking into account 
these factors we can understand why sometimes mild cognitive impairment is reversible. The 
relationship of amyloid deposition and the presence of neurofibrillary tangle in mild cognitive 
impairment is not been explored widely. The presence of neurofibrillary tangles in the mesial 
temporal structures does correlate with mild cognitive impairment (Morris JC., 2001; Mitchell 
TW., 2002). By doing the comparison of MCI with normal and AD subjects, it is reported that 
MCI subjects have intermediate amounts of Alzheimer’s disease pathological findings identified 
by silver stain (Bennett DA et al., 2005) with amyloid deposition and tau-positive tangles 
(Mufson JC et al., 1999) in the mesial temporal lobes. Mutations in apolipoprotein E alleles also 
increase the risk of MCI to progress to AD (Petersen RC., 1995; Petersen RC., 2005; Aggarwal 
NT., 2005). 
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 Dementia phases can be divided into “mild”, “moderate” and “severe” conditions, on the 
basis of cognitive impairment. Usually, clinicians use the neuropsychological test score Mini-
Mental State Examination (MMSE) of Folstein (trial evaluating the overall efficiency of 30 
points) for the boundaries between these three stages: a score between 18 and 24 is generally 
at a stage of mild dementia, between 10 and 18 at a stage of moderate dementia and finally a 
score below 10 is a severe dementia (Folstein et al., 1975). 
To characterize the AD, symptoms study is a good option but it is not sufficient. It is 
necessary to take into account some additional parameters because the memory disorder is not 
only the result of the AD, but it is also found in other neurological diseases such as vascular 
dementia, encephalitis, dementia with Lewy bodies etc. All this makes it more difficult for the 
clinical diagnosis of AD and requires some additional tools. 
1.2. Mechanism of pathology 
In Alzheimer's disease, the patient's brain suffered a double process of degeneration 
and inflammation. It is characterized by two types of lesions, each caused by a buildup of 
protein resulting in a malfunction of the cell. The Different Progressions in these two types of 
atrophies involved in more global brain atrophy. These two types of lesions are1) 
extracellularly, the accumulation of β-amyloid peptide causes amyloid plaques.2) Intracellularly, 
the accumulation of tau protein called neurofibrillary tangles. Figure 10 
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Figure 10shows the example of normal brain (left side) and Alzheimer’s brain (right 
side).Reference:http://www.interet-general.info/article.php3?id_article=13241 
β Amyloid Plaque: 
It corresponds to the extracellular buildup of beta-amyloid (Aβ), which results from the 
two divisions of the amyloid precursor protein (APP) by secretase. This protein is the result of 
an abnormal cleavage by beta-secretase and gamma-secretase. (Figure 11) 
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Figure 11 shows the diagram which represents the APP protein by three types of secretase. 
Reference (Sisodia et al., 2002) 
Amyloid plaques are largely involved in neurodegenerative diseases, Alzheimer's disease 
etc. In AD, the primarily development of plaques are mostly in the areas responsible for 
memory and other cognitive functions. The deposits of beta-amyloid are insoluble (cannot be 
dissolved). The accumulation of amyloid plaques in AD occurs primarily in the neocortex. The 
progress of amyloid plaques can also be divided into different stages. In the work of Thal et al., 
2002, there are five possible stages:  
Stage 1: Extensive accumulation in the neocortex, Stage 2: arrive at innermost regions 
such as the entorhinal cortex, amygdala, insula, anterior cingulate cortex , Stage 3: after that 
more advanced clinical stage where subcortical nuclei are affected, such as the striatum , 
thalamus and hypothalamus, followed by other brainstem nuclei (Stage 4) and finally the 
cerebellum ( stage 5).  
 
 43 
 
Neurofibrillary Tangles 
In 1980s, many scientists revealed that the protein which is responsible for the 
accumulation of neurofibrillary tangles (NFTs) was the microtubule-associated protein, tau 
(Iqbal et al., 1986, Koshik et al., 1986, Wood et al., 1986)  
 
Figure 12. NFTs are composed of filamentous tau polymers that consist of a portion of 
the fibrillar pathologies in Alzheimer’s disease (AD)—the other elements being the neuropil 
threads and the dystrophic neurites that occupy a subset of amyloid plaques (neuritic plaques) 
(Goedert.M et al., 1998). These types of brain regions control different cognitive function which 
suffers during the process of AD, the density of tau is positively correlated with global and 
regional aspects of cognitive impairment and decline (Arriagada .P.V, 1992, Ghoshal.N., 2002, 
Mitchell.T.W, 2002).It is assumed that the tau pathology is harmful as it occurs in the cell 
bodies. It has been discovered that there is an involvement of tau in many forms of 
frontotemporal dementia (FTD)(Spillantini et al., 1998), strongly recommended that the 
accumulation of tau into filaments which further results in a toxic gain of function much like 
that hypothesized for Aβ accumulation in AD. In vitro data obtained using mutated tau 
(Gamblin et al., 2000, Nacharaju et al.,1999) and specific tau isoforms (King et al.,2000) in 
assembly paradigms hold up with this proposition.  
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Figure 12shows the example of a healthy neuron 
and an affected neuron clearly showing the 
presence of neurofibrillary tangles associated with 
microtubules. 
Reference: http://www.neur-one.fr 
 
 
 
The presence of NFTs begins in the temporal cortex (temporal pole cortex, inferior 
temporal) (Delacourte et al., 1999). The increase in NFTs will follow a spatio-temporal pattern 
characteristic in the cortex, which seems to explain the development of clinical symptoms. So 
far, only NFTs have clearly shown correlated with the clinical manifestations (Arriagada et al, 
1992. Bierer et al., 1995). According to initial pathological studies of Braak and Braak, NFTs 
shows a characteristic distribution pattern which allows dividing it into six stages. The first and 
second stages were characterized by either mild or severe changes of the transentorhinal layer 
Pre-α (transentorhinal stages 1 and 2). The two typesof limbic stages (stages 3 and stage 4) 
were distinct by a conspicuous affection of layer Pre-(x in both transentorhinal region and 
proper entorhinal cortex. The hallmark of these two isocortical stages (stages 5 and 6) was the 
destruction of virtually all isocortical. These stages can be further summarized in three main 
stages:-transentorhinal, limbic and finally neocortical (Braak and Braak , 1991). 
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Cortical Atrophy 
Alzheimer's disease is due to loss of neurons and synapses in the cerebral cortex and 
certain sub cortical regions. This abnormal loss causes impairment in the regions, including the 
parietal lobe, part of frontal cortex and cingular gyrus. The brain can thus lose 8-10% of its 
weight every ten years, against 2% in a healthy subject. Cortical atrophy is accompanied by 
expansion of the cerebral ventricles and sulci as well as neuronal loss particularly affecting the 
cholinergic system (basal nucleus of Meynert, septum, entorhinal cortex, amygdala and 
hippocampus). Studies using MRI and PET scans have noticed a reduction in some regions in AD 
subjects when patient progress from MCI to AD and comparison of old healthy subjects 
(Desikan et al., 2009). 
1.3. Brain Imaging in Alzheimer disease 
The ambiguity in the clinical diagnosis of AD has motivated a search for different 
diagnostic imaging markers. A confirm diagnosis still requires histopathological evidence. Earlier 
CT scans and then MRI imaging were used as a replacement to avoid the surgical processes. But 
nowadays, position emission tomography (PET) is playing an important role in identifying 
characteristic patterns functional of and structural brain impairment. With the help of amyloid 
imaging, we can also see the molecular pathology of the disease amyloid deposit. Imaging is not 
only helpful for the detection al Alzheimer’s disease but it also contributes an important part in 
differential diagnosis by identifying the changes or/and contributory pathologies. It also 
become pivotal to identify the vascular and other degenerative pathologies and also 
contributed in the identification of the prevalence of mixed pathology in dementia. In mild 
cognitive impairment (MCI), the determination of primary pathology carries immediate 
prognostic importance. A recent study shows that the patients with MCI are at greater risk to 
progress to clinical AD with rate of progression is over 10–15% per year (Petersen RC et al., 
2010). The clinical research diagnosis of MCI due to AD is mostly based on core clinical criteria 
used in almost all clinical settings without any need of high specified tests and the clinical 
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research criteria with the use of biomarkers. Normalized thickness index-based criteria may 
also help with early detection of Alzheimer's disease at the single subject level, particularly for 
educated individuals, up to 2 years before clinical criteria for Alzheimer's disease diagnosis are 
applicable (Querbes O., 2009). Obviously, it will be very important to predict about any MCI 
subject which have to progress to the AD. It is a little difficult now because of the unavailability 
of disease-modifying treatments, but will be obligatory when these treatments will be available. 
Nowadays brain Imaging has proved that there is a preclinical and presymptomatic period 
where the pathological effects of alzheimer’s disease are visible. 
Some of them directly diagnose the pathology of AD, including positron emission 
tomography (PET), amyloid imaging and cerebrospinal fluid (CSF) beta amyloid (Aβ) 42 while 
other biomarkers projects neuronal injury associated with AD, including CSF tau , 
fluorodeoxyglucose (FDG)-PET and MRI imaging. Many studies have compared the predicted 
value of two or more biomarkers at a time but their result were inconsistent (Forsberg A et al., 
2008; Jack CR et al., 2009; Landau SM et al., 2010). Alzheimer's disease (AD) is defined 
histologically by the presence of extracellular β-amyloid (Aβ) plaques and intraneuronal 
neurofibrillary tangles in the cerebral cortex. The diagnosis of dementia, along with the 
prediction of who will develop dementia, has been assisted by magnetic resonance imaging 
(MRI) and positron emission tomography (PET) by using different radiotracers which are being 
used commercially such as 11C ,18F etc.  
1.3.1. Magnetic Resonance Imaging (MRI) in 
Alzheimer’s disease 
MRI follows the principle that due to the angular momentum of the protons, it polarized 
in a magnetic field. So a pulse of radiofrequency changes the energy state of protons and in the 
absence of the pulse, the proton will come to its original energy state by emitting a 
radiofrequency signal. By combining different gradients and pulses in MRI, many sequences are 
designed according to tissues characteristic. Structural MRI in Alzheimer’s disease can be 
separated into assessing the impairment and alteration/change in tissue characteristics which 
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cause the signal changes on certain sequences such as white matter hyperintensities on T2-
weighted MRI as a result of vascular damage.  
Magnetic resonance imaging (MRI) is very helpful in visualizing the progressive brain 
atrophy (T1-weighted sequences; Figure 13) which is the key feature of neurodegeneration. 
Many MRI research on regional (e.g., hippocampal) volumes demonstrates that these are 
directly correlated to neuronal counts at autopsy (Jack et al., 2002, Gosche et al., 2002).  
 
Figure 13 shows that from left to right are the series of T1 images, acquired annually, by magnetic 
resonance imaging (MRI). There is progressive hippocampal atrophy and an enlargement of the 
ventricles over time. The arrows point the hippocampus. The patient progressed from some memory 
complaints (t=0) to MCI (t=1y) to AD (t=2y). From (Keith A johnson et al., 2012). 
AD is characterized by an inevitable progression of cerebral impairment which first 
appears in the medial temporal lobe, MTL (Scahill et al. 2002). This evolution of cerebral 
atrophy on MRI results in providing stages for the increase of neurofibrillary tangles (Braak and 
Braak 1991).The entorhinal cortex is normally the primary part of atrophy, afterwards it is 
hippocampus, parahippocampus and amygdala (Dickerson et al. 2001, Killiany et al. 2002,Chan 
et al. 2001). MRI provides us the acquisition a good tissue contrast and resolution, even less 
than millimeter. Also to assess the important of the atrophy visual analysis scales were created, 
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to establish the degree of severity of atrophy. These scales provide a great help, make the 
decision fast and simple in clinical practice. In clinical routine, they remain a useful tool for 
imaging. In different diseases, the pattern of loss is different showing the selective neuronal 
weakness and regional disease expression. 
 
 
 
 
 
Many methods of manual segmentation of medial temporal structures have been 
developed to measure the volumes very precisely (Frisoni et al., 2008; Pruessner et al., 2002; 
Pruessner et al., 2000). Some studies also show interest in volume by manual segmentation to 
assess the temporal atrophy in Alzheimer’s disease. (Jack et al., 1999). 
Assessment of medial temporal atrophy has also shown a positive result is predicting 
the value of AD. With the help of visual assessment, the specificity and sensitivity for the 
differentiation of AD from normal aging is 80-85%. (Scheltens et al.,1992; Burton et al., 
2009).The most important and difficult thing is to predict that which MCI subject will progress 
to AD disease or will remain stable. For this purpose, medial temporal atrophy on MRI is 
Figure 14 shows the coronal manual segmentation 
of medial temporal regions. 
A=Amygdale ; HC=Hippocampes 
Reference : Insausti et al., 1998 
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capable of differentiating (with the specificity and sensitivity of 50-70%) the patients who will 
progress from MCI to AD and who will not (Decarlie et al., 2007; Korf et al., 2004).To measure 
the temporal atrophy looks a good helping tool for characterizing the AD during the early stages 
(Querbes et al., 2009; Xu et al., 2000; Chupin et al., 2009a). Some longitudinal studies even 
suggest that medial temporal atrophy is able to predict clinical degeneration (Desikan et al., 
2008; DeToledo-Morrell et al., 2004).  
Voxel-based morphometry is another approach used for the differentiation between 
different groups of AD and normal subjects. With this technique, it was found a temporal 
atrophy (Karas et al., 2003, Frisoni et al., 2002, Good et al., 2002), undergoing a progressive 
change from the middle cerebral regions, like hippocampus and entorhinal cortex, up to the 
inferior-lateral regions. Moreover, several studies have showed that atrophy affect firstly the 
parietal regions (posterior cingulate gyrus and precuneus) in the early stages which move to 
other temporo-parietal regions (DeCarli et al., 2000) then frontal regions (Baron et al, 2001. 
Scahill et al., 2002) and finally the occipital lobes (Thompson et al, 2003).Usually the cerebral 
atrophy develops bilaterally, but in literature it seems to affect more the left hemisphere (Janke 
et al., 2001; Scahill et al., 2002;Thompson et al., 2003). An individual who is mildly affected by 
Alzheimer’s disease (who have MMSE score between 24-30), has already a decrease in 
hippocampus volume of about 15-25% and up to 20-30% decrease in the entorhinal volume 
(Chan et al.,2001; Schuff et al.,2009). 
Diffusion-weighted imaging has been also used to characterize AD. The diffusion tensor 
is a multidimensional parameter that characterizes the directionality of the diffusion of water 
molecules in an anisotropic medium such as the fibers in the white matter of the brain. The 
diffusion tensor imaging (DTI) is a type of imaging to study the diffusivity of networks of nerve 
fibers, through special factors, such as the fraction anisotropy (FA) and mean diffusivity (MD), 
reduced in the presence of obstacles such as fiber membranes. Studies of AD in DTI show 
decreased FA and an average increase in the coefficient of diffusivity of patients with the 
disease, especially in the corpus callosum, the cingulum, also the temporal and prefrontal lobes 
(Teipel et al., 2012; Oishi et al., 2011; Takahashi et al., 2002). 
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Another non-invasive technique for measuring the brain activity is functional magnetic 
resonance imaging (fMRI). It is able to measure the brain activity with high spatial precision 
during any cognitive task or at rest. It is based on the BOLD signal "blood-oxygen level-
dependent", which reflects the variations in the amount of oxygen carried by hemoglobin, 
variation in blood flow and blood volume (Logothetis et al., 2001). Earlier the studied which 
have been done with fMRI were mostly focused on medial temporal lobe and hippocampus. In 
literature for fMRI studies, there is a decrease in hippocampal activity during the encoding of 
new information (Rombouts et al., 2000; Gron et al., 2002; Golby et al., 2005). Many fMRI 
studies also reported a decline in medial temporal lobe (MTL) activity in MCI subjects 
(Machulda et al., 2003; Petrella et al., 2006; small et al., 1999). Some other studies have shown 
that during tasks there is an increase of activity in different cerebral regions such as frontal, 
parietal and hippocampus (Celone et al., 2006; Pariente et al., 2005; Dickerson.,2004).  
Recently the approach based on BOLD fMRI technique to measure the brain activity and 
the correlation between different cerebral regions during resting state was applied to explore 
the default mode network dysfunction in AD. Echo planar imaging of the default mode 
networks (DMN) has potential to be a sensitive marker for preclinical AD patho-physiology. 
These default networks may be particularly affected by the neurodegenerative process of AD 
(Buckner et al., 2008). With this, several groups have reported both reduced resting-state 
connectivity (Buckner et al., 2005) and alterations in fMRI task-induced deactivation responses 
in mild cognitive impairment (MCI) (Rombouts et al., 2005) and AD patients (Buckner and 
Vincent, 2007, Lustig et al., 2003, Persson et al., 2008, Rombouts et al., 2005, Sorg et al., 
2007 and Wang et al., 2006, 2007) compared to healthy controls. 
In another study it is suggested that resting fMRI may be more readily applied to 
patients who are clinically at risk as compare to task fMRI (Fleisher et al.,2009). The resting-
state DMN analysis demonstrated nine regions in the prefrontal, orbital frontal, temporal and 
parietal lobes that distinguished two risk groups 
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One advantage to resting-state fMRI is that it is not dependent on differential task 
performance such as memory encoding, which is of particular concern when studying 
neurodegenerative processes and evaluating disease modifying therapies for prevention and 
treatment of dementia. Imaging of the resting state avoids performance related variability seen 
in activation fMRI and may be more effective at identifying functional pathology associated 
with AD risk compared to non-resting fMRI techniques.. 
1.3.2. Positron emission tomography (pet) in 
Alzheimer’s disease 
The analysis of cerebral metabolism also helps for the detection of Alzheimer’s disease. 
Fluorodeoxyglucose (18F) commonly abbreviated as 18F-DG or FDG is a radiopharmaceutical 
used in the medical imaging modality positron emission tomography (PET).It is known that the 
brain mainly uses glucose for energy production. Labeling glucose with [18Fluorine] allows 
quantitative (or semi-quantitative) measurement of the local metabolism of the synaptic 
terminals in their neuron-astrocyte functional unit, as the greater part of glucose utilization 
happens at the synaptic level. Reference grey matter cerebral metabolic rate for glucose 
(CMRglc) values ranges from about 40 to 60 mmol glucose/100 g of brain tissue/ 1 min. at rest 
in a normal adult; in the white matter it is about 1/3 to 1/4 as compared to the grey matter. 
The highest values are found in the basal ganglia, the thalami and the occipital polar and mesial 
cortex, while the medial temporal cortex and the cerebellum show the lowest values. 
FDG-PET has proved itself as a robust biomarker for brain impairment and dysfunction 
in AD and neurodegeneration with which hypometabolism and hyper metabolism can be 
observed which are further used to predict the rate of cognitive decline in the subjects which 
are later transformed in AD. Cognitively normal individuals with one or two APoEε4 alleles 
already have reduced CMRgl in some of the regions affected by AD (Langbaum et al.,2009). A 
single study of a small group of MCI patients (Drzezga et al.,2005) has demonstrated complete 
separation of those that rapidly converted to AD and those remaining stable ,sing a 
combination of reduced CMRgl in AD-typical regions and APoEε4 status. FDG hypometabolism 
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also predict that rate of memory decline in APOE ε4 carriers with mild memory impairment 
over 24 months.  
  
Figure 15 shows the images of a normal 
subject and Alzheimer’s disease subject. The 
transaxial FDG-PET images show the 
hypometabolism in parietal, lateral temporal, 
precuneus and in medial temporal lobes. 
Reference:   keith A Johnson.,2012 
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Many studies have concentrated on the spatial relationship between metabolic activity and 
cerebral impairment. Hypometabolism predominates atrophy in many brain regions such as 
posterior cingulate, orbitofrontal regions and inferior temporo-parietal, suggesting the 
variation of a functional network (Chetelat et al., 2008). However, other structures such as the 
hippocampus show a degree of hypometabolism similar to atrophy. In some longitudinal 
studies it has been shown that in AD, amyloid accumulation in different cerebral regions has 
plateaued (Engler et al., 2006; Jack et al., 2009), but FDG decrease with cognitive function 
(Engler et al., 2006). Many studies have noticed high amyloid accumulation in parietal regions 
which can be related with the localization of FDG hypometabolism which reflects a local toxicity 
(Edison et al., 2007; Engler et al., 2006; Cohen et al., 2009). More and more longitudinal data 
will be needed for the better understanding of these relations, but one thing is clear that FDG 
metabolism change as amyloid accumulates. It is possible that FDG data can specify an 
intermediate stage between the start of the disease and the development of synaptic failure 
and neurodegeneration (Cohen, et al., 2009). 
Numerous studies in positron emission tomography (PET) have been conducted to 
reveal the presence of amyloid plaques. Many markers have been developed which are specific 
for amyloid. Some markers are currently under consideration and some are already used in 
research. These markers have potential for the identification of Amyloid plaque. So far, the 
marker most commonly used in research is Florbetapir AV-45, 11C-Pittsburgh Compound-B 
(PiB) that seems to effectively discriminate AD patients from healthy subjects.The only 
drawback of PiB in research is its short half life: as radioactive carbon compound, its half-life is 
about 20min. So it is only useful in the imaging centers which are capable of synthesizing it. To 
overcome this drawback, other markers were developed using fluorine as a radioactive base, 
whose half-life is much longer than the PiB (about 110min). So many other fluorine compounds 
in vivo markers of amyloid protein are being studied, including fluorinated analogues of PiB. 
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Florbetapir, 18F-AV-45,is one of the markers used as a diagnostic tool for the early 
detection of Alzheimer's disease. It fixes to beta-amyloid, its long life span allowed the tracer to 
fix more in the AD brains, particularly in the regions which are related with beta-amyloid 
deposits. Like other biomarkers, 18F-AV-45 (Florbetapir) also has strong affinity for amyloid 
proteins in AD brain homogenates (ki 10±3.3 M) and more fast in vivo kinetics (Choi SR.,2009). 
In amyloid imaging, the use of Florbetapir has been validated in an autopsy study (Clark CM et 
al.,2011) and it allows to use it in different clinical applications in brain imaging (Lin KJ et 
al.,2010). In 2012, Camus and his team conducted a study by comparing 16 AD with 16 healthy 
control subjects. They found that Florbetapir (AV-45) binds to amyloid proteins which make it 
able to differentiate AD patients from healthy control subjects. The kinetics of AV-45 allow to 
have as less as 10 minutes image sessions (50 to 60 min or 60-70min after injection) (Wong DF 
et al.,2010).An increased uptake of AV-45 is observed in the posterior cingulate region in MCI 
subjects as compared to control subjects (Camus V et al.,2012). 
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Z  
Figure 16 shows thecoronal, sagittal and axial(A) florbetapir-negative images of a normal subject, (B) a 
MCI patient, (C) florbetapir-positive images of a MCI patient (D) an AD patient. 
Reference: Camus V et al., 2012 
In 2011, a multicenter study done at 31 United States research centers, they considered 
82 normal, 62 Alzheimer Disease and 62 MCI patients. They concluded that both, quantification 
show high sensitivity and specificity for differentiation AD patients from MCI patients and 
elderly healthy control subjects (Fleisher AS et al.,2011). These results lead to the conclusions 
that Florbetapir (AV-45) is a helpful biomarker for differentiating AD and MCI subjects from 
normal subjects. 
For amyloid imaging, the very common marker is 11C -Pittsburgh Compound- B ( PiB ) , 
carbon compound which is widely established and evaluated for discriminating AD subjects 
from healthy subjects (Klunk et al., 2004; Rowe et al., 2010) shown in Figure 17. In AD patients 
the fixation pattern of PiB typically found in frontal lobe, precuneus and posterior cingulate. 
The association between amyloid plaque and fixation of PiB was confirmed by pathological 
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studies. PiB specifically fix into fibrillar Aβ plaques in the patients (Driscoll et al., 2012; Kadir et 
al., 2011). 
 
Figure 17 shows the pattern of fixation of PiB in control subject and in AD subject. 
Reference: Klunk et al., 2004 
 
Some studies who focused on the early stages of the alzheimer’s disease have shown 
correlations between PiB uptake and cortical atrophy, especially in the regions which are more 
sensitive to degeneration ,such as the temporal and parietal lobes ( Frisoni et al., 2009 ; Tosun 
et al., 2011) . These results do not hold for the last stages of the disease.  
Most studies which have used PiB and AV-45 as imaging markers, found some important 
fixation of these markers also in healthy control subjects. Approximately 30% of healthy 
individuals have increased uptake of amyloid marker in different regions than the rest of the 
healthy groups (Doraiswamy et al., 2012; Rowe et al., 2010) , Sometimes these fixations are 
similar to the levels  of patients ( Hatashita and Yamasaki., 2010, Wong et al., 2010) and in same 
regions (Aizenstein et al., 2008) . This problem raised the question either these markers are for 
amyloid plaque or it can mark other forms too? Some studies in PiB suggest that (Johnson et al., 
2007; Bacskai et al., 2007) these markers would also have fixation in the vascular amyloid, 
found around the cerebral vessels in amyloid angiopathy. In a recent article, it is also reported 
that about 81%of healthy individuals showing a PiB marked higher amyloid burden  will see this  
burden increase in 2 ½ years (Vlassenko et al., 2011).  
Some longitudinal studies have found the relationship between the cognitive evolution 
of control individual and their amyloid burden. In one study it is showed that the control 
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subjectsAV45 - positive, representing 14% of the control group, showed a more pronounced 
cognitive decline than the AV45 - negative control subjects over a period of 18 months                    
(Doraiswamy et al., 2012). Similarly it is also reported that among the 31% of PiB - positive 
controls, 16% will be diagnosed with MCI or AD in 20 months and 25% within three years                      
(Villemagne et al., 2011). A positive correlation is reported between retention of PiB in the 
inferior temporal lobe and the degree of atrophy of the hippocampus (Bourgeat et al., 2010). 
By considering all the results it can be suggested that the amyloid markers would help in 
determining the early process of deposition of amyloid which can predict and help in early 
detection of AD. But this is still at the assumptions, and requires further investigation. 
1.4. Diagnosis of Alzheimer disease 
Till date it is not possible to diagnose the Alzheimer’s disease but clinicians can diagnose 
probable AD, based on the combined analysis of several factors. At every stage of the disease 
the analysis can be made to do the exact prediction. The diagnosis of AD is difficult when it 
relies only on the clinical data. It is quite important to optimize the diagnostic criteria’s based 
specifically on the clinical data and equally paraclinical involvement. Moreover, people 
diagnosed with these criteria have arrived in dementia stage of the disease. But it is necessary 
to detect the presence of the disease as soon as possible. The medical and scientific 
communities are doing their best to improve the early diagnosis of AD and develop therapeutic 
research. Recent advances in the use of markers demonstrating in vivo the presence of AD has 
stimulated the development new criteria  which conceptualize the diagnostic around a specific 
pattern, combining the clinical evaluation of cognitive changes in structural and biological 
evidence. 
In 1984, Mckhann and team proposed criteria for dementia of the AD type (Described in 
DSM-IV, see Card 1), (Mckhann et al., 1984, see Card 2). These criteria were based on the 
clinical and neuropsychological evaluation. This criteria was adopted by many studies by giving 
the sensitivity of 83% to 98% (Kazee et al., 1993; Lim et al, 1999) And the specificity of 70% 
(Kazee et al, 1993) and in one study the specificity was about 23% only (Varma et al, 1999). 
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Mckhann and team revised their diagnostic criteria for probable AD (see Card 3) in order to 
clarify certain aspects (Mckhann et al., 2011). In their revised version, they mainly focused on 
the exclusion criteria for different neurological syndromes other than AD found in different 
studies as sharing common features with it. 
There is no proper agreement for the criteria of MCI. Generally MCI are the individuals 
who have cognitive impairment but not as severe to be consider as dementia. In 2004, Petersen 
defines the diagnostic criteria for MCI (Petersen RC, 2004). 
 
 
 
 
 
 
 
The development of neuroimaging and biomarkers in vivo gave rise to early diagnostic 
criteria, combining clinical, biological markers, and imaging. In 2007, Dubois and colleagues 
present diagnostic criteria (see Card 4) for AD, based on a multimodal assessment, which will be 
applicable to the prodromal stage (Dubois et al., 2007).If for the moment we put aside the 
genetic forms of the disease, these criteria show the association of many other modalities 
which are added to the clinic in order to increase the diagnostic accuracy. A longitudinal study 
confirms the importance and relevance of the neuropsychological assessment, showing that 
verbal memory tests can discriminate among MCI patients who will progress to AD at a 
Diagnostic criteria for MCI 
Peterson RC., 2004 
These criteria were as follows: 
1. Memory complaint, preferably corroborated by an informant. 
2. Objective memory impairment for age 
3. Relatively preserved general cognition for age 
4. Essentially intact activities of daily life 
5. Not demented 
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dementia stage within 3 years, those who remain stable (71% sensitivity and 92% specificity) 
(Sarazin et al., 2007). 
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Card 1 
Diagnostic Criteria for Dementia of the Alzheimer’s Type  
(DSM-VI)* 
 
 
A. The development of multiple cognitive deficits manifested by both 
a. memory impairment (impaired ability to learn new information or to recall 
previously learned information) 
b. one (or more) of the following cognitive disturbances: 
i. aphasia (language disturbance) 
ii. apraxia (impaired ability to carry out motor activities despite intact motor 
function) 
iii. agnosia (failure to recognize or identify objects despite intact sensory 
function) 
iv. disturbance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting) 
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in 
social or occupational functioning and represent a significant decline from a 
previous level of functioning. 
C. The course is characterized by gradual onset and continuing cognitive decline 
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following: 
a. other central nervous system conditions that cause progressive deficits in 
memory and cognition (e.g., cerebrovascular disease, Parkinson's disease, 
Huntington's disease, subdural hematoma, normal-pressure hydrocephalus, brain 
tumor) 
b. systemic conditions that are known to cause dementia (e.g.,hypothyroidism, 
vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcemia, neurosyphilis, 
HIV infection) 
c. substance-induced conditions 
E. The deficits do not occur exclusively during the course of a delirium. 
F. The disturbance is not better accounted for by another Axis I disorder (e.g., Major 
Depressive Disorder, Schizophrenia). 
 
*Diagnostic and statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) 
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Card 2 
Diagnostic Criteria of Probable AD 
(Mckhann et al., 1984) 
 
A. The criteria for the clinical diagnosis of PROBABLE Alzheimer’s disease include: 
a. dementia established by clinical examination and documented by the Mini-Mental Test, 
Blessed Dementia Scale, or some similar examination, and confirmed by neuropsychological 
tests: 
b. deficits in two or more areas of cognition: 
c. progressive worsening of memory and other cognitive functions; 
d. no disturbance of consciousness; 
e. onset between ages 40 and 90, most often after age 65: and 
f. Absence of systemic disorders or other brain diseases that in and of themselves could account 
for the progressive deficits in memory and cognition. 
 
B. The diagnosis of PROBABLE Alzheimer’s disease is supported by: 
a. progressive deterioration of specific cognitive functions such as 
b. language (aphasia), motor skills (apraxia), and perception (agnosia); 
c. impaired activities of daily living and altered patterns of behavior; 
d. family history of similar disorders, particularly if confirmed neuropathologically 
e. laboratory results of: 
1. normal lumbar puncture as evaluated by standard techniques, 
2. Normal pattern or nonspecific changes in EEG. such as increased slow-wave 
activity,  
3.  Evidence of cerebral atrophy on CT with progression documented by serial 
observation. 
 
C. Other clinical features consistent with the diagnosis of PROBABLE Alzheimer’s disease, after 
exclusion of causes of dementia other than Alzheimer’s disease, include:  
a. plateaus in the course of progression ofthe illness: 
b.  Associated symptoms of depression, insomnia, incontinence, delusions, illusions, 
hallucinations, catastrophic verbal. emotional, or physical outbursts, sexual disorders, and 
weight loss:  
c. other neurologic abnormalities in some patients, especially with more advanced disease and 
including motor signs such as increased muscle tone, myoclonus, or gait disorder; 
d.  seizures in advanced disease,  
e. CT normal for age. 
 
D. Features that make the diagnosis of PROBABLE Alzheimer’s disease uncertain or unlikely include: 
a. sudden, apoplectic onset; 
b. focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, and in 
coordination early in the course of the illness 
c. Seizures or gait disturbances at the onset or very early in the course of the illness. 
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Card 3 
Diagnostic Criteria of Probable AD 
(Mckhann et al.,2011) 
 
 
Probable AD dementia is diagnosed when the patient meets the criteria for dementia described in 
(Mckhann et al., 2011) and in addition, has the following characteristics 
 
A. Insidious onset. Symptoms have a gradual onset over months to years, not sudden over hours or 
days; 
B. Clear-cut history of worsening of cognition by report or observation; 
C. The initial and most prominent cognitive deficits are evident on history and examination in one of 
the following categories. 
 
a. Amnestic presentation: It is the most common syndromic presentation of AD dementia. 
The deficits should include impairment in learning and recall of recently learned 
information. There should also be evidence of cognitive dysfunction in at least one other 
cognitive domain, as defined earlier in the text. 
b. Non-amnestic presentations: 
i. Language presentation: The most prominent deficits are in word-finding, but 
deficits in other cognitive domains should be present. 
ii. Visuospatial presentation: The most prominent deficits are in spatial cognition, 
including object agnosia, impaired face recognition, simultanagnosia, and alexia. 
Deficits in other cognitive domains should be present.  
iii. Executive dysfunction: The most prominent deficits are impaired reasoning, 
judgment, and problem solving. Deficits in other cognitive domains should be 
present. 
 
D. The diagnosis of probable AD dementia should not be applied when there is evidence of  
 
a. Substantial concomitant cerebrovascular disease, defined by a history of a stroke 
temporally related to the onset or worsening of cognitive impairment; the presence of 
multiple or extensive infarcts severe white matter hyper intensity burden; 
b. Core features of Dementia with Lewy bodies other than dementia itself  
c. Prominent features of behavioral variant frontotemporal dementia;  
d. Prominent features of semantic variant primary progressive aphasia or 
nonfluent/agrammatic variant primary progressive aphasia;  
e. Evidence for another concurrent, active neurological disease, or a non-neurological 
medical comorbidity or use of medication that could have a substantial effect on cognition. 
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Card 4 
Diagnostic Criteria of AD 
(Dubois et al.,2007) 
 
Probable AD: A plus one or more supportive features B, C, D, or E 
 Core diagnostic criteria 
A.Presence of an early and significant episodic memory impairment that includes the following features: 
1. Gradual and progressive change in memory function reported by patients or informants over more than 6 
months. 
2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall 
deficit that does not improve significantly or does not normalize with cueing or recognition testing and after 
effective encoding of information has been previously controlled. 
3. The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of 
AD or as AD advances. 
 
 Supportive features 
B. Presence of medial temporal lobe atrophy 
 Volume loss of hippocampe, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using 
visual scoring (referenced to well characterize population with age norms) or quantitative volumetry of 
regions of interest (referenced to well characterized population with age norms). 
C. Abnormal cerebrospinal fluid biomarker 
 Low amyloid β1–42 concentrations, increased total tau concentrations, or increased phospho-tau 
concentrations, or combinations of the three. 
 Other well validated markers to be discovered in the future. 
D. Specific pattern on functional neuroimaging with PET 
 Reduced glucose metabolism in bilateral temporal parietal regions. 
 Other well validated ligands, including those that foreseeably will emerge such as Pittsburg compound B or 
FDDNP. 
E. Proven AD autosomal dominant mutation within the immediate family. 
 
 Exclusion criteria 
History 
 Sudden onset 
 Early occurrence of the following symptoms: gait disturbances, seizures, behavioral changes 
Clinical features 
 Focal neurological features including hemiparesis, sensory loss, visual field deficits 
 Early extrapyramidal signs  
Other medical disorders severe enough to account for memory and related symptoms 
 Non-AD dementia 
 Major depression 
 Cerebrovascular disease 
 Toxic and metabolic abnormalities, all of which may require specific investigations 
 MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are consistent with infectious or 
vascular insults 
 
 Criteria for definite AD 
AD is considered definite if the following are present: 
 Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the NIA-
Reagan criteria for the post-mortem diagnosis of AD; criteria must both be present. 
 Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; criteria must both be 
present 
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1. MACHINE LEARNING 
Machine learning is a branch of artificial intelligence which involves the design of 
algorithms. Such algorithms can train to make intelligent decisions based on their recognition of 
complex patterns. The algorithms are applied in many fields including medical diagnosis, 
handwriting recognition and stock market analysis. There are many approaches to machine 
learning such as clustering, support vector machine (SVM), artificial neural networking, decision 
tree learning etc. In this study we used support vector machine and artificial neural network 
(ANN) as algorithms for the image based classification. Classification is basically determining a 
decision function, by considering the features values and predicts the class. Feature is a general 
term used in machine learning to be the set of attributes describing a certain example. To get 
the decision function, we must divide our data into training set and test set. Training the 
classifier means to create a relationship between the features and the class label by assigning a 
weight  to each feature. This weight corresponds to the relative contribution of the feature to 
successfully classify into two or more classes. 
1.1. The Support Vector Machine 
A two-class support vector machine (SVM) classifier aims to construct a hyper plane that 
maximizes the margin, the distance between the closest points on either side of the boundary. 
These points are known as the support vectors. Vapnik and Lerner, (1963) developed the 
original SVM algorithm. It was a linear classifier, but there have been many modifications 
afterwards to deal with data that are not linearly separable. A soft-margin formulation, which 
allows for mislabeled data, has been proposed byCortes & Vapnik (1995), as well as a way to 
use the kernel trick to create nonlinear classifiers (Boser et al, 1992). 
 In Dukart et al, 2013, the authors built a classifier which was based on SVM to 
discriminate AD dementia from Frontal temporal lobe degeneration. They used multimodality 
imaging and volume of interest extracted from FDG-PET and MRI from ADNI cohort (28 AD 
patients and 28 healthy control subjects) and the MPI (cohort)(21 AD patients and 13 healthy 
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control subjects). By combining both modalities, they found the discrimination accuracy of 88% 
for ADNI and 100% for MPI.  When they trained their classifier with ADNI data and did the test 
with MPI data they obtained an interesting result: up to 91% of accuracy. Rik Vandenberghea, 
2013 from the University of Leuven, Belgium, applied a leave-one-out cross validation 
technique to test SVM-based classifiers with (18)F-Flutemetamol PET and volumetric MRI 
imaging data of  27 probable AD, 20 aMCI and 25 healthy controls. They obtained 100% of 
accuracy in discrimination when they took into account the voxels with highest feature weights, 
those being in the striatum, precuneus, cingulate and middle frontal gyrus. Overall sensitivity of 
the classifiers on PET and MRI data were in both cases identical (85.2%), albeit with discordant 
classification in three cases. Specificity for PET data was 92% compared to 68% for MRI data. 
Chaves et al , 2012 from the University of Granada, Spain, arrived at building an SVM-based 
classifier in order to improve the diagnosis of AD when dealing with SPECT and PET imaging 
data. The performance of classifier was evaluated by using k-fold cross-validation technique. 
They found the yielding accuracy92.78%,, sensitivity 91.07% and specificity 95.12% (for SPECT 
data) and for PET data it was 90.67%, 88.01% and 93.33%  respectively.  Regions of Interest 
(ROIs) were selected by means of a t-test carried out on 3D normalized Mean Square Error 
(NMSE) features. The dimension of the resulting feature space was further reduced by Large 
Margin Nearest Neighbors (LMNN) and Partial Least Squares (PLS).Abdi et al., (2012)from the 
University of Texas, USA, introduced multiblock barycentric discriminant analysis (MUBADA). 
This technique integrates multiple regions of interest (ROIs) obtained with SPECT or PET 
modalities in order to analyze the functional brain images of cerebral blood flow or 
metabolism. They included total 104 patients including frontotemporal dementia (FTD), 
Alzheimer's disease (AD) and elderly normal controls. 28 ROIs (59,845 voxels) were selected for 
the analysis of brain images for clinical relevance. By using MUBADA they resulted in having 
two factors explaining 74% and 26% of the total variance: Factor 1 isolated FTD, and Factor 2 
isolated AD. They identified the ROIs that best discriminated groups: for example ROIs 
separating FTD were middle temporal gyri, left inferior, bilateral inferior and middle frontal. 
Also the ROIs separating AD were middle temporal gyri, middle frontal, bilateral thalamus, 
inferior parietal gyrus, inferior temporal gyrus and left precuneus. 
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 Daoqiang Zhang, 2012, from the University of North Carolina, USA, built a multi-kernel 
SVM with a sparse linear regression model. This model was designed for the early prediction of 
cerebral changes for mild cognitive impairment (MCI) patients. These changes included 
qualitative change (i.e., conversion to Alzheimer's disease (AD)) and quantitative change (i.e., 
cognitive scores) at 5 different time spans. For this study they used MRI, FDG PET imaging data 
and for clinical scores MMSE and ADAS-Cog, corresponding to 88 ADNI MCI subjects.  They 
report their regression system delivered good performance to predict the clinical scores at 24 
months by using the multimodality data at previous time points. They also concluded that by 
using multimodality data, the transformation of MCI subject to AD are at a time point which are 
at least 6-month in advance of the conversion. In Padilla et al., 2012, from the University of 
Granada, Spain, a computer-aided diagnosis (CAD) tool used to classify SPECT and PET 
functional imaging data corresponding to AD patients and healthy control subjects. Their CAD 
tool is a classifier based on an SVM with bounds of confidence for decision. For feature 
extraction, they used Fisher discriminant ratio (FDR) and nonnegative matrix factorization 
(NMF) techniques. They obtained the classification accuracy up to 91% of with high sensitivity 
and specificity up to 90%. 
Linear SVM 
In linear SVM, if we have two classes then main aim to estimate the decision boundary 
or design a hyperplane which maximize the margin and linearly separates the two classes. ( 
Figure 18). Each class in an input vector                  having M number of features 
(i.e.,   in  ) and is belong to one of the two classes             . In case of PET studies, 
the input vectors xi have the average time of the acquisition and features can be set of voxels 
extracted during each time point;        indicates the condition A and        indicates 
condition B. 
Let us suppose that our data is linearly separable. It means we can draw a straight line  
on a graph of the feature     and the feature     dividing  the two classes when      and 
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a hyperplane on graphs of                    when    , the SVM produces the 
discriminant function f with the largest possible margin: 
          Eq 2 
Wis the weight of hyperplane, b is bias and it translates the hyperplane away from the origin of 
the feature space, and · is the inner product: 
   = ∑          
   Eq 3 
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(a) 
 
(b) 
Figure 18shows the example of linear support vector machine.(a) shows the hard margin 
where two classes are easily separable and there is no training error(b) allowed the soft 
margin where we found some training errors. f(x) are the support vectors. 
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 Soft Margin 
Sometimes the data is not linearly separable. To improve the classifier performance and 
allow some errors slack variables      , for all            , is used: 
                    ,     Eq 4 
for all                    
When      , for all               (i.e., (7)), the hard margin is the distance between two 
classes when there is no training error.          means that the training errors should be 
between the hyperplane and the margin. Whereas       permits some training errors. In this 
case the margin is classified as soft margin. 
Non- linear SVM 
Non linear support vector machines are used when linear SVM is unable to separate the 
data linearly. So the vectors are mapped into higher dimensional feature space by using a 
function g(x). In this case, the decision function will base on the hyperplane: 
        ∑                   
 
   Eq 5 
A kernel trick can be applied on equation 5 which depends on the dot product of two vectors. It 
permits a nonlinear operator, written as a linear one in a space higher dimension. Generally, 
the dot product is replaced by a kernel function                       which does not need 
to be explicitly computed reducing the optimization problem to the linear case: 
     ∑   
 
      (    )    Eq 6 
In support vector machine models, many kinds of kernels can be used. The most 
common kernel types are polynomial kernels and radial basis functions (RBFs).The polynomial 
kernels is defined as  
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            Eq 7 
Where  and  are important for the decision boundary curvature. 
Figure 19 shows the decision boundary with two different values of         . We 
note that the case with     and     is a linear kernel. Radial basis function (RBF) kernel is 
defined by 
                                                  
        
|    |
 
   
 Eq 8 
Where  is a hyper parameter.  
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(a) 
 
(b) 
Figure 19 Decision boundary with polynomial kernel   2(a) and   4    and    . 
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Optimization Problem 
The aim of support vector machine is to construct a model which predicts output values 
of the data instances in the testing set which are given only the attributes. According to Chin-
Wei Hsu et al, Given a training set of instance-label pair (    ) ,          where     
  and 
           SVM need the solution of the case: 
                                                          
 
 
     ∑   
 
   Eq 9 
Subject to       
                           
C>0 is the penalty parameter of the error term. Furthermore,                
       is 
called kernel function. 
1.2. The Artificial Neural Network 
The artificial neural network information process is, in some extends, inspired by the 
normal human brain. It acts like a information processing system which have numerous 
processing neurons strongly interconnected. All the processing neurons acts together, receiving 
the information from input, do some processing to produce the output. In many studies, for the 
analysis of medical images, numerous algorithms using artificial neural network (ANN) have 
been used. The application of neural networks in computer-aided diagnosis shows the 
importance of computational intelligence in medical imaging (Mhd. Saeed Sharif, et al., 2012), 
(Gutierrez-Celaya et al., 2011); (Sahiner, Chan, & Hadjiiski, 2006),(Qian, Zhukov, Song, & 
Tockman, 2007);(Scott, 2004).  
Many research studies have been carried out in the medical field using ANN for medical 
image segmentation and classification with different medical imaging modalities. In (Mhd. 
Saeed Sharif, et al., 2012), the authors used ANN for tumor detection, classification, and 
quantification in positron emission tomography (PET) imaging at early stage. They used ANN in 
the wavelet domain with different training procedure and found the Levenberg-Marquardt 
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back propagation training algorithm as the best training approach. In (Jayasurya et al., 2010), 
the authors compared the models of Bayesian network and support vector machine to predict 
two-year survival of lung cancer patients treated with radiotherapy. They used PET images and 
found that BN models perform as well as SVM with the advantage that they are better at 
handling missing data than SVM models. The research described in (Bose et al., 2008) is more 
related to our work since this study is in the brain dysfunction domain, the main objective of 
the author was to find out whether the application of ANN could provide the better result in 
classification of the images, and to improve the specificity and sensitivity of [18F] DOPA as a 
potential diagnostic test for the patients of schizophrenia. The ANN model was able to provide 
the identification of 94% of the controls and 89% of the patients means that sensitivity was 89% 
and specificity was 94%.In (Gutte et al., 2007a), they tried to develop a automated method 
which was based on image processing techniques for [(18)F] Fluorodeoxyglucose (FDG) positron 
emission tomography (PET) and computed tomography (CT) images for the diagnosis lung 
cancer and also try to determine their stages. These techniques included CT images for 
segmentation of the lungs and PET images for the detection of lesions. After CT images 
segmentation the lung boundaries were further taken into account for localization of lesions in 
the PET images in the feature extraction process. They used 8 features to train the ANN for the 
classification. The classifier performance measured as the area under the receiver operating 
characteristic curve, was 0.97 in the test group, with an accuracy of 92%. The sensitivity was 
86% at a specificity of 100%.In (Vesselle, Turcotte, Wiens, & Haynor, 2003), the authors 
proposed to train a back-propagation artificial neural network on a cohort of surgically proven 
non-small cell lung cancers (NSCLCs) and compare its accuracy with that of a trained (18)F-FDG 
PET reader. The artificial NN correctly predicted the N stage in 87.3% of the testing cases 
compared with 73.5% for the (18)F-FDG PET expert reader. Accuracy of the NN increased to 
94.8% (PET, 89.4%) when comparing N(0) + N(1) with N(2) or N(3) status and to 94.9% (PET, 
91.9%) when comparing N(0) + N(1) with N(2) + N(3) status. 
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Basic Structure Of Neural Networks 
(Jiang, Trundle, & Ren, 2010) 
The author explains the basic structure of a neuron as shown in Figure 20. Where          
          the inputs and Y are corresponds to the output of the structure. Every input x, is 
multiplied with their respective weight, w. Then this product ‘xw’ a bias b is associated with 
each neuron and their sum goes through a transfer function  as shown in figure 20. The 
association between input and output can be written as follows. 
    ∑     
 
          Eq 10 
 
 
Figure 20:The theoretically modeled structure of neuron.(Jiang, et al., 2010) 
There are many transfer functions which can be used to process the biased and 
weighted inputs. The four most common transfer functions are hard limit, linear , RBF and 
sigmoid are shown in Figure 21. 
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Figure 21:The four widely adopted transfer functions for medical image processing are (a) 
Hard limit, (b) Linear, (c) RBF,  (d) Sigmoid. (Jiang, et al., 2010). 
By choosing a transfer function and connection to neurons, a lot of neural networks can 
be made to be trained in order to produce specific output. In the case of medical image 
processing, the learning paradigms for neural networks generally include both types of learning. 
Supervised and unsupervised. In the earlier case, a single set of input and output are used to 
train a network. For each training dataset there will be a set of inputs and one or more 
associated output values. The main aim is to decrease the output error by adjusting the weight 
associated with each input along with weights and bias by using a specific training algorithm.  
The training set does not consist of any output information in the case of unsupervised 
learning. In this case a cost function is constructed to measure the accuracy of the network. 
This cost function uses the input and output values to produce the cost of network 
configuration. This main objective was unsupervised learning is to control the cost of inputs 
vectors in the training set. 
Feed-Back Network 
In feed-back network, by using loops the signal may travel to both directions. It can 
propagate values back to input layer from hidden and output layers. Their positions keep on 
changing their state until they arrive to an equilibrium point. If another input is introduced, 
they will again try to have equilibrium point. The feed-back networks are considered as a 
powerful tool but sometimes it become very difficult to apply.  
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A common type of feedback network is Hopfield network. It is designed as a way that it 
can perform as form of associative memory. The aim of associative memory is to converge to a 
state remembered from training when only part of the state is presented as an input. There is 
no specific input and output for Hopfield network. All the neurons can act as input as well as 
output. Each neuron is connected to every other neuron in either direction.  It receives the 
input at once from all the neurons, and output to each other till they found their equilibrium. 
These networks are very helpful for medical imaging applications. In case of brain tumors 
classification where the output value (either the tumour is malignant or benign) must be 
derived from partial or similar patterns to those seen during training. 
Radial Basis Function Networks 
It is a three-layer supervised feed-forward network. Normally radial based function 
networks (RBF) uses a linear transfer function for the output neurons and nonlinear transfer 
function for the hidden neurons. The RBF is applied to the input of single neuron to produce a 
radial function of the distance between each pattern vector and each hidden unit weight 
vector. 
RBF networks are very flexible with respect to their sizes. These networks are very 
suitable for many problems, used to a number of visual processing and analysis problems, 
analysis of 3D structures and time-series data. 
Feed-Forward Network 
It is the most common type among different other neural network used in medical 
imaging processing and its application. In this case the signal travels in one direction from the 
input layer to hidden layer to output layer. Each neuron is connected to the next neuron in next 
layer. The connections are of one direction which means every neuron is connected with the 
neuron in the next layer.  
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The back propagation (BP) supervised learning algorithm is used in feed forward 
networks to alter the weight, w, and bias, b, for each neuron. The BP algorithm works by 
changing the weight of neurons based on the error in the network's original output when it is 
compared to the target output. The real change of weights is done by using a gradient descent 
algorithm, where the weights alter after each training set in the network. 
A multilayer perceptron (MLP) is a type of feed-forward networks which use3 or more 
layers. In this case the transfer function is non linear in the hidden layer neurons. For non linear 
separable data, it correlates the training patterns with the outputs. These networks are useful 
for applications in medical imaging where the inputs and outputs are numerical and pairs of 
input/output vectors gives a clear basis for training in a supervised manner. 
1.3. Classifier Performance 
To measure the performance of the classifier, it is required to assess the applicability of a 
trained algorithm using independent test data, as well as for the optimization of parameters 
during training. The simplest performance metric is accuracy, the proportion of examples that 
are correctly labeled by the classifier. The technique of cross-validation may be used to assess 
the generalization performance of a classifier, as there is often no appropriate independent 
dataset available for testing. A cross-validation involves in dividing the data into two subsets, so 
that it may be trained using one and tested using the other. Results are generally reported as 
the average over multiple rounds in which different partitions of the data are used. 
Cross Validation 
The parameters of a classifier are optimized based on the training data. An independent 
test set is therefore required for making a reliable assessment of the applicability of the 
classifier to new data. Cross-validation provides a way to measure this generalization 
performance when no such test data are available. One commonly used method is k-fold cross-
validation, in which the data are randomly partitioned into k subsets. A single cross-validation 
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fold involves using       subsets for training the classifier, and the remaining data for testing. 
This process is repeated k times, such that each of the subsets is used once for testing, and the 
results are averaged over the folds. An alternative method for cross validation is called 
repeated random sampling, in which the dataset is randomly partitioned into training and test 
sets of fixed sizes. For example, a single round may involve randomly selecting 75% of the data 
for training, with the remaining 25% used for testing. This process can then be repeated, and 
the results averaged over the repetitions. Repeated random sampling has the advantage that 
the proportions of the training and test sets are not dependent on the number of repetitions. 
However, there may be some overlap between test sets, and the method also exhibits Monte 
Carlo variation. This means that the results will vary if the analysis is repeated using different 
partitions of the data. 
If two classes C1 and C2 are not of equal size, the training and test sets should be 
selected such that they contain examples from the two classes in approximately equal 
proportions to the full dataset. This is known as stratified cross-validation, and has been shown 
to produce results with a lower variance than regular cross-validation (Kohavi, 1995). Both the 
k-fold and repeated random sampling cross-validation methods generate a distribution of 
performance values which may be averaged across the folds or repetitions. The statistical 
significance of differences between the results of two classifiers may be assessed by performing 
unpaired t-tests between these distributions. In addition, permutation testing may be applied 
to assess whether the results of a classifier are significantly different from chance. Permutation 
testing involves performing cross-validation on data for which the diagnostic labels have been 
randomly permuted. This results in a distribution of classification results under the null 
hypothesis that the classifier cannot accurately predict the clinical labels from the data. 
Unpaired t-tests between the distribution of observed results and that obtained from 
permutation testing indicate whether the observed results are significantly different from 
chance. General definition of cross validation given by(Geisser, 1975)which is as follows. 
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Let     be an integer and   
   
    
   
 a series of non empty proper subsets of       . 
 is any measureable mapping,   is a given sample. The cross validation of the risk of       , 
with training sets (   
   
       is defined by 
 ̂  (        
         )  
 
 
∑  ̂      (       
   )Eq 11 
Leave one out cross validation (LOOCV) is procedure of cross-validation (Stone, 1974), 
(Geisser, 1975). It is a k fold CV where k is the number of instances in the data set. A rate 
estimation of LOOCV is considered to be unbiased. If we chose,       is left out of the 
data and used for validation then 
Keeping in mind the definition general cross validation, we can define LOO by 
 ̂          
 
 
∑           
                                                Eq 12 
Where  
            . 
 
Performance Metrics 
Machine-learning algorithms have some parameters which can change their 
performance and behavior. The evaluation of the model can be done by maximizing accuracy 
metric. Let us suppose a basic two-class classification problem, let true positives TP, 
representing correctly identified AD, and true negatives TN, representing correctly identified 
healthy controls. The number of examples incorrectly labeled by the classier may be divided 
into false positives FP, representing healthy controls incorrectly classified as AD, and false 
negatives FN, representing AD incorrectly classified as healthy controls. Then, a representation 
of classification performance can be formulated by a confusion matrix (contingency table), as 
illustrated in Figure 22. 
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For a classifier, there may be four types of outputs. If the subject is positive and it is 
classified as positive, it is considered as a true positive (TP); if the subject is positive and is 
classified as negative, it is considered as a false negative (FN). If the subject is negative and it is 
classified as negative, it is considered as a true negative (TN); if it is classified as positive, it is 
counted as a false positive (FP). The accuracy metric is defined as  
            
     
              
                                                  Eq 13 
The sensitivity and specificity are as follows 
Sensitivity = 
  
         
      Eq 14 
Specificity = 
   
     
      Eq 15 
These can provide the better assessment of the overall performance of the classifier. 
Figure 22 shows the Confusion matrix for performance evaluation. 
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2. FEATURE EXTRACTING TECHNIQUES 
In many disciplines such as support vector machines and neural network, the basic 
problem is to find out the suitable representation of multivariate data i.e. random vectors. The 
information or the measurements provided from different scientific modalities are often mixed 
up. A basic goal is to find the original signal or processes that give the information that is not 
clearly observed or measured from the original data. 
2.1. Principle Component Analysis 
Principal Component Analysis (PCA) is used to transform all the available correlated 
variables into less number of uncorrelated variables. The main advantage of this technique is 
that we can represent the data with just few parameters. These parameters are the orthogonal 
linear transformations of the original data. PCA is able to provide the internal structure of the 
data set which further helps in explaining the variance of the data. Eigenvectors and their 
respective eigenvalues find the dimensions by keeping the same variance as the original data 
set with a little bit error. The first principal component has the maximum variance; the second 
component has the second greatest variance and so on.  
Principal component analysis involves matrix algebra to minimise the dimensions of the 
data set. Covariance matrixes are used to obtain eigenvectors and their respective eigenvalues 
of the transformed data set by subtracting the mean from each dimension of the data. The 
eigenvectors which have the highest eigen values are selected to be treated as a feature 
vectors. The dimensions of the original data are reduced by multiplying the data with the 
feature vector. 
let suppose our data is in     matrix A 
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,  ̂                                             Eq 16 
where n are the observations and d are the variables. The data is centered in one frame and 
represented as  ̂. 
The principle component analysis is the linear combination: 
   ∑   
  
    ̂    
  ̂                                                 Eq 17 
Where   is and n dimensional weight vector.   is the first principle component  if the variance 
of the component is large. The first component is therefore found by using    that maximizes 
the variation of   . The criteria to maximize it is 
     
     
           Eq 18 
Under the constraint that norm is equal to 1.‖  ‖     
‖  ‖     
    
 
                                                                                   ⁄ Eq 19 
The     matrix    is estimated as  { ̂ ̂
 }  The solution of 1 is given by the eigenvectors of 
the covariance matrix    
  =                                                                  Eq 20 
Where               Therefore, by calculating eigen vectors and corresponding eigen values 
of the covariance matrix , the i’th principal component  can be expressed as  
     
  ̂                                                                     Eq 21 
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The reduction of data set can be achieved by using the first principal components: 
 ̂  ∑     
 
                                                     Eq 22 
The error is defined as the sum of eigen values for the eigen vectors. 
      ∑                                                             
 
     Eq 23 
Where  are m eigen values. 
2.2. Independent Component Analysis 
Independent component analysis (ICA) is the method of linear transformation of the data, 
such as factor analysis and principal component analysis (PCA). Independent component 
analysis (ICA) is capable of separating the components and sources mixed up in the observed 
data in many cases where the classical methods fail. ICA separates the original components or 
sources by some simple assumptions of their statistical properties. ICA uses the data which is 
having a non-Gaussian structure. It is essential for recovering the underlying components that 
created the data. This property makes ICA different from PCA. The basic function of ICA is 
represented in Figure 23. 
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Figure 23shows the basic function of ICA. 
Normally two random independent variables are correlated. But all uncorrelated random 
variables may not be always independent. An example of ICA can is shown in Figure 24 
 
Figure 24 shows the schematic representation of ICA. a) PCA identifies the orthogonal 
direction which shows the more variance (a second order statistic) where as ICA extracts the 
independent vectors by using higher order statistic. b)  the projection of PCA and ICA for a 
linear mixture of s1 and s2 and a plot of the two independent signals in a scatter-plot. PCA 
finds the orthogonal vectors but cannot identify the independent vectors. Whereas, ICA is 
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able to find the independent vectors of the linearly mixed signals and is thus able to restore 
the original sources.(Vince D. Calhoun, Liu, & Adalı, 2009). 
Basic Theory 
Let suppose we have the observed variables               and          
where,   is observed data index and   is the time index. The       isobserved signal obtained 
from any mean. We suppose they can be presented as a linear combinations of hidden 
variables              , with some unknown coefficients    , 
      ∑    
 
            Eq 24 
for all            . So we can see that we have variables               the mixing 
coefficients   and independent components      are to be estimated. This is called blind 
source separation. The basic idea is illustrated in Figure 25. 
 
Figure 25 illustrates the basic idea of ICA. (a) Shows the example of four observed signals (b) 
shows that ICA separated all the four mixed signals.(Hyvarinen, 2013). 
This ICA model can be explained in different ways. Typically,   
 
and    are the random 
variables. Moreover, the   
 
 are usually collected into a vector x of dimension n, the same is 
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done for the   and the coefficients    are collected into a mixing matrix A of size    . Then, 
the model becomes 
          Eq 25 
Where   and   are now random vectors, and   is a matrix of parameters. We can 
equally create a matrix notation where the observed       are collected into a     matrix  , 
with   giving the row index and t giving the column index, and likewise for       giving     
                                                                                   Eq 26 
Where     is the same matrix as it is in Eq 11. 
Structural Equation Modeling 
Let’s suppose    and     are observed random variables which are correlated. If we 
assume that the relationship between the two variables is in the form of a linear regression 
model, we are basically left with the following model selection problem. Choose between the 
following two models, Eq 13 & Eq 14: 
          Eq 27           Eq 28 
where    and    are regression coefficients. Now, if we consider Eq 27, we can say 
that    causes   , and if Eq 28 is the case, we can say that    causes   . The residuals    , 
    are supposed to be independent of the regressors    and    , respectively. 
if we suppose the variables    and    are standardized to unit variance, the regression  
coefficients are equal, i.e.     ; they are equal to the correlation coefficient 
between    and    . The variances of the residuals    ,   are thus also equal, and the models 
are completely symmetric with respect to     and    . There is no way of distinguishing 
between the two models.  
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However, if the data are non-Gaussian, then our situation is different. We can formulate 
the two models as ICA models, 
(  
  
)  (        
         
) (  
  
)Eq 29 
(  
  
)  (            
            
) (  
  
)         Eq 30 
Where one of the components turn out to be equal to one of the observed variables. 
The two components on the right-hand side are, by definition, independent and non-Gaussian; 
so these are proper ICA models. Thus, selecting the direction of causality is simply reduced to 
choosing between two ICA models. A good way to choose between the models can be based on 
likelihood ratios of the two models (Hyvarinen, Ramkumar, Parkkonen, & Hari, 2010). 
2.3. Group Independent Component Analysis 
There are basically two methods to the group ICA. One is to do ICA separately on each 
data matrix and then combine the results, which further help us to test the significance of the 
components. The second method is to estimate some average decomposition. For example, if 
we suppose that the mixing matrices are almost the same, then we can estimate the average 
mixing matrix. 
In our work, we used GIFT software (V. D. Calhoun, Adali, Pearlson, & Pekar, 2001) 
approach for doing group ICA which includes multiple data reduction steps along with data 
concatenation to reduce the computational load, followed by back reconstruction and 
statistical comparison of individual maps and time courses following ICA estimation. This 
approach involves a mixing matrix which has separations that are different to each subject. 
Once the mixing matrix is estimated, for each subject the component maps can be created by 
projecting the single subject data onto the inverse of the partition of the mixing matrix that 
corresponds to that subject. In the result we will have time courses for each subject which can 
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be further used to make group and inter-group inferences. Data reduction steps involve in 
group ICAto reduce the amount of memory. 
Mathematically, if say         be the     reduced data matrix from subject  , where 
   is the     data matrix,    is the     reducing matrix from subject    is the number of 
voxel and K be the number of PET scans and  T is the time of the time dimension following 
reduction. The data is concatenated into a single matrix. The      reduced matrix for M 
subjects is 
     [
    
 
 
    
]   Eq 31 
where    is an     reducing matrix and multiplied by     concatenated matrix for M 
subjects. For ICA estimation we know X=AS where A is    matrix and   is     map. 
Replacing this expression into above equation by multiplying with   we get 
  ̂ ̂  [
    
 
 
    
]                            Eq 32 
Separating   by subject we can get 
[
  
 
 
  
]  ̂ ̂  [
    
 
 
    
]                                  Eq 33 
For subject  , the equation becomes 
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   ̂ ̂                                          Eq 34 
The matrix    in above equation contains the single subject maps for   subject and is calculated 
from the following equation 
 ̂      ̂ 
          Eq 35 
Multiply both sides of equation 21 by    and write 
        ̂      Eq 36 
Which provides the ICA decomposition of the data from subject   contained in matrix,  
  . The     matrix   contains the N sources maps and     matrix       is the single 
subject mixing matrix and contains the time course for each of the N components. 
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1. DATA/POPULATION 
The brain 18-FDG and AV45 images were acquired from center of PET, hospital Purpan, 
Toulouse under the protocol name of FAIRAD (FDG and AV-45) and NIMAD (AV45). Some part 
of data(FDG 30min, FDG 60min and AV-45) was also obtained from the ADNI database 
(http://www.loni.ucla.edu/ADNI).  
1.1. Diagnostic Criterias 
As we know that FDG and AV-45 are important biomarkers for the detection of early AD. 
These biomarkers have increasingly strengthened their place in the diagnostic criterias. In 
amyloid imaging it is now found that amyloid plaques appears very early in the process of AD 
sometimes even in preclinical stage. Now-a-days the studies using this AV-45 PET showed 
higher fixation in the last stage of the patients and in MCI patients compared with control 
subjects and the studies using FDG PET predicts the stage of disease by observing the cerebral 
metabolism. 
As we know we have three types of cohorts. For each cohort we have specific diagnostic 
criteria. 
 For the cohort ADNI, the diagnostic criteria adopted for the detection of AD was 
NINCDS/ADRDA criteria for probable AD (Mckhann G., 1984). 
 For the cohort FAIRAD, the diagnostic criteria followed was NINCDS-ADRDA criteria for 
probable AD (Mckhann G.,1984) and DSM-IV criteria for Alzheimer’s type dementia or 
diagnostic criteria for amnestic MCI (Petersen RC et al,1999, Sarazin M et al,2007).  
 For the cohort NIMAD, the criteria followed was Revising the NINCDS-ADRDA criteria. 
(Dubois B.,2007). 
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ADNI FDG-PET 
The ADNI FDG-PET images had been acquired using Siemens, GE and Philips PET scanners 
according to two protocols.(30-60min dynamic and 0-60 min dynamic). Each subject received 
an intravenous injection of 185±19 MBq to acquire the images. For 30-60 min dynamic, the 
images were of 30 minutes duration, starting from 30 minutes post injection. All the data were 
corrected for attenuation. Further details are available in ADNI site 
(http://adni.loni.ucla.edu).We have two different protocols of ADNI FDG data. Table 3 and Table 
2 shows the subject group characteristics. 
 a 30 minute dynamic, six frame scan acquisition (6 five-minute frames),with scanning 
from 30-60 min post-FDG injection.  
 a 60 minute dynamic, consisting of 33 frames with scanning beginning at injection and 
continuing for 60 minutes. 
 
 
Table 3ADNIFDG 60 min subject group characteristics. 
 
 
ADNI 
(FDG-30min) 
 Controls AD MCI 
Number 43 33 37 
Male/Female 28/15 20/13 30/7 
Age           75.2±4.5 72.3±5.1 76.5±3.4 
Table 2  ADNI FDG-30min subject group characteristics. 
 
 
ADNI 
(FDG-60min) 
 Controls AD MCI 
Number 17 - 14 
Male/Female 17/0 - 14/0 
Age 74.3±1.4 - 74.9±9.08 
MMSE 28±1.44 - 27.21±2 
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ADNI AV-45 
The ADNI AV45-PET images had been acquired using Siemens, GE and Philips PET scanners. 
Each participant received an intravenous injection of 370 MBq of Florbetapir 18F prior to AV45 
PET imaging. The brain AV45 pet imaging was of 20 minutes duration, starting from 50 minutes 
to post injection. All the data were corrected for attenuation. With ADNI AV-45 protocol, Table 
4 shows the summaries of the  group characteristics of ADNI AV-45 subjects. 
 a 20 minute dynamic, 4 frame scan acquisition (5 five-minute frames), with scanning 
from 50-70 min post injection.  
Further details are available in ADNI site (http://adni.loni.ucla.edu). 
 
FAIRAD AV-45 and 18 FDG 
The FAIRAD AV45-PET images were acquired using Siemens PET scanners installed in Center 
of Positron emission tomography (PET), Hospital Purpan TOULOUSE. All the images were 
attenuated corrected. Each participant received an intravenous injection of 3.70 MBq/kg 
weight of participant. The time for the fixation post injection was 50 minutes and the duration 
of acquisition was 20 minutes.  
The FAIRAD 18FDG-PET images were acquired using Siemens PET scanners installed in 
Center of Positron emission tomography (PET), Hospital Purpan, TOULOUSE. Each participant 
received an intravenous injection of 18.5 MBq/10kg weight of FDG. The time for the fixation 
 
ADNI 
(AV-45) 
 Controls AD MCI 
Number 20 9 47 
Male/Female 6/14 6/3 26/21 
Age 72.9±6.9 76.2±10.89 72.7±7.1 
Table 4 summary of ADNI AV-45 subjects group statistics. 
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post injection was 30 minutes and the duration of acquisition was also 30 minutes. For protocol 
FAIRAD, We have same subjects underwent FDG-pet imaging and AV-45 PET imaging at 
different times. Table 5 shows the summaries of group characteristics of FAIRAD cohort 
subjects. 
 For AV-45, a 20 minute dynamic, 4 frame scan acquisition (5 five-minute frames), with 
scanning from 50-70 min post AV-45 injection.  
 For 18-FDG, a 30 minute dynamic, consisting of 6 frames scan acquisition (5 minutes 
frame) with scanning from 30-60 min post-FDG injection. 
 
FAIRAD 
(18-FDG) 
 Controls AD MCI 
Number 2 5 7 
Male/Female 1/1 1/4 6/1 
Age 69.5±0.5 77±4.2 78.28±4.39 
FAIRAD 
(AV45) 
Number 2 4 6 
Male/Female 1/1 1/3 5/1 
Age 69.5±0.5 78.25±3.89 78.5±4.71 
Table 5: Summary of FAIRAD18 FDG and AV-45 subject group characteristics. 
NIMAD AV-45 
The NIMAD AV45 images were acquired using Siemens PET scanner installed in Center of 
Positron emission tomography (PET), Hospital Purpan TOULOUSE. Each participant received an 
intravenous injection of 4MBq/kg weight of the AV-45. The brain AV45 PET images were of 20 
minutes duration, starting from 50 minutes post injection. All the data collected were 
attenuated corrected. 
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 For AV-45, a 20 minute dynamic, 4 frame scan acquisition (5 five-minute frames), with 
scanning from 50-70 min post injection. Table 6 show the summaries of group 
characteristics of the subjects in NIMAD AV45 cohort. 
NIMAD(AV-45)  Controls AD MCI 
Number 17 22 - 
Male/Female 7/10 12/10 - 
Age 69.88±4.66 72.37±4.88 - 
MMSE score 28.41±0.69 24.91±2.41 - 
Table 6: Summary of NIMAD AV-45 group characteristics. 
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2. METHODOLOGY 
2.1. Feature Extraction 
In order to analyze the statistical information available from the PET image datasets, we 
studied the statistical distribution of the variance in suitable statistical subspaces – PCA and ICA 
seemed appropriate subspace projection techniques to be compared one another in such study 
since they have been amply used, studied and reported as outperforming techniques in the 
domains of pattern recognition and machine learning. Furthermore, for the sake of discriminant 
power in building classifiers, PCA is frequently applied as a preliminary step to compute ICA 
vectors. They can get along with one another since both of them are considered as blind-
source/signal-separation unsupervised techniques. 
ICA is used to apply to single subject and single session analyses. Group analysis of PET is 
important to study specific conditions within or between groups of subjects. It is not clear how 
ICA can be applied on a group of subjects as different individuals in the group will have different 
time courses. (V. D. Calhoun, et al., 2001), developed a model to extend ICA to group studies. 
There are three main steps of group ICA; data compression, ICA and back reconstruction .We 
used this method to analyze our data. It is a temporal concatenation approach and has the 
advantage of performing one ICA, which can further segmented into subjects specific regions, 
hence the comparison of subjects differences within a component is easy to do. For each 
subjects the common group map and specific time courses for each subject can be calculated 
by doing temporal concatenation, whereas unique maps and common time courses can be 
obtained by doing the spatial concatenation. For fMRI data, temporal concatenation performs 
better as compare to spatial concatenation.(Schmithorst & Holland, 2004), and has been widely 
used for group ICA for fMRI data. F 
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2.1.1. Process Involved In Feature Extraction 
Here we describe the process involved in feature extraction. Process contains data 
reduction, ICA process and ICA algorithms used to calculate the group ICA. 
Data Reduction 
Data reduction is a step to reduce the size of the subject's data. Each data-set is reduced 
using Principle Components Analysis (PCA). These reduced data-sets are then concatenated into 
two groups and this process is repeated twice. Figure 26show three data-sets passed 
throughtwo data reduction steps. The next stage is applying ICA on this reduced data-set. 
 
Figure 26shows that data set is reduced using PCA where R shows the data reduction. (picture 
adapted from Gift Manual). 
Independent Component Analysis 
Independent Component Analysis (ICA) is used to find the independent components 
(ICs,  
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Figure 27. There are a lot number of ICA algorithms that are used but we used Infomax 
for calculating ICs.The concatenated data from the data reduction step is used and the 
aggregate ICA components are calculated. 
 
 
 
 
 
 
 
 
Figure 27: The reduced dataset from data reduction stage is used and ICA is applied to 
calculate ICs.(Picture adapted from Gift manual). 
 
Back Reconstruction 
The components resulting from ICA represent group components were added to Back 
Reconstruction (BR). The aggregate components and the results from data reduction are used 
to compute the individual subject components (Figure 28).The single subject maps and time 
courses are calculated using the following formula. 
                                                                                                                 Eq 37 
where:   is the ICA decomposition from subject  ,    is the inverse (or pseudo-inverse) 
of the reducing matrix determined by PCA decomposition,    is the subject specific part of the 
subject I in the global matrix   used for group reduction where  is mixing matrix and   the is 
PCA R 123 
Component 1 
Component n 
Group 
Component 
.
.
. 
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the inverse of the reducing matrix (also determined by PCA decomposition),   contains the N 
source maps . 
 
 
 
 
 
 
 
Figure 28 shows the  individual subject components calculated from the group 
components.(Picture adapted from Gift manual) 
 
Calibrating Components 
The data is used to scale the components from arbitrary units to percent signal change 
or z -scores. Calibrated image maps (Figure 29) are computed using the individual image maps 
and time courses. 
 
PCA R 123 
Subj 1 
Group 
Components 
PCA  123 Subj 2 
Subj 3 
 107 
 
 
Figure 29 shows the individual subject components which are calibrated to percent signal 
change. (picture adapted from Gift manual) 
2.2. The SVM Model 
Because of their non-probabilistic nature SVM techniques have become a de facto trend 
in building supervised-learning classifiers in the machine learning and pattern recognition 
domain with application to discriminating mental conditions in cognitive functional 
neuroscience. Very often SVM models are evaluated with cross-validation techniques because 
of either a lack of data samples (data corpus is very reduced), or an attempt to find the best 
model while varying parameter values.  
In our case, we use a generic soft-margin separation SVM to discriminate subjects 
amongst three types of conditions picking them out two at a time: {AD,healthy}, {MCI,healthy} 
and {AD,MCI}.We think of such discrimination as a classification task where an SVM model is 
built given a training set of M data points which have been labeled accordingly to the pairs of 
mental conditions:                  where     
  and                     Figure 30 
shows our model classifier. 
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Figure 30 shows the SVM model classifier. 
 
Therefore a data point is viewed as a vector    of   dimensions where   corresponds to 
the number of un-correlated or independent parameters.  
The separation of classes can be supposed to be carried out linearly by a hyperplane of 
  –    dimensions found with the maximal margin in such a dimensional space (into which all x i 
are mapped). 
The discriminant mapping function is an inner product:                 where w is 
the normal weight vector of the separating hyperplane, and b is a bias from the origin of the 
feature space which is equivalent to the utilization of a linear kernel function 
           
   Eq 38 
While trying to maximize the margin          we found that               is 
supposed to represent the optimal hyperplane of separation as a result of an optimization 
problem:  
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              ∑          Eq 39 
Subject to                –             
Where:        is a parameter that allows us to have a soft margin (i.e. classification 
errors are allowed) and       is the penalty parameter of the error term. 
Then the support vectors of our model are the well-classified data points that are closer 
to the margin. The minimum number of such data points that separate the classes becomes the 
main objective though. 
As we wanted to map our data points into a nonlinear higher dimensional space (i.e. 
giving place to the hypotheses that the relation between the data points and their condition 
labels could be nonlinear) we chose a radial-basis-function (RBF) kernel  
 (     )      ( –   ||   –   ||  )                                    Eq 40 
For our SVM model with default values concerning its width, the optimizer and the 
penalty parameter C (e.g. Γ=1 unit, optimizer=“libsvm”, and C=an “infinite” value). 
Besides, the choice of an RBF kernel also seems justified since the data points to handle come 
out of imaging sources – RBF kernels behave as low-pass filters then a smoothing effect is not 
odd for our data despite the fact that we do not handle images anymore. We have to deal with 
PCA and ICA instead.  
2.3. The ANN Model 
We have built a supervised neural network-based classifier up on a classic multilayer 
perceptron (MLP) structure with three layers: input, hidden and output ones(Figure 31). By using 
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such classifier on cerebral images we enter into multi-voxel pattern domain. (Norman, Polyn, 
Detre, & Haxby, 2006). 
Let’s see each layer of the neuron network for further detail of our method. 
Input Layer: It is basically a receiver of parameter vector of each input image 
volume     . The total input nodes belongs to the independent factor axes (non 
correlated). These factors are calculated with the help of principal component analysis 
(PCA) and independent analysis (ICA) for         nged up to m.                     . 
The activation function is normally defined just to transfer the input to respective 
network. 
Hidden Layer: This layer acts as a class separator. The size of the hidden layer may 
affect the training effectiveness or may be the entire network. Generally every node 
gives us the decision boundary for separating the class. In our case we have tried with 
different sizes and realize that 20 to 25 nodes provide better performance.  
 
OutPut layer: This layer gives a value for each class. The value obtained will tell that the 
input vector belongs to which class. The size of the output layer depends on the size of 
the input. If we have three classes to identify, the size of the output layer will also be 3. 
i.e.one node for each class. The activation function for output layer is defined as a 
sigmoid function. These functions allow defining the output probability values for each 
class which can be identified by the image vector              . 
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Figure 31 shows the layers of the neural network are shown.(model for AV-45,AD,MCI 
and normal). 
We used back propagation algorithm to train our classifier i.e. ANN (artificial neural 
network) with X ={xlearn}. To minimize the mean square error between output value and target 
value, such techniques are used by means of the gradient descent optimization technique.  
In neural network the initializing steps have kind of stochastic nature so we can start at 
any given point in the working space and start a very small weight value at around 10-1, for very 
node. The variation must be done by gradually adding small increments so that we get the 
value near the optimal point by avoiding over-fitting on the network and missing interesting 
local maxima. The bias values and weight of the network that follows some probability 
distributions within a Bayesian framework can be considered as one of the solutions to the 
parameter-value optimization. Different statistical techniques are applied to estimate the 
random: the parameters are linked to the variances which are associated to the probability 
distributions. This technique is named as Bayesian Regularisation (MacKay, 1992). 
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1. STUDY 1: CLASSIFICATION 
To find the appropriate non-invasive technique for the early detection of Alzheimer’s 
disease is pivotal to develop the early treatment of the disease. In this chapter we used support 
vector machine (SVM) and the artificial Neural network (ANN) for the classification of 2-classes 
and 3-classes.The aim of this study was to propose a new approach for automatic classification 
of PET( AV-45 and 18FDG) images in order to distinguish Alzheimer disease (AD), mild cognitive 
impairment (MCI), and healthy subjects. We used AV-45 and FDG-PET images for the 
classification of AD, MCI and healthy subjects. Set of data used in this chapter is in Table 7. For 
FDG-PET we used FDG 30 minutes and FDG 60 minutes to see whether it makes any change on 
the results. Feature extraction of the group of all the images (AD, MCI,NOR) were done using 
ICA and PCA as explained in chapter 4. We used the time courses of the components for the 
classification. Each subject is characterized by a vector of 4 dimensions (AV-45), 6 for (FDG30) 
and 20 for (FDG60). These time courses are obtained after back reconstruction. Each time 
course consists of a drastic reduction of information in feature space. 
 ADNI-AV45 
n=76 
AD=9,MCI=47,NO
R=20 
 
NIMAD-AV45 
n=39 
AD=22,NOR=17 
FAIRAD-AV45 
n=12 
AD=4,MCI=6,NOR
=2 
ADNI-FDG-30 
n=113 
AD=33, 
MCI=37,NOR=4
3 
ADNI-FDG-60 
n=31 
NOR=17,AD=14 
H vs AD     NA 
H vs MCI  NA    
AD vs MCI  NA   NA 
Table 7 shows the availability of data for their respective comparisons. 
To verify the classification performance of our approach, we did training, cross-validation and 
test. For the cross-validation, we used leave one out cross validation (LOOCV). It iteratively 
holds a subject for test while training the classifier for the rest of the subjects. We did the 
random permutation of the subjects, by changing the labels of the subjects. This approach 
permitted us to study the evolution of the accuracy of function of permutation. We introduced 
the function of overlapping of random permuted data with original data. 
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Preprocessing: 
First of all we did the realignment of all the subjects individually, making sure that all of 
them were consistent with each other in the spatial atlas. Then all the aligned images were 
normalized to a template image which we have created. In this process all the images were 
resliced and voxel volume was set to 2*2*2 mm3. The output were further smoothed on FWHM 
[8 8 8] mm. All the preprocessing of the data was carried out with the help of MATLAB toolbox 
SPM. 
1.1. Assessment by Leave One Out Cross Validation 
As we make use of the same PET image data sets to both train and test for the classifier 
then a cross validation technique appears appropriate to estimate the expected level of fit of 
the SVM model and artificial neural model (ANN) to the data sets in terms of classification rate 
i.e. the average success rate (ASR) from a confusion matrix in our case. This way we can see 
that the image data sets comprise a good amount of potential image observations for testing. 
We went for leave-one-out cross validation (LOOCV) then. For a target group, let F be a 
technique of evaluating the success in image classification, and Pi(F) a measure of its 
performance i; applying LOOCV on our image dataset consists of: 
 Dividing the database in equally sized N samples: 1 sample = all images of a single 
subject: m ,image per subject 
 Select any one random sample for testing, suppose sample 1, and perform learning on 
the rest of the N – 1 sample. On the other hand we can say that we select one patient 
image as a testing and rest of the patient images to train our classifier. That is to say: i.e 
                                  
                                                                   Images,  at a given period of time. 
 Measuring performance          
 By changing the sample i from 1 to N and restart while the range is not completely 
swept. 
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The final performance, PT, is given by the average computation taking into account every 
measured performance : 
     ⁄ ∑     [  ]        Eq 41 
In fact, PT is the ASR of our classifier in classifying subjects’ PET images. 
1.2. RESULTS 
 Support Vector Machine Results 
In order to do the cross validation using support vector machines (SVM), we divided the data 
into different groups mentioned in Table 7. The feature matrixes were obtained by doing ICA 
group analysis. The results obtained are as follows 
ADNI AV-45 
AV45 ADNI H vs AD 
 Component 
1matrix 
ofconfusion (%) 
Component 
2matrix of 
confusion (%) 
Component3matrix 
of confusion (%) 
Component4matrix 
of confusion (%) 
ICA 80          20 
66.67     33.33 
1000.00 
0.00       100 
95             5 
11.11       88.89 
95            5 
77.78      22.22 
PCA 80          20 
77.78     22.22 
70           30 
66.67     33.33 
90             10 
44.44        55.56 
100           0 
0               100 
Table 8 shows the percentage of classification rate of each Component in ADNI H vs AD . 
Results obtained with SVM 
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AV45 ADNI H vs MCI 
 Component 1 
matrix of confusion 
(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion 
(%) 
ICA 100          0.00 
0.00        100 
100         0.00 
0.00       100 
65            35 
12.77      87.23 
85          15 
6.38       93.62 
PCA 35            65 
38.30      61.70 
50            50 
21.28      78.72 
55              45 
23.40        76.60 
100            0 
0               100 
Table 9 shows the percentage of classification rate of each Component in ADNI  H vs MCI . 
Results obtained with SVM 
 
AV45 ADNI AD vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrixof confusion 
(%) 
ICA 100      0 
0          100 
0              100 
21.28       78.77 
11.11       88.89 
29.79      70.21 
100      0 
4.26       95.74 
PCA 0            100 
10.64     89.36 
55.56      44.44 
4.26       95.74 
55.56      44.44 
10.64     89.36 
100       0 
0           100 
Table 10 shows the percentage of classification rate of each Component in ADNI  AD vs MCI. 
Results obtained with SVM. 
FAIRAD AV-45 
AV45 FAIRAD H vs AD 
 Component 1 
matrix of 
confusionnumber of 
subjects) 
Component 2 
matrix of confusion 
(Number of subjects) 
Component 3 
matrix of confusion 
(Number of subjects) 
Component 4 
matrix of confusion 
(Number of subjects) 
ICA 2           0 
0            4 
0             2 
2             2 
0                 2 
2                 2 
0           2 
3            1 
PCA 0              2 
3             1 
0              2 
2              2 
0                  2 
1                3 
1                1 
1                3 
Table 11 shows the number of Healthy (n=2) and AD patients( n=4) assigned to each class in 
FAIRAD H vs AD. Results obtained with SVM. 
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AV45 FAIRAD H vs MCI 
 Component 1 
matrix of confusion 
(Number of subjects) 
Component 2 
matrix of confusion 
(Number of subjects) 
Component 3 
matrix of confusion 
(Number of subjects) 
Component 4 
matrix of confusion 
(Number of subjects) 
ICA 0               2 
2               4 
2            0 
0             6 
0              2 
1              5 
1              1 
1              5 
PCA 0              2 
3              3 
0                   2 
2                   4 
0               2 
2              4 
0                 2 
1                 5 
Table 12 shows the number of Healthy (n=4) and MCI patients( n=6) assigned to each class in 
FAIRAD Healthy vs MCI. Results obtained with SVM 
 
AV45 FAIRAD AD vs MCI 
 Component 1 
matrix of confusion   
(Number of subjects) 
Component 2 
matrix of confusion 
(Number of subjects) 
Component 3 
matrix of confusion  
(Number of subjects) 
Component 4 
matrix of confusion 
(Number of subjects) 
ICA 2             2 
4             2 
3              1 
1              5 
3             1 
1             5 
3          1 
0          6 
PCA 0             2 
3             3 
0              2 
3              3 
3              1 
3              3 
1          3 
3          3 
Table 13 shows the number of AD patients (n=4) and MCI patients( n=6) assigned to each 
class in FAIRAD AD vs MCI. Results obtained with SVM. 
NIMAD AV-45 
AV45 NIMAD H vs AD 
 Component 1 
matrix of confusion   
(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion (%) 
ICA 100            0 
0                100 
100          0 
0             100 
41.18        58.82 
22.73        77.27 
64.71       35.29 
36.36        63.64 
PCA 52.94       47.06 
45.5         54.55 
35.29       64.71 
63.64       36.36 
41.18         58.82 
59.09        40.91 
58.82        41.18 
63.64        36.36 
Table 14 shows the percentage of classification rate of each Component in NIMAD  H vs AD. 
Results obtained with SVM 
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ADNI FDG-30MIN 
FDG-30min ADNI H vs AD 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion 
(%) 
ICA - - - - 
PCA 81.40 18.60 
24.24 75.76 
79.07 20.93 
18.18 81.82 
95.35 4.65 
33.33 66.67 
97.67 2.33 
33.33 66.67 
Accuracy: 84.21 
Table 15 shows the percentage of classification rate of each Component in ADNI  H vs AD. 
Results obtained with SVM 
 
FDG-30min   ADNI H vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion (%) 
ICA - - - - 
PCA 86.05 13.95 
21.62 78.38 
 
93.02 6.98 
43.24 56.76 
 
100.000.00 
13.51 86.49 
Accuracy: 93.75 
95.35 4.65 
27.03 72.97 
Table 16 shows the percentage of classification rate of each Component in ADNI  H vs MCI. 
Results obtained with SVM. 
 
FDG-30min   ADNI AD vs MCI 
 Component 1 
matrix of confusion 
(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion 
(%) 
ICA - - - - 
PCA 90.91 9.09 
18.92 81.08 
87.88 12.12 
18.92 81.08 
 
100         0 
24.32 75.68 
Accuracy: 87.14 
75.76 24.24 
13.51 86.49 
Table 17 shows the percentage of classification rate of each Component in ADNI  AD vs MCI. 
Results obtained with SVM. 
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ADNI FDG-60MIN 
FDG-60min   ADNI H vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of confusion 
(%) 
ICA 100       0 
0            100 
 
100        0 
0        100 
100        0 
0        100 
100        0 
0        100 
PCA 64.71      35.29 
53.85      46.15 
58.82      41.18 
61.54      38.46    
64.71       35.29 
30.77       69.23 
47.06       52.94 
61.54        38.46 
Table 18 shows the percentage of classification rate of each Component in ADNI  H vs MCI. 
Results obtained with SVM. 
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 The Artificial Neural Network Results: 
In order to do the cross validation using Artificial Neural networking (ANN) we used the same 
data as for SVM results. The results obtained are as follow 
ADNIAV45 
AV45ADNI H vs AD 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of 
confusion(%) 
ICA 75         25 
0.00     100 
 
100       0 
0           100 
90       10 
0         100 
60         40 
0           100 
PCA 85.00 15.00 
66.67 33.33 
95.00 5.00 
44.44 55.56 
 
95.00 5.00 
0.00 100.00 
 
100 0 
0 100 
Table 19shows the percentage of classification rate of each Component in ADNI H vs AD. 
Results obtained with NN. 
 
AV45 ADNI H vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of 
confusion(%) 
Component 3 
matrix of confusion  
(%) 
Component 4 
matrix of 
confusion(%) 
ICA 75         25 
0.00     100 
 
100       0 
0           100 
90       10 
0         100 
60         40 
0           100 
PCA 70.00 30.00 
4.26 95.74 
85.00 15.00 
10.64 89.36 
90.00 10.00 
8.51 91.49 
100 0 
0 100 
Table 20 shows the percentage of classification rate of each Component in ADNI  H vs MCI. 
Results obtained with NN. 
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AV45 ADNI AD vs MCI 
 Component 1 
matrix of confusion 
(%) 
Component 2 
matrix of confusion 
(%) 
Component 3 
matrix of confusion 
(%) 
Component 4 
matrix of 
confusion(%) 
ICA 100       0 
0          100 
 
100            0 
0                 100 
80             20 
0              100 
90            10 
0              100 
PCA 55.56 44.44 
8.51 91.49 
55.56 44.44 
0.00 100.00 
66.67 33.33 
0.00 100.00 
100 0 
0 100 
Table 21 shows the percentage of classification rate of each Component in ADNI  AD vs MCI. 
Results obtained with NN. 
NIMAD AV45 
AV45 NIMAD H vs AD 
 Component 1 
matrix of confusion 
(%) 
Component 2 
matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of 
confusion(%) 
ICA 100       0 
0          100 
 
100            0 
0                 100 
70.59 29.41 
27.27 72.73 
64.71 35.29 
22.73 77.27 
PCA 64.71 35.29 
22.73 77.27 
29.41 70.59 
9.09 90.91 
64.71 35.29 
27.27 72.73 
64.71 35.29 
27.27 72.73 
Table 22 shows the percentage of classification rate of each Component in NIMAD  H vs AD. 
Results obtained with NN. 
 
FDG-30MIN 
FDG-30m ADNI H vs AD 
 Component 1 
matrix of confusion 
(%) 
Component 2 
matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of 
confusion(%) 
ICA - - - - 
PCA 86.05 13.95 
30.30 69.70 
65.12 34.88 
33.33 66.67 
65.12 34.88 
24.24 75.76 
79.07 20.93 
45.45 54.55 
Table 23 shows the percentage of classification rate of each Component in ADNI  H vs AD. 
Results obtained with NN. 
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FDG-30m ADNI H vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of confusion(%) 
ICA - - - - 
PCA 86.05 13.95 
24.32 75.68 
79.07 20.93 
37.84 62.16 
74.42 25.58 
10.81 89.19 
88.37 11.63 
29.73 70.27 
Table 24 shows the percentage of classification rate of each Component in ADNI  H vs MCI. 
Results obtained with NN. 
FDG-30m ADNI  AD vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
Matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of confusion(%) 
ICA - - - - 
PCA 81.82 18.18 
13.51 86.49 
75.76 24.24 
13.51 86.49 
66.67 33.33 
10.81 89.19 
63.64 36.36 
5.41 94.59 
Table 25 shows the percentage of classification rate of each Component in ADNI  AD vs MCI. 
Results obtained with NN. 
 
FDG-60MIN 
FDG-60m ADNI  H vs MCI 
 Component 1 
matrix of 
confusion(%) 
Component 2 
Matrix of 
confusion(%) 
Component 3 
matrix of 
confusion(%) 
Component 4 
matrix of 
confusion(%) 
ICA 94.12      5.88 
0.00       100.00 
82.35      17.65 
0              100 
100          0 
0              100 
58.82         41.18 
0                 100 
PCA 81.82 18.18 
13.51 86.49 
75.76 24.24 
13.51 86.49 
66.67 33.33 
10.81 89.19 
63.64 36.36 
5.41 94.59 
Table 26 shows the percentage of classification rate of each Component in ADNI H vs MCI. 
Results obtained with NN. 
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1.3. CONCLUSIONS 
The results shows that the differentiation accuracy of the classifier using leaving-one-out-cross-
validation. We used all datasets containing FDG and AV-45 Table 7 using ICA and PCA values. 
For FDG30 min, we are not able to calculate the classifier accuracy because ICA matrix was not 
fully converged for some unknown reasons. So they were not in good condition to be taken into 
account. For FIRAD dataset, by having small number of data set, we have given our results in 
number of subjects. 
SVM  
 For data set ADNI AV-45,we can see that for ICA values it is component #2 which gives 
100% classification accuracy for H vs AD and H vs MCI but for AD vs MCI Table 10 it is 
component # 1 which has shown 100% accuracy. For PCA values, it is component # 4 which has 
shown 100% accuracy for each comparison For both ICA and PCA values the specificity and 
sensitivity of the classifier was also 100%.(Table 8,Table 9,Table 10). 
 For dataset FAIRAD, its independent component # 1 which was able to discriminate all 
the healthy from AD subjects and for PCA values it is component # 4 which is able to well 
discriminate the healthy subjects from AD. We can see that for PCA , our classifier well 
discriminated 3/4 AD subject where as it put 1/2 healthy into AD. According to Table 12, for ICA 
values the component # 2 was able to well discriminate all the subjects where for PCA values its 
component #4 which is better in discriminating MCI subjects but it remained unable to 
discriminate healthy subjects. According to Table 13, ICA component # 4 well discriminated all 
the MCI subjects but put 1 AD subject into MCI where as for PCA values, component # 3 
showed better results; It discriminated  3 AD out of 4 but for MCI it put 3/6 MCI into AD. (Table 
11,Table 12,Table 13).For NIMAD dataset, Table 14 shows that ICA component # 1&2 showed 
100% classifier accuracy for discriminating Healthy and AD where as for PCA values component 
# 1 showed 53% classification accuracy. The specificity and sensitivity of the classifier were also 
53%.(Table 14) 
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 For dataset ADNI FDG 30min, according to Table 15,Table 16&Table 17, the max 
classification accuracy varied from 84.21- 93.75%.(Table 15,Table 16,Table 17). For dataset 
ADNI FDG 60min, according to Table 18, for ICA values component #2 &3 gives 100% 
classification accuracy whereas for PCA values the accuracy in component # 3 is 66.97%. The 
sensitivity and specificity of the classifier was 66% and 68% respectively.(Table 18). 
ANN 
 For data set ADNI AV-45,we can see that for ICA values it is component #2 which gives 
100% classification accuracy for H vs AD (Table 19),H vs MCI (Table 20) and AD vs MCI (Table 
21).For PCA values, it is component # 4 which has shown 100% accuracy for all 3 comparison. 
For both ICA and PCA values the specificity and sensitivity of the classifier happened to be 
100%. 
 For NIMAD dataset, Table 22 shows that ICA component # 1&2 showed 100% classifier 
accuracy for discriminating Healthy and AD whereas for PCA values component # 4 showed 68% 
classification accuracy. The sensitivity and specificity of the classifier were also 70% and 67% 
respectively. 
 For dataset ADNI FDG 30min, from PCA values, the classification accuracy for 
discriminating healthy from AD was 77%. The sensitivity and specificity was 73% and 83% 
respectively (Table 23). The classification accuracy for discriminating healthy from MCI was 
80%. The sensitivity and specificity was 77% and 84% respectively (Table 24). The classification 
accuracy for discriminating AD from MCI was 84%. The sensitivity and specificity was 85% and 
82% respectively (Table 25). 
 For dataset ADNI FDG 60min, according to Table 26, for ICA values component # 3 gives 
100% classification accuracy whereas for PCA values the max accuracy found in component # 1 
which is 84%. The sensitivity and specificity of the classifier was 85% and 82% respectively. 
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1.4. DISCUSSION 
Here we have demonstrated that the automatic method based on ICA and PCA for the 
classification of PET ( 18FDG and AV-45) images is very helpful in differentiating among AD, MCI 
and healthy subjects. We used two classifiers, support vector machine and artificial neural 
networking (ANN). To the best of our knowledge, it is the first study done on PET- AV-45 for the 
classification using SVM and ANN. 
The SVM results shows that our method can successfully differentiate subjects with 
Alzheimer disease, mild cognitive impairment and normal subject with classification rate up to 
100%. For ADNI-AV45, for both ICA and PCA values the classification accuracy, sensitivity and 
specificity were achieved 100%. For dataset NIMAD, for ICA and PCA values the classification 
rate was 100% and 53% respectively. For FDG-30 the classification accuracy varies from 84.21%-
93.75% by using PCA values. For ADNI FDG-60, by using ICA values the classification accuracy 
was 100% whereas for pca values it was 66.97%. 
We can compare our results with other related studies. (Yang et al., 2011) did a study on 
ICA based automatic classification of PET-FDG images from ADNI using SVM to distinguish 
between AD from Healthy found 86.78% average classification accuracy. Same author did 
another study in 2010 on ICA based automatic classification on MRI images using ADNI data. He 
found classification rate between 78.4-85.7 % for H vs AD and 71-79.2% for H vs MCI. 
In (López et al., 2009),two pattern recognition methods were applied to PET and SPECT 
images. .PCA was applied over the data to reduce the dimension of the feature space. By using 
SVM classifier, they achieved the classification accuracy of 98.33% for PET and for SPECT they 
got 93.41%. In another study (Illán et al., 2011)proposed an approach by means of leave-one-
out method. They used SVM based on RBF kernel to obtain classification accuracy of 87.06% by 
extracting features with ICA and 88.24% by PCA. 
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 (Gutman, Wang, Morra, Toga, & Thompson, 2009) did an Alzheimer’s disease study 
based on global shape description of hippocampal surface model found 82.1% of classification 
rate in leave-one-out test. In (Vemuri et al., 2008)and (Kloppel et al., 2008) the overall leave-
one-out-accuracy was in between 89-96%.(Chupin et al., 2009)in their experiments on AD, MCI 
and healthy, the classification rate appears to be 76-80% for AD vs NC and 61-63% of MCI vs 
healthy.  
In another study,(Dukart, Mueller, Barthel, Villringer, Sabri, Schroeter, et al., 2013)used 
support vector machine using  combined volume of interest information from MRI and ADNI 
FDG-PET based on comprehensive quantitative meta analysis investigating dementia syndrome 
in comparison to single modality classification. The author found that for the ADNI data set the 
accuracy rates were up to 88% with a sensitivity and specificity of 89.3% and 82.1 % 
respectively. For the Leipzig cohort, he obtained accuracy of 91% with classification rate of 
100%. 
Our ANN results are also proving it right that our approach to discriminate the 
Alzheimer disease from MCI and normal subjects is a valid approach. For ADNI-AV45 data set, 
using ICA and PCA values the classification accuracy, sensitivity and specificity were achieved 
100%. For dataset NIMAD, for ICA and PCA values the classification rate was 100% and 68% 
respectively. For FDG-30 the classification accuracy varies from 77%-84% by using PCA values. 
For ADNI FDG-60, by using ICA values the classification accuracy was 100% whereas for pca 
values it was 84%. 
 (López, et al., 2009), two pattern recognition methods were applied to PET and SPECT 
images. .PCA was used to reduce the dimension of the feature space. By using feed forward 
neural network, they achieved the classification accuracy of 98.33%.  
In a study done by (Bose, et al., 2008), they used ANN to do the classification of images 
of 18F DOPA as a potential diagnostic test for schizophrenia. The author found that ANN model 
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identifies the control and patients with the accuracy of 94% and 89% respectively. The author 
found the sensitivity and specificity of 89% and 94%. 
In another study done by (Gutte et al., 2007b), they used ANN approach for the 
interpretation of combined 18F-FDG and CT images for lung cancer. The author obtained the 
classification accuracy 92%.The sensitivity and specificity was 86%and 100%. 
If we do the comparison of our results between SVM and ANN networks for the 
classification, then we can see that for ADNI-AV45 both classifiers has given same results with 
an accuracy of 100% for ICA and PCA values. For dataset NIMAD, the accuracy obtained from 
ICA values was 100% for both classifiers .For PCA values ANN has given better result with an 
accuracy of 68% where for SVM it was 53%. For data set ADNI-30min, using SVM classifier the 
max accuracy obtained was 93.75%where s for ANN this reduce to 84%. For FDG60min dataset, 
the obtained accuracy was 100% using ICA values for both classifier whereas for PCA values, 
ANN obtained 84% accuracy which reduced to 66.97% for SVM.
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2. STUDY 2: ROBUSTNESS OF THE CLASSIFICATION 
AGAINST IMPERFECT TRAINING  
In real life situations the observation vector are noisy and robustness of the classifier is 
usually understood as the robustness against the noise that introduce some uncertainty on the 
values for the classification. It is desired that the classifier should be robust to such uncertainty. 
To minimize the training error can decrease the performance of classification for new unlabeled 
data. Because of over fitting problem, these approach can face bad generalization error (Vapnik 
& Chervonenkis, 1991). Many improvements have been made to solve this; one of the common 
methods is minimizing a combination of the training-error and a regularization term. The 
regularization term is usually chosen as a norm of the classifier. The performance of the 
obtained classifier is good on the new data. This approach is commonly interpreted from a 
statistical learning theory: the regularization term restricts the complexity of the classifier; 
hence the deviation of the testing error and the training error is controlled.(Evgeniou, Pontil, & 
Poggio, 2000; Koltchinskii & Panchenko, 2002; Smola, Scholkopf, & Muller, 1998) 
In our case, analysis begins with a feature extraction stage that makes a numerical 
representation of the example images in form of feature vectors, followed by a statistical 
analysis that creates a description of characteristics between the two groups. The approach 
showed in several studies is to train classifier’s function that can learn how to label new 
examples(Csernansky et al., 1998; Golland, 2002).The two data sets are completely different if 
the classifier label the new examples are labelled with better than random accuracy and the 
classifier also distinguish the differences. Their training algorithm does not assume 
independence among features but they arrive at discriminating between the two groups based 
on the entire ensemble of highly localized features. Their approach is important for us to use 
since they use the classifier performance as a measure of robustness of the detected 
characteristics. Thus, coming back to our case, By testing it on a different data set we can 
estimate accuracy of our classifier, as the average test error is an unbiased estimator of the 
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expected performance, but the small size of our test set is not sufficient for the variance of this 
estimator to be low enough to lead to a useful bound on how close we are to the true expected 
error(Guyon, Makhoul, Schwartz, & Vapnik, 1998). Moreover, the total number of available 
data might be so small that we have to re-sort to cross-validation since splitting data into 
training set and test set is not feasible. Furthermore, the high dimensionality of the dataset 
often renders many theoretical limitations based on the complexity of the dataset.  
In this chapter, we will show how permutation tests are able to provide a statistical 
significance. We apply permutation tests to identify the differences between two classes. The 
null hypothesis is that our classifier can learn to predict labels based on the given training set.  
2.1. HYPOTHESIS TESTING 
In two-class comparison hypothesis testing, the differences between two data 
distributions are measured using a data set statistic, which is a function 
 
                    Eq 42 
Such that for a given data set             
   where       
   are the observations and            
are the respective class labels.                    is a measure of how similar the subsets  
                        are. 
The null hypothesis typically assume that the two classes have identical data distributions, 
                        Eq 43 
The main aim of hypothesis testing is to reject the null hypothesis at a certain level of 
significance, which defines the maximal acceptable probability of false positive. For any value of 
the statistic, the corresponding p-value is the highest level of significance at which the null 
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hypothesis can still be rejected. In classical statistics, the data are often assumed to be one-
dimensional (n= 1), but any multi-variate statistic F can be used in this fairly general framework. 
2.2. PERMUTATION TESTS 
Suppose we have chosen an appropriate statistic F and the significance level . Let 
{(          
  be the examples and    be the set of all permutation       The permutation 
procedure that consist of M iteration is defined as 
 repeat M times (index I =1,-, M). 
 sample a permutation    from a uniform distribution over    . 
 compute the statistic value      (                 }  
 Construct an empirical cumulative distribution 
        
 
 
∑                 Eq 44 
where  is the step function                            
 compute the statistical values for the actual labels,                      . 
 if     , rejects the null hypothesis. 
 
2.3. RESULTS 
LEARNING SET IS ADNI AND TEST SET IS NIMAD 
In this study we used ADNI AV-45 data set and NIMAD AV-45 data set as seen in Table 7. We 
considered first ADNI data set as a learning set and introduced NIMAD set as a test. The feature 
matrix were obtained by doing ICA of the whole Group  
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RESULT WITH ICA VALUES 
 Average 
% 
Std 
MAX A 
% 
MIN A 
% 
CORR P 
Accuracy of 
classification 
 
47.20 16.76 100 7.69 
 
0.4 
 
3.3x10-10 overlapping 
 
 
56.93 9.11 100 37.93 
Table 27 shows the statistics regarding the accuracy of classification and overlapping.(Results 
with ICA, learning set is ADNI and test set is NIMAD) 
 
 
Plot 1 shows the tendency between % of classification and overlapping (Result with ICA 
values, learning set is ADNI and test set is NIMAD). 
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RESULTS WITH PCA VALUES 
 Average 
% 
Std 
MAX A 
% 
MIN A 
% 
CORR P 
Accuracy of 
classification 
 
48.76 5.78 66.6 35.89 
 
 
  -0.20 
 
 
  0.4 
Overlapping 
 
 
58.89 8.39 82.75 37.93 
Table 28 shows the statistics regarding the accuracy of classification and overlapping.(results 
with PCA, learning set is ADNI and test set is NIMAD) 
 
 
Plot 2 shows the tendency between % of classification and overlapping (Result with PCA 
values, learning set is ADNI and test set is NIMAD). 
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LEARNING SET IS NIMAD AND TEST SET IS ADNI 
We considered first NIMAD data set as a learning set and introduced ADNI set as a test and 
obtained the results as follows. 
RESULT WITH ICA VALUES 
 
Average% Std 
MAX A 
% 
MIN A 
% 
CORR P 
Accuracy of 
classification 
47.55 13.89 100 17.24 
0.55 8.5x10-6 
Overlapping  51.79 9.48 100 30.76 
Table 29 shows the statistics regarding the accuracy of classification and overlapping.(Results 
with ICA, learning set is NIMAD and test set is ADNI) 
 
 
Plot 3 shows the tendency between % of classification and overlapping (Result with ICA 
values, learning set is NIMAD and test set is ADNI). 
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RESULT WITH PCA VALUES 
 Average% Std MAX A% MIN A% CORR P 
Accuracy of 
classification 
44 15.8 75.8 24.13 
-0.028 0.29 
Overlapping 51.17 8.04 71.7 33.33 
Table 30 shows the statistics regarding the accuracy of classification and overlapping.(Results 
with PCA, learning set is NIMAD and test set is ADNI) 
 
Plot 4 shows the tendency between % of classification and overlapping (Result with PCA 
values, learning set is NIMAD and test set is ADNI). 
2.4. DISCUSSION 
In continuation of the previous results, we applied a permutation test to assess whether 
the result of the classifier are significantly different from chance. The aim of this approach was 
to estimate the accuracy of the classifier. We chose two data sets, ADNI and NIMAD. We used 
one data set as learning and the other one as test set.  We use the standard permutation test to 
understand the behavior under the null hypothesis where data points and labels are 
independent. We produced 100 random permutations of the class labels for both the data sets 
ADNI and NIMAD, and perform the same leave-one-out cross-validation procedure to obtain a 
classification error for each randomized dataset.  
y = -0,0146x + 51,822 
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On the randomized samples of ICA values for all the data when used ADNI SET as learning 
set and test set NIMAD, we obtain an average accuracy of classification 47.20%, a standard 
deviation 16.76% and a minimum classification accuracy of 7.69%. The overlapping rate was 
56.93% with standard deviation of 9.11%, and minimum overlapping rate was 37.93%. These 
values result in p value 3.3x10-10 and a correlation coefficient was 0.4. For ICA values the 
classification rate before permutation of the ADNI data was obtained 100%. 
The randomized samples of PCA values for ADNI data set when used as learning set and 
test set NIMAD, we obtain an average accuracy of classification 48.70%,a standard deviation 
5.78% and a minimum classification accuracy of 35.89%. The overlapping rate was 58.89% with 
standard deviation of 8.39, and minimum overlapping rate was 36.91%. These values results in 
p value of 0.4 and a correlation coefficient of -0.20. For PCA values, the classification rate 
before permutation of the ADNI dataset was 100%. 
On the randomized samples of ICA values for all the data when used NIMAD SET as 
learning set and test set ADNI, we obtain an average accuracy of classification 47.50%,a 
standard deviation 13.89% and a minimum classification accuracy of 17.24%. The overlapping 
rate was 51.79% with standard deviation of 9.48%, and minimum overlapping rate was 30.76%. 
These values result in p value 8.5x10-6 and a correlation coefficient was 0.5. For ICA values,  the 
classification rate before permutation of the NIMAD data was 100%. 
The randomized samples of PCA values for NIMAD data set when used as learning set and 
test set ADNI, we obtain an average accuracy of classification 44.70% ,a standard deviation 15. 
8% and minimum classification accuracy is 24.13%. The overlapping rate was 51.17% with 
standard deviation of 8.04, and minimum overlapping rate was 33.31%. These values results in 
p value of 0.29 and a correlation coefficient of -0.028. For PCA values, the classification rate 
before permutation of the NIMAD data was 53%. 
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We have seen that we got the random result of 50%. Following the proof of contradiction 
we verify the negative of the null hypothesis. Thus we can say that the classifiers are significant 
under the null hypothesis that our data and labels are independent.  
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3. STUDY 3: LEARNING SET IS DIFFERENT FROM 
TESTING SET WITH INDIVIDUAL PCA ICA. 
So far we have built a classifier that has learned to discriminate AD and healthy subjects 
from the same imaging data set. Its good performance results leads us to think of it as a 
classifier that has consolidated main information features that are sufficient enough to deal 
with generalizations. However the previous results were obtained in case of PCA and ICA group 
analysis and this could introduce a bias. In real experiment each subject should be treated 
individually. We conducted individual PCA and Ica for each subject. This raises the issue 
described in chapter 8 of correspondence between the components drawn for group analysis 
and the components calculated from individual analysis, which individual component 
corresponds to which group component. To overcome this problem we defined the 
correspondence between components by choosing the component with maximum correlation 
of their time courses.  
To validate this statement we have thought of testing our classifier on another imaging 
data set, that is to say we build the classifier with one image set, let’s say the ADNI, and test it 
on another one, let’s say the NIMAD. Then we interchange the order. The results coming out of 
such tests will tell us the degree of robustness of the learning step and its capability of 
generalization. We have applied identical preprocessing feature extraction and learning 
algorithms to both data sets accordingly. 
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3.1. RESULTS 
RESULTS WITH SUPPORT VECTOR MACHINES (SVM) 
In this study we used ADNI AV-45 and NIMAD AV-45 datasets as shown in Table 7. We used 
Support vector machines (SVM) as a classifier The results are obtained by considering only ICA 
values.  
HEALTHY VS AD USING ICA 
 
 
 
 
HEALTHY VS MCI 
 
 
 
 
Le
ar
n
in
g 
Se
t 
Test Set 
 NIMAD 
confusion matrix (%) 
ADNI 
confusion matrix (%) 
NIMAD 
100               0 
18.18         81.82 
Accuracy: 89.41 
100                0 
22.22            77.78 
Accuracy: 93.10 
ADNI 
100               0         
27.27         72.73 
Accuracy: 84.62 
100                0 
18.18            81.82 
Accuracy: 89.74 
Table 31 shows the confusion matrix of H vs AD using AV-45 with two data sets ADNI & NIMAD. 
(Result with SVM-ICA, Hvs AD) 
Le
ar
n
in
g 
Se
t 
Test Set 
 ADNI 
matrix of confusion (%)  Accuracy # of IC 
ADNI 
45        55 
0.0       100 
83.58%       3 
Table 32 shows the confusion matrix of H vs MCI using AV-45 with data set ADNI. (Result with 
SVM-ICA,H vs MCI) 
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AD VS MCI 
 
 
 
RESULTS WITH ANN 
In this section we used Support vector machines (SVM) as a classifier The results are obtained 
by considering only ICA values. 
HEALTHY VS AD USING AV45 AND ICA-ANN 
 
 
Le
ar
n
in
g 
Se
t 
Test Set 
 ADNI 
matrix of confusion              
(%)  
Accuracy # of IC 
ADNI 
44.44    55.56 
0.00    100.00 
 83.58%       3 
Table 33 shows the confusion matrix of AD vs MCI using AV-45 with data set ADNI. (Result 
with SVM-ICA, AD vs MCI) 
Le
ar
n
in
g 
Se
t 
Test Set 
 NIMAD 
confusion matrix(%) 
ADNI 
confusion matrix(%) 
NIMAD 
100.00      0.00 
22.73     77.27  
Accuracy : 87.18 
95.00       5.00 
44.44      55.56  
Accuracy : 82.76 
ADNI 
100.00     0.00 
27.27      72.73  
Accuracy : 84.62 
100.00      0.00 
44.44      55.56  
Accuracy : 86.21 
Table 34 shows the confusion matrix of H vs AD using AV-45 with two data sets ADNI & NIMAD. 
(Result with ANN-ICA, H vs AD) 
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HEALTHY VS MCI USING AV45 AND ICA-ANN 
 
 
AD VS MCI USING AV45 AND ACI–ANN 
 
 
3.2. DISCUSSION 
These results show that the accuracy in AD discrimination from healthy varies from 84.62 
up to 93.10 with SVM method and from 82.76 to 87.18 with ANN method. The misclassification 
errors are from the Alzheimer patients, some of them are labelised as normal, where as normal 
subjects are always recovered completely (100%) with SVM except in the case of learning and 
testing with ADNI data when ANN method is used.  
So in the confusion matrix of normal vs AD, the specificity is the first term on the diagonal 
and the sensibility is the second term. 
We can see that the specificity of our classifiers is very high reaching very often 100%, 
whereas the sensibility is lower varying from 72.73 to 81.52 for SVM and from 55.56 to 77.27 
Le
ar
n
in
g 
Se
t Test Set 
 ADNI 
matrix of confusion (%)  Accuracy # of IC 
ADNI 
50.00  50.00 
2.13  97.87 
83.58%       3 
Table 35 shows the confusion matrix of H vs MCI using AV-45 with data set ADNI. (Result with 
ANN-ICA, H vs MCI) 
Le
ar
n
in
g 
Se
t 
Test Set 
 ADNI 
matrix of confusion 
(%)  
Accuracy 
 (%) 
# of IC 
ADNI 44.44 55.56 
4.26 95.74 
 87.50%       3 
Table 36 shows the confusion matrix of AD vs MCI using AV-45 with data set ADNI. (Result 
with ANN-ICA, AD vs MCI) 
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for ANN. This is the main difference between the two methods; SVM seems to have a much 
better sensibility in normal vs AD discrimination. 
The discrimination of normal vs MCI and AD vs MCI were hindered by the scarcity of the 
data, only ADNI data could be used with a limited number of Alzheimer patients (n=9). 
Nonetheless, we can see that the discrimination normal or Alzheimer’s from MCI is difficult 
although the accuracy is 83.58 (Healthy vs MCI) and 98.21 (Alzheimer’s vs MCI) for SVM and 
83.58 (normal vs MCI) and 87.60% (AD vs MCI) for ANN. The MCI patients are recovered 
completely but more than half of the normal or AD is classified as MCI except for SVM in 
Alzheimer vs MCI discrimination (88.89 %). 
NORMAL VS ALZHEIMER 
2/20 Normal        subjects 2 7 20               weigths :0.2076   0.5470   0.4514 
4/9 AD :               subjects 1 2 4                 weigths : -0.5113  -0.2114  -0.4834 
Weigths of time course :0.2654    0.2311    0.2731         0 
NORMAUX VS MCI 
2/20 Normal subjects 2 7 20weigths : 0.2164   0.5685   0.4695 
2/47 MCI :subjects 26  33 weigths : -0.3268  -0.6275  
Weigths of time course :0.3270    0.2732    0.2852        0 
ALZHEIMER VS MCI 
8/9 AD  subjects 2 7 20 weigths :1.0e+006 for 7 and 0.44590e+006 for the 8th 
18/47 MCI       subjects weigths: All negative Varying between -0.0510 0e+006 and -1.0e+006 
Weigths of time course: 1.0e+005 (0    4.1253    1.0751    2.3960) 
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Both SVM and ANN successes to discriminate healthy from Alzheimer’s with an accuracy 
reaching 93.10% for SVM when the learning set (NIMAD) is different from the test set (ADNI). 
The differences seen between ADNI set and NIMAD set either as training set or test set should 
be examined carefully because ADNI set is largely unbalanced, the number of normal subject is 
2,3 larger than the number of Alzheimer patients, whereas in NIMAD the ratio is 1.3 in favor of 
Alzheimer. Due to this unbalance, the sensitivity and specificity should also be taken with care. 
When it comes to the discrimination of MCI from normal or Alzheimer, the accuracy falls 
down even if it stays comparable to that found in the literature. SVM and ANN performed 
equally for Healthy vs MCI (83.58%) but ANN showed better result (87.5) than SVM. Again the 
sensitivity and sensibility should be taken with care because the number of MCI (n=47) is much 
larger than the number of normal or Alzheimer. 
When we look at the support vectors and their weights, we can see that the model found 
for any discrimination task is very sparse, a very few of subjects are included in the model  and 
even the weights of the time courses are also sparse, only 3 among the four are used, the forth 
is set to 0. The sparse nature of SVM method is an advantage to avoid the overfitting. 
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4. STUDY 4: SPATIAL INTERPRETATION OF ICA 
The aim of the study was to analyse the spatial differences between the ICA image of a 
AD, MCI and normal subject. Infact each ICA component is caracterised by a specific time 
course (we have used for classification in results presented earlier) and one image. In this study 
the IC image does not show the rate of fixation of the tracer but it reflects the similarity 
between the time course of each pixel in the subject with the time course so the component 
itself. It shows the similarity of the time course in the subject at the time course of component. 
In other words, rate of fixation of tracers do not depend on the relationship of time courses. 
The rate of fixation of AV 45 can be seen in Table 37 that it is much higher in AD subjects for 
each time frame as compare to other subjects in other groups.  
In the previous results (results from classification and random permutation), we have 
noticed that independent component # 2 provided best results in discriminating the healthy 
subjects from AD and MCI. So we will consider this component for further study. We will see 
the relationship of time course associated with this component with the time courses 
associated with original images. 
Time Course Normal MCI AD 
 Mean Std Mean Std Mean Std 
T1 1.3037 0.0917 1.3379 0.0788 1.5634 0.0621 
T2 1.3044 0.0954 1.3467 0.0911 1.5627 0.0659 
T3 1.3085 0.1051 1.3419 0.0866 1.5690 0.0751 
T4 1.3048 0.0963 1.3504 0.0842 1.5701 0.0713 
Table 37 shows the rate of fixation of tracer AV 45 (ADNI) in different time frames. We can see that 
rate of fixation of tracer is much higher in every frame of time in AD as compare to MCI and normal 
subjects. 
We have decided to include ADNI AV-45 images for this study. We have divided out 
analysis in three groups Healthy vs AD, Healthy vs MCI and MCI vs AD. All the comparisons were 
done with the help of statistical parametric mapping (SPM) implemented in matlab. 
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4.1. RESULTS 
RESULTS WHEN NORMAL>AD 
The regions which shows higher values in normal subjects as compare to AD are left cuneus, 
bilateral middle frontal gyrus, Right superior frontal gyrus (BA 10) and left post central gyrus 
(BA 3).Figure 32,Table 38. 
 
Figure 32 shows the regions which 
reflect the high similarity in the time 
courses of the IC and the time courses 
of the original images of normal 
subject as compare to AD. (P<0.01 
and S=100). 
 
 
 
 
 
 
Region of Interest 
MNI Coordinates Cluster 
size 
T value 
Z Score 
x y z 
Left cuneus -10 -96 6 491 4.98 4.16 
Left inferior frontal gyrus -50 24 -6 
361 
5.15 4.26 
Left middle frontal gyrus (BA 11) -40 32 -12 3.56 3.19 
Right middle frontal gyrus 24 68 6 
399 
5.13 4.25 
Right superior frontal gyrus (BA 10) 26 64 -10 4.60 3.92 
Left postcentral gyrus(BA 3) -42 -24 60 254 5.04 4.20 
Right orbital gyrus (BA 47) 22 26 -28 
437 
4.66 3.96 
Right inferior frontal gyrus 28 30 -24 3.80 3.37 
Table 38 statistical results of different brain regions have higher value in normal subjects as compare 
to AD. (P<0.01,S=100) 
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RESULTS WHEN AD>NORMAL 
The regions which show higher values in AD subjects as compare to normal subjects are left 
putamen, mid brain, left precentral gyrus (BA 44) and left cerebellum. Table 39 
Figure 33, 
 
 
 
Figure 33shows the regions which reflect the 
high similarity in the time courses of the IC 
and the time courses of the original images 
of AD subject as compare to normal 
subjects. (P<0.01 and S=100) 
 
 
 
 
Region of Interest 
MNI Coordinates 
Cluster size T value 
Z Score 
x y z 
Left putamen -20 6 0 902 5 .19 4.29 
Midbrain 6 -22 -2 
664 
5.18 4.28 
Midbrain 12 -20 -18 4.66 3.96 
Left cerebellum -20 -56 -32 301 4 .53 3.87 
Left precentral gyrus(BA 44) -50 10 4 
220 
5.26 4.33 
Left precentral gyrus -48 2 10 4.54 3.89 
Table 39 shows the statistical results of different brain regions which have higher value in AD subjects 
as compare to Normal. (P<0.01, S=100) 
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RESULTS WHEN MCI>AD 
The regions which show higher values in MCI subjects as compare to AD subjects are left. 
Supramarginal gyrus, right precentral gyrus, left precuneus, left fusiform gyrus.  
Figure 34,Table 40 
 
 
Figure 34shows the regions which 
reflect the high similarity in the 
time courses of the IC and the time 
courses of the original images of 
MCI subject as compare to AD 
subjects. (P<0.01 and S=100). 
 
 
 
 
Region of Interest 
MNI Coordinates Cluster 
size 
T value 
Z Score 
x y z 
Right precentral gyrus (BA 6) 68 -6 26 459 5.57 4.93 
Left supramarginal gyrus(BA 40) -60 -58 36 205 4.22 3.90 
Left precuneus (BA 7) -2 -58 66 167 3 .82 3.58 
Right inferior temporal gyrus (BA 37) 60 -62 -12 166 5.20 4.66 
Left fusiform gyrus (BA 19) -22 -84 -12 140 3.88 3.63 
Right Lingual gyrus 10 -96 -16 146 4.64 4.24 
Table 40 shows the statistical results of different brain regions have higher value in MCI subjects as 
compare to AD. (P<0.01,S=100) 
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RESULTS WHEN AD>MCI 
The regions which show higher values in AD subjects as compare to MCI subjects are left. 
Inferior frontal gyrus (BA 47), right putamen, left cerebrum and left medial frontal gyrus.Figure 
35, Table 41. 
 
Figure 35shows the regions which reflect 
the high similarity in the time courses of 
the IC and the time courses of the 
original images of AD subject as compare 
to MCI subjects. (P<0.01 and S=100). 
 
 
 
 
Regions of Interests 
MNI Coordinates 
Cluster size T value 
Z Score 
x y z 
Left inferior frontal gyrus (BA 47) -38 16 -4 335 3.66 3.45 
Right putamen 22 16 -2 175 4.23 3.92 
Left cerebrum -22 -24 -4 151 3.69 3.47 
Left medial frontal gyrus -12 62 -6 134 4.09 3.80 
Table 41 shows the statistical results of different brain regions have higher value in AD subjects as 
compare to MCI. (P<0.01, S=100) 
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4.2. DISCUSSION 
The present study demonstrates the cerebral changes in Alzheimer’s disease (AD), Mild 
cognitive impairment and healthy subjects using the voxel based statistical parametric mapping 
(SPM).We considered the IC’s components which proved to be excellent in discriminating 
healthy from AD in ADNI AV-45. We selected ADNI AV-45, with component number 2 is 
providing maximum accuracy so we selected ICA component # 2 to be considered for this study. 
In this study, we observed alteration in different cerebral regions in healthy subjects from MCI 
and AD. Some of them are already observed, some are contrary to previous studies and some 
of them are reported first time in this study.  
Voxel based analysis of ADNI AV-45; firstly we did the comparison between normal 
subjects and AD subjects. We found that the regions where normal subjects show more 
changes are mostly frontal areas. Such as left cuneus, bilateral middle frontal gyrus, Right 
superior frontal gyrus (BA 10), left superior temporal and left post central gyrus (BA 3).The left 
IFG is extremely important for language production and verb comprehension (left side 
corresponds to the 'dominant side', for right-handed persons),commonly known as "Broca's 
Area". The temporal superior areas are involved in the perception of emotions in facial stimuli. 
(Bigler et al., 2007; Radua & Mataix-Cols, 2009). Furthermore, the superior temporal gyrus is an 
essential structure involved in auditory processing, as well as in the function of language in 
individuals who may have an impaired vocabulary, or are developing a sense of language. The 
regions which show higher values in AD subjects as compare to normal subjects are left 
putamen, mid brain, left precentral gyrus (BA 44) and left cerebellum. The regions which show 
higher values in MCI subjects as compare to AD subjects are left. Supramarginal gyrus, right 
precentral gyrus, left precuneus, left fusiform gyrus. The regions which show higher values in 
AD subjects as compare to MCI subjects are left. Inferior frontal gyrus (BA 47), right putamen, 
left cerebrum and left medial frontal gyrus 
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The literature based on Alzheimer’s disease have shown that the early development of 
AD occur in a prodromal stage, years before when it can be clinically detected, may encourage 
some other approaches to participate in the detection. In this advancement, nuclear imaging 
plays an important role. The effectiveness of nuclear imaging in the early diagnosis of AD has 
been widely studied, through qualitative analysis (Braak & Braak, 1997; Cummings JL., 1998; 
Hoffman JM, 2000 Nov), or by voxel-wise statistical analysis. Nowadays in brain imaging, 
computer aided approaches are proved to be powerful analysis tools. This approach allows to 
consider a single scan (all the voxel in single scan) for whole brain analysis unlike SPM. 
Selecting classification technique means choosing the rules that form the basis of the 
annotation process. Numerous classification strategies have been developed. Earlier nearest 
neighbor-based tools were used e.g. (Deselaers, Keysers, & Ney, 2005; Guld, Thies, Fischer, & 
Lehmann, 2005) but later, discriminative approaches such decision trees (Setia, Teynor, 
Halawani, & Burkhardt, 2008) as well as Support Vector Machines(Setia, et al., 2008)  and 
Artificial Neuron Networks (ANN) (Gutierrez-Celaya, et al., 2011; Mhd Saeed Sharif, Abbod, 
Amira, & Zaidi, 2010)became more and more common and outperformed the nearest 
neighbor–based approaches. The training sets are used as the image database and the test sets 
are used to query it. Analogous to feature combination, classifier combination has also been a 
popular way to improve performance (Rahman, Desai, & Bhattacharya, 2006). These techniques 
tend to perform much better while dealing with multi dimensional and continuous features. 
Moreover, they also perform well when we have a large dataset. 
The aim of this work has not been to introduce a new classification approach but 
instead to use a readily available SVM and ANN classifiers along with feature extraction 
approach for improving the classification amongst different diagnostic groups. In our work, we 
have investigated classification accuracy for discriminating AD, MCI and normal subjects using 
18-FDG and AV-45. We adopted two machine learning techniques, support vector machines 
(SVM) and artificial neural networks (ANN) classification algorithms. 
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The machine learning approaches used for classification purposes may suffer with the 
dimensionality issues  These issues occurs when the number of available features are much 
larger in number as compare to the available training examples. To solve this issue in 1991, 
Pentland developed a solution based on the eigen image approach. It was originally applied on 
the face detection problem.(pentland, 1991). The decomposition of eigen image of Principal 
component analysis (PCA) or independent component analysis (ICA) allows to find the 
underlying specific patterns. These patterns help to differentiate the population even if the 
differences are very minor. When it is required to diagnose AD, where eigen image analysis has 
been successfully used many times(Álvarez et al., 2009; Lopez et al., 2009) and for PET imaging 
(L et al., 2011). We used ICA based feature extraction technique (V. D. Calhoun, et al., 2001) for 
classification. Very pertinent and high accuracies for discriminating between AD patients ,MCI 
patients and controls subjects were obtained using only 18-FDG or only AV-45 or by data 
trained on one and test on other. To verify the statistical significance of the classifier, 
Permutation testing approach was adopted. 
Support vector machines(Cortes & Vapnik, 1995)  is a very popular classifier and one of 
the machine learning approach based on the statistical learning theory, has been recently used 
to help distinguish AD subjects from other healthy controls using PET images (Chaves, Ramirez, 
Gorriz, Illan, Gomez-Rio, Carnero, et al., 2012; Dukart, Mueller, Barthel, Villringer, Sabri, 
Schroeter, et al., 2013). Artificial Neural Networking (ANN) is a technique which has a capability 
to learn from a dataset, construct a weight matrix to represent the learning patterns. This 
technique has many applications like feature extraction, classification and function 
approximation. 
We investigated classification accuracies of machine learning techniques for detection 
of AD and MCI using PET-18FDG and PET-AV45 using single modality. Thereby, using GroupIca 
approach (Khabbazi et al., 2012), we extracted ICA and PCA feature  matrixes for SVM and ANN 
classification. For discrimination between AD patients from MCI and control subjects, very high 
accuracies up to 100% were obtained from both classifiers. If we do comparative analysis of our 
results between SVM and ANN classifiers, we can see that for ADNI-AV45 both classifiers have 
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given same results with an accuracy of 100% for ICA and PCA values. For dataset NIMAD, the 
accuracy obtained from ICA values was 100% for both classifiers .For PCA values an accuracy of 
68% and 53 % were obtained from ANN and SVM respectively. For data set ADNI-30min, using 
SVM classifier the accuracy 93.75% and 84% was obtained using SVM and ANN respectively. For 
FDG60min dataset, the obtained accuracy was 100% using ICA values for SVM and ANN 
whereas for PCA values, ANN obtained 84% accuracy which reduced to 66.97% for SVM. 
SVM and ANN classification techniques not only enables us to do the classifications 
using single modality and single biomarker but it also provides a tool for the combination of 
information from different modalities and biomarkers within the same classification model. This 
not only helps improving detection (Hinrichs, Singh, Xu, & Johnson, 2009)but also 
differentiation of Alzheimer’s disease and frontotemporal lobar degeneration (Dukart et al., 
2011a). 
Some studies like (Dukart, et al., 2011a) considered information from FDG-PET and MRI 
while training classifier on one cohort for the prediction of other cohort. While all studies 
applying multivariate statistical methods(Chaves, Ramirez, Gorriz, Illan, Gomez-Rio, Carnero, et 
al., 2012; Davatzikos, Resnick, Wu, Parmpi, & Clark, 2008; Hinrichs, et al., 2009)have 
demonstrated a good differentiation rates for different dementia syndromes, some high 
accuracies are obtained  with a trade-off in generalizability of the proposed approaches to new 
datasets. This is due to the feature extracted for the purpose of classification was obtained 
from biased methods. 
We also suggest that GroupIca is a good approach for extracting the feature in order to 
differentiate AD from MCI and normal subjects. Additionally, our results suggests that our 
classifiers SVM and ANN are well trained on ADNI, which is an open access and multicenter 
database, result in very good discrimination accuracy for new data (NIMAD) ,This approach 
even increase its application in clinical environment using, ADNI data to train artificial neural 
network(ANN) and support vector machine (SVM) classifier using the reported feature 
coordinates. It is necessary to do some preprocessing of these algorithms and to make them 
 160 
 
constant between training and test sets, because the preprocessing may affect the feature 
weight distribution. Once the preprocessing is done, the classifier can then be applied for the 
discrimination of the classes. The approach not only provides the binary predicted level and 
also the probability of the subject to belong to certain class. There by improving single subject 
diagnosis of AD as a supportive feature. 
We used the time courses of Independent Components of principal component to 
characterize the subjects and as features to discriminate between controls and AD/MCI. This is 
a large information reduction compared to the VOIs approach which tries to take into account 
the FDG uptake on numerous regions. On other hand our approach is a dynamic one is more 
informative on the temporal change of the uptake compared to the single frame approach. This 
seems very discriminative information even if it is very few. To handle the temporal image 
information, the best approach is to use functional MRI, but fMRI is specific to the 
hemodynamic aspect and we lose the metabolism utilization aspect (FDG) and brain amyloid 
quantification possibility offered by AV45. However we cannot exclude the hemodynamic side 
in our dynamic data even if it is a very global measure. Regarding the hemodynamic account 
many useful knowledge can be drawn from the BOLD fMRI imaging. The BOLD signal is typically 
used as a surrogate of neuronal activity in cognitive studies of aging, and the amplitude and 
extent of BOLD signal changes are often compared between young and older adults. Some 
studies have shown that such comparisons are biased, since aging is associated with a 
decreased BOLD reactivity. This change in hemodynamic properties in the older adults means 
that similar BOLD signal changes in response to a task may in fact reflect different underlying 
neuronal responses. It is important to assess how hemodynamic response changes during aging 
before to use it as disease biomarker. 
Some studies explored the neural basis of age-related performance declines by 
comparing the BOLD index of neural activity in older and younger adults during visual task 
performance (Buckner, 2001; Huettel, Singerman, & McCarthy, 2001; Hutchison, Lu, & Rypma, 
2012; Pasley, Inglis, & Freeman, 2007; Ross et al., 1997). They used fMRI to measure BOLD 
activity through the hemodynamic response function (HRF, the time-response function that 
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describes the relationship between neural and vascular activity; (Gössl, Fahrmeir, & Auer, 
2001). Age-related changes in BOLD activity across cortex and tasks are often considered as 
age-related alterations in neural activity e. g (CL., 2002; Gabrieli, 2004).Such a straightforward 
interpretation is complicated by the fact that neural activity is only one of several factors that 
can change with age and lead to BOLD signal differences (Moeller JR, 1996; Rypma, Berger, 
Genova, Rebbechi, & D'Esposito, 2005; Rypma & D'Esposito, 2000). (Hyder, 2004) 
demonstrated that fractional changes in cerebral metabolic rate of oxygen (ΔCMRO2) closely 
approximate neural activity (measured by extracellular recording) during sensory stimulation. 
Thus, ΔCMRO2 would be preferable to the BOLD response as an index for neural activity.  
In PET imaging, 18F-FDG is used for the assessment of glucose metabolism in the brain. 
18F-FDG is taken up by cells, and retained by tissues with high metabolic activity. As a result the 
measurement is likely to be less dependent on hemodynamic than BOLD measurement. 
However we don’t know at what extend this is true. The other tracer we tested is the18F-AV-45 
(Florbetapir F-18) which is a novel 18F-labelled positron emission tomography (PET) tracer for 
in vivo imaging of cerebral amyloid deposition. Again the specificity of that tracer is likely to 
make the measurement independent, at some extent, from the hemodynamic response.  
Our population is matched in age and gender and so we performed all classification 
experiments without accounting for the effects of age and gender. However in future age and 
gender experiments should be taken into account. This can be done by regressing out age and 
gender at the level of the original scans. In this dissertation we do the classification using single 
imaging modality. As SVM and ANN classification techniques enables for the combination of 
information from different modalities and biomarkers within the same classification model. So 
in future we will expand our work to used multimodality and different biomarkers to combine 
the information and further explore the results. 
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We investigated the applicability of our support vector machines (SVM) and artificial 
neural network (ANN) approaches for the discrimination of Alzheimer’s disease (AD) from mild 
cognitive impairment (MCI) and control healthy subjects by using 18-FDG and AV-45. Our 
approach differed from the very few studies using PET imaging to discriminate AD, MCI from 
Controls by two respects, the first one is the utilization of dynamic imaging and the second is 
the adjunction of AV45 tracer to the FDG tracer.  Feature extraction to feed the classifier was 
based on the time courses of components obtained by PCA and ICA. We compared AV45 and 
FDG. We found AV45 outperformed the FDG tracer.  It seems that ICA is not suitable for FDG 
images; the process of extraction of Independent Components does not converge.  
Globally, our results were in accordance with previous studies, some results proved to 
be better. When we used group ICA we reached 100% accuracy, suggesting that the results we 
obtained in case of individual ICA are certainly perfectible, depending on the way the individual 
components are projected on the group components. This aspect should be explored more 
deeply in future experiments.  
When we compare SVM method to the AAN method, we found that SVM is more 
specific than AAN in some situations. The relevance of such methods to the clinical applications 
is depending on reproducibility, we have shown that our approach is powerful enough to give 
considerable results in case of training on one set and testing subjects from another sets 
coming from different centers and no special requirements of acquisition normalization. 
However we cannot argue that the classification using PET images is now the standard gold, we 
think that this method could be very helpful when used in conjunction with other imaging 
technique as MRI or fMRI
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RESUME en FRANÇAIS 
INTRODUCTION 
 La maladie d'Alzheimer (AD) nommée d'après le médecin allemand Alois Alzheimer a été 
documentée en 1907. Elle est définie comme la démence progressive qui se traduit par de 
graves troubles cognitifs et la perte de mémoire. En France, la maladie d'Alzheimer touche 
850 000 personnes. 225 000 nouveaux cas sont recensés tous les ans. La neuro-imagerie a joué 
un rôle majeur dans l'étude de la maladie d'Alzheimer. Différentes modalités d'imagerie telles 
que la tomographie par émission de positons (TEP) et l'imagerie par résonance magnétique 
(IRM) ont montré quêtes changements dans le cerveau de patients AD statistiquement 
significatifs sont caractéristiques de cette maladie. Pour l'imagerie TEP, différents bio 
marqueurs d'imagerie ont été utilisés, tels que le F-18 FDG PET qui montre un hypo 
métabolisme du glucose et le Florbetaben AV45-PET qui donne une indication sur la charge β 
amyloïde, connue pour être utile dans le diagnostic de la maladie d'Alzheimer. Cependant le 
diagnostic reste difficile : la moitié ou plus des patients ne seraient pas reconnus au début de la 
maladie. Diagnostiquer plus tôt la maladie permettrait de pouvoir retarder son évolution et de 
mieux comprendre sa genèse. L'enjeu est double : d'une part mieux prendre en charge les 
patients et d'autre part, développer de nouveaux médicaments. 
De nombreuses études ont été menées avec différentes méthodes pour pour fournir un 
outil automatique qui aide le clinicien dans le processus de diagnostic de la MA ( Garibotto V et 
al., 2013; Frederiksen KS et al., 2012; Duara R et al., 2012; Dukart J et al., 2013; Gray KR et al., 
2013; Gray KR et al., 2012; Vandenberghe R et al., 2013; Caroli A et al., 2012; Joshi AD et al., 
2012; Zhang D et al.,2012; Padilla P et al.,2007; Segovia F et al.,2010). Ces approches peuvent 
être subdivisées en deux catégories: univariée et multivariée. L'approche univariée comprend la 
cartographie paramétrique statistique (SPM) et ses nombreuses variantes. SPM est une analyse 
voxel à voxel, en comparant statistiquement les valeurs des images étudiées aux valeurs 
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moyennes d'images de groupe obtenues chez des normaux. Les voxels significativement 
différents sont détectés en utilisant la théorie des champs aléatoires. La méthode SPM est plus 
adaptée pour des comparaisons de groupes plutôt que pour décider pour un sujet donné s’il est 
normal ou Alzheimer. L'approche multivariée est basée, le plus souvent, sur l'analyse des 
images, l'extraction de caractéristiques et la classification des sujets à partir de ces 
caractéristiques dans les différentes classes. Les méthodes de classification se décomposent en 
classification supervisée et classification non supervisée. Dans le premier cas, une première 
étape permet au classificateur un apprentissage des caractéristiques moyennes de chacune des 
classes à partir d’un ensemble de sujets dont on sait qu’ils appartiennent à l’une ou l’autre des 
classes. Cette phase d’apprentissage est ensuite suivie d’une phase de classification où il est 
possible de connaître, avec une certaine probabilité,  à quelle classe appartient un sujet donné. 
La classification « non supervisée » suit le même principe sauf que dans l’ensemble 
d’apprentissage la classe de chacun des sujets n’est pas définie a priori, c’est le programme qui 
décompose cet ensemble en différentes classes. 
Dans la première partie de cette thèse, qui couvrira les chapitres de 1 à 3, nous 
présentons les aspects fondamentaux de la modalité d’imagerie, de la maladie d’Alzheimer 
ainsi que des techniques et des algorithmes qui ont été utilisés dans ce travail ainsi que l’état de 
l’art. Dans la deuxième partie, au chapitre 4, nous décrirons les différentes expériences d’où 
ont été prises les données traitées, la méthodologie d’extraction des caractéristiques, et la 
manière dont les classificateurs ont été mis en œuvre. Dans le chapitre suivant, nous donnerons 
les résultats obtenus dans différentes situations, d’abord lors de la validation croisée, en cas 
d’apprentissage imparfait, et lorsque la classification est faite sur des données différentes de 
celles de l’apprentissage. Enfin nous examinerons l’interprétation spatial des composantes 
ayant fourni le meilleur taux de classification. Un dernier chapitre sera consacré à la discussion 
qui sera suivie de la conclusion.  
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MATERIEL et METHODES 
L’un des principaux problèmes qui se pose pour l’application de ces techniques est le 
choix des caractéristiques, notamment lorsque leur nombre est plus important que le nombre 
d'échantillons disponibles dans la base d’apprentissage. Une solution consiste à utiliser 
l'analyse en composantes principales pour réduire la dimensionnalité de l’espace des 
caractéristiques, ce qui offre l’avantage supplémentaire de ne prendre en considération que les 
caractéristiques les moins corrélées. L’autre possibilité est de ne prendre qu’un nombre limité 
de régions d’intérêt ou VOIs connues pour être impliquées dans la maladie d'Alzheimer. 
Cependant ce choix peut masquer certaines différences qui n’étaient pas prévisibles à l’avance 
et limiter ainsi les possibilités de différentiation entre patients et sujets normaux. 
Les classificateurs les plus utilisés sont: Support Vector Machines (SVM) et les réseaux 
de neurones (NN).En ce qui concerne les images TEP, les méthodes SVM (Dukart et al, 2011b; 
KR Gray et al, 2011) et les réseaux de neurones artificiels (ANN) (M. López, 2009), (BC Calhoun, 
Gomes, Robert, et Jain, 2001) ont montré qu’elles pouvaient aider à la détection et la 
différenciation des patients Alzheimer, des sujets avec une atteinte cognitive modérée (Mild 
Cognitive Impairment ou MCI) et des sujets normaux. Habituellement, les auteurs utilisent une 
procédure de recalage d’images pour mettre toutes les images dans un même cadre (souvent le 
cadre ou « template » du Montreal Neurological Institute ou MNI), ce qui permet de définir 
facilement des VOIs. Les valeurs moyennes de ces VOIs sont les données d’entrées du 
classificateur. (Dukart, et al, 2011b) ont sélectionné 9 régions: gyrus angulaire (BA 39, Gauche 
et Droit), sillon temporal supérieur postérieur (BA 21/22), le cortex frontal antérieur médian 
droit (BA 9/10), gyrus cingulaire antérieur (BA 32), le precuneus droit (BA 31), le cortex 
cingulaire postérieur (BA 23), le sillon temporal supérieur postérieur gauche (BA 21/22), et le 
sillon temporal inférieur moyen (BA 20). Ces VOIs sont été choisis car il a été observé des 
réductions maximales d'utilisation du glucose chez les AD par rapport aux normaux. Les auteurs 
ont également utilisé 6 VOIs à partir d'images anatomiques IRM pour analyser l’atrophie 
corticale  
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Dans l’étude rapportée dans. (Katherine R. Gray et al. , 2012) , les auteurs ont sélectionné 83 
régions dans les images TEP-FDG, définies à partir d'images IRM anatomiques. Ils ont utilisé 
deux images une image de référence et une image à 12 mois d’intervalle afin d'évaluer l’intérêt 
de leur utilisation combinée pour le classification. 
Pour pouvoir comparer les images MCI AD et des sujets contrôle, il est nécessaire de normaliser 
l'intensité dans les images, en effet la valeur absolue dans un pixel donné dépend de plusieurs 
paramètres (injection du produit radioactif, débit sanguin cérébral, …). Cette  normalisation est 
souvent réalisée par rapport à la moyenne globale cérébrale. Toutefois , en raison de la nature 
du processus de la maladie , les patients MCI et AD ont un taux de métabolisme du glucose 
inférieur aux normaux à travers l'ensemble du cerveau. La normalisation par la moyenne 
globale cérébrale peut donc augmenter de manière artificielle les valeurs des intensités chez les 
patients tout en révisant à la baisse celles des normaux, ce qui entraîne une sous-estimation du 
l’hypométabolisme chez les patients par rapport aux normaux (Iakouchev et al. , 2009). En 
outre, il est possible d’observer un hypermétabolisme chez les patients comparativement aux 
sujets normaux dans des régions qui sont peu affectées par la maladie d’Alzheimer, telles que le 
cervelet , le tronc cérébral , les noyaux gris centraux , et le cortex sensori-moteur ( Herholz et 
al. 2002 ). Quelques travaux suggèrent que l'amélioration de la discrimination de groupe peut 
être réalisée en utilisant l'intensité du signal dans ces régions relativement préservés du 
cerveau pour la normalisation, plutôt que la valeur moyenne globale (Borghammer , Aanerud , 
et Gjedde 2009, Iakouchev , 2009). Encore faut-il être sûr que ces régions ne sont pas affectées 
par la maladie. Nous avons utilisé la normalisation par la moyenne et par le cervelet, nous 
retrouvons des résultats de classification semblables dans les deux cas. 
Notre approche diffère de l'approche de sélection de VOI, nous avons utilisé des 
données temporelles qui permettent la décomposition des images en composantes principales 
et composantes indépendantes. Nous avons utilisé le décours temporel de ces composantes 
comme caractéristiques pour classer les sujets. L’application de l’ICA est très nouvelle en 
imagerie TEP pour la discrimination entre AD, MCI et Normaux, puisque l'ICA est principalement 
utilisée en  IRM fonctionnelle pour analyser l'imagerie dynamique. 
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 Le but principal de notre étude était de mettre au point une méthode de classification 
automatique basée sur la méthodologie « machine learning ». Nous avons utilisé deux 
techniques de classifications différentes, SVM et les réseaux de neurones artificiels (ANN). Nous 
avons utilisé deux bio marqueurs : AV- 45 et 18 -FDG pour la classification des patients atteints 
de MA de MCI et les contrôles. A notre connaissance, c'est la première étude sur le traceur AV-
45 qui combine la classification SVM et l’ICA. Nous avons évalué deux approches de calcul d’ICA 
dans la phase d’apprentissage, une approche ICA de groupe et une autre où les composantes 
sont extraites sujet par sujet. Nous avons testé les performances de nos classificateurs à l’aide 
de la méthode validation croisée LOOCV (Leave One Out Cross Validation). Nous avons 
également utilisé deux ou trois ensembles de données provenant de lieux différents et nous 
avons réalisé l’apprentissage sur un ensemble et tester la classification sur un autre ensemble. 
Nous avons aussi testé la validation de nos classificateurs en faisant des tests de permutation, 
ce qui nous a permis d’évaluer la robustesse des classificateurs en cas d'apprentissage imparfait 
c'est à dire lorsque certains sujets sont pris comme témoins alors qu'ils sont AD et inversement 
quand d'autres sont considérés comme AD alors qu'ils sont témoins. 
L’approche ICA de groupe pour l'extraction de caractéristiques semble si prometteuse 
que certaines composantes nous ont permis de discriminer les AD des sujets normaux avec un 
taux de classification de 100%. Cette étude est la première qui peut distinguer les AD des autres 
avec une précision de 100%. Le résultat des tests de permutation nous a permis de valider la 
performance de notre classificateur. Dans de nombreuses disciplines utilisant les méthodes de 
classification telles que machines à vecteurs supports et réseaux de neurones, le problème 
fondamental est de trouver la représentation appropriée des données multi variées à fournir en 
entrée du classificateur. L'Analyse en Composantes Principales (ACP ou PCA) est l'une des 
méthodes de représentation et de compression des données les plus utilisées. L'APC permet de 
déterminer la structure interne de l’ensemble de données en utilisant le  critère de variance. 
Les vecteurs propres et leurs valeurs propres correspondants déterminent les dimensions qui 
expliquent au mieux la variance des données d'origine. L'importance de cette méthode est que 
l'ensemble de données d'origine peut être représentée avec seulement quelques paramètres 
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qui sont des transformations linéaires orthogonales de l'ensemble de données d'origine. Dans 
les données que nous avons utilisé les images ont été acquises en mode dynamique et chaque 
sujet est représenté par n images, le nombre n de la durée d'acquisition. Ces images ont été 
transformées par ACP puis ICA . 
L'analyse en composantes indépendantes (ICA) est le procédé de transformation linéaire 
des données, semblable à l'analyse factorielle et l'analyse en composantes principales (ACP). 
L’ICA contrairement à l'ICA suppose que les données sont non - gaussiennes. La différence 
essentielle entre l'ACP et l'ICA est que la première produit des composantes non-corrélées et 
donc indépendantes si elles sont gaussiennes tandis que l'ICA recherche des composantes 
indépendantes sans hypothèse de gaussiannité (l'indépendance est d'un ordre supérieur à 2).  
Nous avons utilisé ces deux méthodes (PCA,ICA) dans des analyses de groupes. Le 
problème de l'analyse de groupes est de déterminer un espace de vecteurs propres qui est 
commun à tous les sujets et ensuite de projeter chacun des sujets dans cet espace. Il existe 
essentiellement deux techniques pour les analyses de groupes: la première est de réaliser l'ICA 
ou PCA séparément sur chaque individu, puis de les combiner pour trouver l'espace commun, 
et la deuxième consiste à introduire l'ensemble es sujets dans l'analyse PCA ou ICA pour avoir 
un espace commun et ensuite de projeter chaque sujet dans cet espace. Cette deuxième 
méthode est plus cohérente et plus facile à réaliser et peut être appliquée à condition de 
supposer que l'espace commun existe. Dans notre travail nous avons opté pour cette méthode.  
Nous avons utilisé le logiciel GIFT (VD Calhoun, T. Adali , GD Pearlson , et JJ Pekar , 2001) 
L'approche d'ACP et d'ICA comprend plusieurs niveaux de réduction des données obtenus par 
concaténation successives, suivie d'une reconstruction par sujet. 
Nous avons réalisé la classification en utilisant comme données d'entrée au 
classificateur le vecteur d'évolution temporelle caractérisant chacune des composantes. La 
classification consiste à déterminer une fonction de décision à partir d'un ensemble 
d'apprentissage. Ainsi les données sont divisées en deux ensembles : un ensemble 
 199 
 
d'apprentissage et un ensemble de test. La fonction de décision consiste à modéliser la relation 
entre les caractéristiques et l’étiquette de la classe.  
La méthode SVM de séparation en deux classes consiste à construire une surface de 
séparation qui maximise la distance (qui s'appelle aussi "la marge") entre les points les plus 
proches de part et d'autre de la frontière. Le premier algorithme SVM est dû à Vapnik et Lerner 
en 1963. C'était un classificateur linéaire (on recherche un hyplan), mais il ya eu de nombreuses 
modifications par la suite pour traiter les données qui ne sont pas linéairement séparables. Une 
formulation qui s'appelle "soft-margin" permettant de prendre en compte  des données mal 
étiquetés, a été proposée par (Cortes et Vapnik , 1995) , de même l'introduction de la notion de 
noyaux permet de créer classificateurs non linéaires ( Boser , Säckingen , Bromley, LeCun , et 
Jackel , 1992). Dans notre étude nous nous sommes limités à la séparation linéaire. 
Les réseaux de neurones articiels (ANN) pour le diagnostic assisté par ordinateur 
représentent le courant principal de l'intelligence artificielle en imagerie médicale (BC Calhoun, 
et al, 2001; Brownridge et al, 2001 ; B. Hinrichs et al 2009;  Bogdanovic et al 2009; Dogan et al 
2009). De nombreuses études ont été réalisées dans le domaine médical en utilisant les ANN 
pour la segmentation d'images médicales la classification dans différentes modalités d'imagerie 
médicale. 
La performance du classificateur est déterminé par la proportion de sujets provenant 
d'un ensemble n'ayant pas servi à l'apprentissage qui sont correctement étiquetés par le 
classificateur. La technique la plus employée est la validation croisée qui consiste à diviser les 
données en deux sous-ensembles, l'apprentissage étant fait sur l'un et le test sur l'autre. Ceci 
est répété  plusieurs fois en changeant l'ensemble d'apprentissage. Les données que nous 
avons traitées proviennent d'images TEP (Tomographie par Emission de positons) avec les deux 
traceurs radioactifs, l'AV- 45 et le 18 FDG. Les populations de sujets sont des patients atteints 
de la maladie d'Alzheimer (AD), des patients avec une déficience cognitive légère (MCI), et des 
sujets sains. Pour le FDG, nous avons utilisé acquisitions de 30 minutes (FDG30) et de 60 
minutes (FDG60). L'extraction de caractéristiques du groupe de toutes les images (AD, MCI, 
 200 
 
NOR) a été effectuée en utilisant l'ACI et l'APC comme expliqué plus haut. Nous avons utilisé le 
décours temporel des composants comme données d'entrée du classificateur. Chaque sujet est 
caractérisé par un vecteur de 4 dimensions pour l'AV- 45 , 6 pour FDG30 et 20 pour FDG60.  
Pour évaluer les performances de classification de notre approche nous avons utilisé la 
validation croisée de type  LOOCV (Leave One Out Cross Validation) où à chaque itération 
l'apprentissage est fait sur l'ensemble des sujets moins 1 et le test sur le sujet restant.  
Le tableau suivant récapitule l'ensemble des populations que nous analysées. 
 ADNI-AV45 
n=76 
AD=9,MCI=47,Nx=20 
 
NIMAD-AV45 
n=39 
AD=22,Nx=17 
FAIRAD-AV45 
n=12 
AD=4,MCI=6,Nx=2 
ADNI-FDG-30 
n=113 
AD=33, 
MCI=37,Nx=43 
ADNI-FDG-60 
n=31 
Nx=17,AD=14 
Nx vs AD     NA 
Nx vs MCI  NA    
AD vs 
MCI 
 NA   NA 
 
ADNI sont des sujets provenant de la cohorte de Alzheimer Disease Neuroimaging Initiative 
((http://www.loni.ucla.edu/ADNI).NIMAD et FAIRAD sont des images obtenues au centre TEP 
de l'hôpital Purpan et dont les études  sont menées à l'unité INSERM U825 à Toulouse. 
RESULTATS 
Nous avons utilisé toutes les données FDG et AV- 45 du tableau précédent en utilisant 
l'ICA l'ACP. Les résultats de SVM montrent que notre méthode arrive à différencier les sujets 
atteints de la maladie d’Alzheimer, troubles cognitifs légers et sujet normal avec un taux de 
classification allant jusqu'à 100% . Ainsi pour la population Pour ADNI - AV45, aussi bien pour 
les valeurs PCA qu'ICA, la sensibilité et la spécificité ont été atteints  100%. Pour données 
NIMAD, le taux de classification a été respectivement de 100% pour l'ICA et de 53% pour l'ACP. 
Pour FDG -30 le taux de classification varie de 84.21 % à 93.75 % en utilisant des valeurs de 
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l'APC. Pour FDG30, le calcul de l'ICA n'a pas convergé et l'étude de ces données n'a pas été 
possible. Pour ADNI FDG -60, en utilisant des valeurs ICA le taux de classification est de 100% 
alors que pour les valeurs ACP il est de 66,97 %. 
Nos résultats montrent également que la méthode ANN pour distinguer la maladie 
d'Alzheimer des MCI et des sujets normaux est une approche intéressante. Pour ADNI - AV45 en 
utilisant l'ACI et PCA la sensibilité et la spécificité ont atteint 100%. Pour les données NIMAD, 
pour l'ICA et l'ACP le taux de classification a été respectivement de 100 % et 68%. Pour FDG -30 
la précision de la classification varie de 77 % à 84 % en utilisant des valeurs de l'APC. Pour ADNI 
FDG -60, en utilisant des valeurs ICA la précision de la classification est de 100% alors que pour 
les valeurs ACO il est de 84%. 
Si nous faisons la comparaison de nos résultats entre SVM et réseaux ANN nous 
pouvons voir que pour ADNI - AV45 les deux classificateurs ont donné les mêmes résultats avec 
une précision de 100 % pour les valeurs ICA et PCA. Pour les données NIMAD, le taux obtenu à 
partir des valeurs ICA était de 100 % pour les deux classificateurs. Pour les valeurs PCA, ANN a 
donné un meilleur résultat avec une précision de 68% alors que SVM donne 53% . Pour ADNI-
FDG-30min, avec SVM le taux maximum est de 93,75% , alors que pour ANN ce taux tombe à 84 
%. Pour les données FDG-60min, le taux  est de 100% en utilisant des valeurs ICA pour les deux 
classificateurs alors que pour les valeurs de l’APC, ANN donne un taux de 84%, qui se réduit à 
66,97 % pour SVM. 
Jusqu'à présent, nous avons construit des classificateurs qui ont appris à discriminer AD 
et les sujets sains de la même population. En un deuxième temps nous avons évalué les 
capacités de généralisation en faisant l'apprentissage et le test dans deux populations 
différentes. Par ailleurs les résultats précédents ont été obtenus dans le cas l'ACP et l'ICA ont 
été faite dans le groupe, ce qui pourrait introduire un biais. Dans la vraie expérience chaque 
sujet doit être traité individuellement. Nous avons effectué des ACP et ICA individuelles PCA 
pour les sujets test. Cela soulève le problème de la correspondance entre les composantes de 
groupe et les composantes individuelles: quelle composante individuelle correspond à quelle 
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composante du groupe ? Pour surmonter ce problème, nous avons associé les composantes de 
groupe et les composantes individuelles en choisissant les composantes qui présentent une 
corrélation maximale de leur décours temporel. 
Avec ces deux modifications majeures des données d'apprentissage et de test, les 
résultats obtenus montrent que le taux de distinction des AD varie de 84,62 à 93,10 avec la 
méthode SVM et de 82,76 à 87,18 avec méthode ANN. Les erreurs de classification proviennent  
des patients Alzheimer, certains d'entre eux sont labellisés comme normaux, alors que les 
sujets normaux sont toujours retrouvés complètement (100%) avec SVM et ANN sauf dans le 
cas de l'apprentissage et de test avec des données ADNI lorsque la méthode ANN est utilisé. 
Nous avons trouvé que la spécificité de nos classificateurs est très élevée atteignant 
souvent 100%, alors que la sensibilité varie de 72,73 à 81,52 pour SVM et de 55,56 à 77,27 pour 
ANN. C'est la principale différence entre les deux méthodes; SVM semble avoir un bien 
meilleure sensibilité dans la discrimination AD vs normaux. 
L'étude de la discrimination Nx vs MCI et AD vs MCI a été entravée par la rareté des 
données, seules les données ADNI ont être utilisés avec un nombre limité de patients Alzheimer 
(n = 9). Néanmoins, nous avons trouvé que la discrimination Nx ou AD à partir de MCI est 
difficile même si la précision est de 83,58 (Nx vs MCI) et 98.21 (MCI vs d'Alzheimer) pour  SVM 
et 83.58 (normal vs MCI) et 87,60% (AD vs MCI) pour ANN. Les patients MCI sont retrouvés 
complètement, mais plus de la moitié de Nx ou AD est classé comme MCI à l'exception de SVM 
dans la maladie d'Alzheimer vs MCI discrimination (88,89%). 
CONCLUSION 
Nous avons étudié l'applicabilité des méthodes dite "machine learning" pour la 
discrimination des patient atteints de la maladie d'Alzheimer (AD) de patients avec une 
déficience cognitive légère (MCI) et de sujets témoins en bonne santé en utilisant l'imagerie TEP 
avec les traceurs 18-FDG et AV-45. Les méthodes utilisées sont SVM et les réseaux de neurones 
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artificiels. Notre approche diffère des très rares études utilisant l'imagerie TEP pour discriminer 
AD, MCI et Normaux par deux aspects: le premier est l'utilisation de l'imagerie dynamique et la 
seconde est l'adjonction d'AV45 traceur au traceur FDG-18. L'extraction de caractéristiques 
fournies en entrée du classificateur a été basée sur les décours temporels des composants 
obtenus par ACP et ICA. Nous avons comparé AV45 et FDG et nous avons trouvé que l'AV45 
donne de meilleurs résultats que le FDG. Il semble que l'ACI n'est pas adaptée pour les images 
FDG, le processus d'extraction de composantes indépendantes ne converge pas. 
Lorsque nous avons utilisé l'ICA de groupe nous avons atteint une précision de 100%, ce 
qui suggère que les résultats que nous avons obtenus dans le cas des ICA individuels sont 
certainement perfectibles, en explorant mieux la manière dont les composants individuels 
doivent être projetés sur les composantes du groupe. Cet aspect devrait être exploré plus 
profondément dans les expériences futures. Lorsque nous comparons la méthode SVM à la 
méthode AAN, nous avons constaté que SVM est plus spécifique qu’AAN dans beaucoup de cas. 
L'application de ces méthodes à la clinique dépend de la reproductibilité, nous avons 
montré que notre approche est assez puissante et reproductible pour donner des résultats 
intéressants lorsque l'ensemble d'apprentissage et l'ensemble test proviennent de deux 
populations différentes, sans qu'une procédure de normalisation des acquisitions n'ait été 
établie au préalable. Cependant, nous ne pouvons pas prétendre que la classification en 
utilisant des images PET est maintenant la référence, nous pensons qu'elle pourrait être très 
utile lorsqu'elle est utilisée en conjonction avec d'autres techniques d'imagerie comme l'IRM 
anatomique ou l'IRM fonctionnelle. 
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Différentiation entre la Maladie d'Alzheimer, la déficience cognitive légère (MCI) et l'état normal à 
l'aide de l'imagerie PET FDG et AV45. Une approche par apprentissage et classification. 
Résumé: Nous avons utilisé l'imagerie TEP avec les traceurs F18-FDG et AV45 en conjonction avec les 
méthodes de classification du domaine du "Machine Learning". Les images ont été acquises en mode 
dynamique, une image toutes les 5 minutes. Les données ont été transformées par Analyse en 
Composantes Principales et Analyse en Composantes Indépendantes. Les images proviennent de trois 
sources différentes: la base de données ADNI (Alzheimer's Disease Neuroimaging Initiative) et deux 
protocoles réalisés au sein du centre TEP de l'hôpital Purpan. 
Pour évaluer la performance de la classification nous avons eu recours à la méthode de validation 
croisée LOOCV (Leave One Out Cross Validation). Nous donnons une comparaison entre les deux 
méthodes de classification les plus utilisées,  SVM (Support Vector Machine) et les réseaux de neurones 
artificiels (ANN). La combinaison donnant le meilleur taux de classification semble être SVM et le traceur 
AV45. Cependant les confusions les plus importantes sont entre les patients MCI et les sujets normaux. 
Les patients Alzheimer se distinguent relativement mieux puisqu'ils sont retrouvés souvent à plus de 
90%. Nous avons évalué la généralisation de telles méthodes de classification en réalisant 
l'apprentissage sur un ensemble de données et la classification sur un autre ensemble. Nous avons pu 
atteindre une spécificité de 100% et une sensibilité supérieure à 81%. La méthode SVM semble avoir 
une meilleure sensibilité que les réseaux de neurones. 
L'intérêt d'un tel travail est de pouvoir aider à terme au diagnostic de la maladie d'Alzheimer. 
 
Mots-clé: Classification, Alzheimer, MCI, TEP FDG, AV45, SVM, Réseau de Neurones, ACP, ACI 
 
 
Differentiation of Alzheimer's Disease dementia, Mild Cognitive Impairment and Normal condition 
using PET-FDG and AV45 Imaging. A Machine Learning Approach. 
Abstract: We used PET imaging with tracers F18-FDG and AV45 in conjunction with the classification 
methods in the field of "Machine Learning". PET images were acquired in dynamic mode, an image every 
5 minutes.The images used come from three different sources: the database ADNI (Alzheimer's Disease 
Neuro-Imaging Initiative, University of California Los Angeles) and two protocols performed in the PET 
center of the Purpan Hospital. The classification was applied after processing dynamic images by 
Principal Component Analysis and Independent Component Analysis.  
The data were separated into training set and test set. To evaluate the performance of the classification 
we used the method of cross-validation LOOCV (Leave One Out Cross Validation). We give a comparison 
between the two most widely used classification methods, SVM (Support Vector Machine) and artificial 
neural networks (ANN) for both tracers.  
The combination giving the best classification rate seems to be SVM and AV45 tracer. However the most 
important confusion is found between MCI patients and normal subjects. Alzheimer's patients differ 
somewhat better since they are often found in more than 90%.. 
 We evaluated the generalization of our methods by making learning from set of data and classification 
on another set . We reached the specifity score of 100% and sensitivity score of more than  81%. SVM 
method showed a bettrer sensitivity than Artificial Neural Network method. 
The value of such work is to help the clinicians in diagnosing Alzheimer's disease. 
  
Keywords: Machine Learning, Alzheimer, MCI, TEP FDG, AV45, SVM, Réseau de Neurones, PCA, ICA 
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